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ANTIPSYCHOTIC TREATMENT AND SEXUAL FUNCTIONING
ROLE OF PROLACTIN
Scope of the thesis
Introduction
Since about 1996, a number of patients in our clinic for people with schizophrenia
have requested consultations for sexual problems or amenorrhoea. In the past,
patients reported these problems only occasionally, and our clinicians felt that they
were occurring now with greater frequency. Patients and clinicians felt that the
introduction of a new class of antipsychotic drugs may be involved, but this could
not be confirmed by reviewing the literature. It turned out that systematic studies on
the frequency and quality of sexual functioning in patients with schizophrenia being
treated with antipsychotics were almost entirely lacking. No information was
available on sexual side effects of the newer antipsychotics. The literature hardly
gave any information supporting evidence-based clinical guidance. The limited
information available suggested that some antipsychotics often induce sexual side
effects. Comparative studies were almost completely absent. Apart from some
information on clozapine, there were no studies comparing the sexual side effects
of classical or (new) atypical antipsychotics. The underlying mechanisms of sexual
side effects induced by antipsychotics are only partly known. For instance, the role
of prolactin and other hormones, although sometimes suggested, has hardly been
investigated. These findings or rather lack of findings, prompted several studies,
and finally the writing of this thesis.
Aims of the thesis
• To investigate the frequency and nature of sexual side effects and
hormonal alterations related to treatment with antipsychotics.
• To increase insight into the pathophysiological mechanisms of sexual side
effects induced by antipsychotics.
• To generate information in order to improve clinical guidance of patients
treated with antipsychotics. 
Content of the thesis
Chapter 1 reviews the literature about sexual functioning in patients with
schizophrenia. After a short historical overview, the impact of schizophrenia on
social and sexual functioning is presented. The major impact of antipsychotics on
sexual functioning is discussed. The individual dimensions of sexual functioning,
together with what is known about the influence of antipsychotics, sexual
physiology and possible pathophysiology, are summarized. Our knowledge about
the frequency and impact of sexual side effects of antipsychotics is far from
complete, partly because of a lack of systematic research. This is possibly related
to the sexual taboos many physicians and patients experience. 
Chapter 2 describes a pilot study comparing sexual side effects and serum
prolactin levels in patients treated for six weeks with either risperidone or classical
antipsychotics, primarily pimozide. The findings are discussed, and hypotheses
about possible mechanisms are generated. The discussion focuses on the
regulation of prolactin secretion as it relates to the pharmacological profile of
antipsychotics in general and risperidone in particular.
Chapter 3 presents the development of the Antipsychotics and Sexual Functioning
Questionnaire (ASFQ), a questionnaire evaluating sexual side effects of
antipsychotics in patients with schizophrenia. The questionnaire is described, and
preliminary data on its validity and reliability are presented.
Chapter 4 reports on an open randomized study comparing sexual side effects
and prolactin levels in patients being treated for six weeks with either olanzapine or
risperidone. The majority of patients included in this study were men. Differences
between the antipsychotics are presented. Possible mechanisms and clinical
consequences are discussed.
Chapter 5 describes a second randomized study, which compares the impact on
sexual functioning of quetiapine with risperidone. Data are presented for men and
women. The differences found are discussed with regard to the possible
mechanisms and clinical consequences.
Chapter 6 attempts to explore the mechanisms through which risperidone induces
serum prolactin levels to elevate. The correlations between serum levels of
risperidone, the main metabolite 9-hydroxy risperidone, and prolactin are
examined. The pharmacological and pharmaco-dynamical properties of risperidone
and 9-hydroxy risperidone are discussed. In the discussion the question is raised
why risperidone, contrary to the hypothesis about dopamine and serotonin
blockage, induces major elevation of serum prolactin levels.
Chapter 7 starts by presenting the seemingly contradictory findings in the
literature, i.e. that clozapine, in comparison with classical antipsychotics, seems to
induce the same frequency of sexual side effects. This is followed by the
preliminary results of a study involving patients being treated with classical depot
antipsychotics versus clozapine. Questions about persistence of sexual side
effects over time are addressed by only including patients who have been under
treatment for more than six months.
Chapter 8 reviews the literature on the sexual side effects of antipsychotics, and
presents data pooled from ongoing open naturalistic follow-up studies and from a
randomized trial comparing risperidone and olanzapine. These data permit
comparisons between classical antipsychotics, clozapine, risperidone and
olanzapine, for men and women.
Chapter 9 presents data gathered from one open and two controlled studies,
which permits multiple comparisons of sexual dysfunctions induced by various
antipsychotics (classical antipsychotics, clozapine, olanzapine, quetiapine and
risperidone) and examines associations between dosage, plasma levels of
antipsychotics and prolactin levels. Possible mechanisms of antipsychotic-induced
sexual dysfunctions are discussed, focusing on the role of dopamine and prolactin.
The clinical implications of the findings in this chapter are also considered.
Chapter 10 forms the last part of the thesis. In this chapter, the results of the
studies of the earlier chapters are briefly summarized and then presented in a
broader perspective. Results of recent animal and human studies, on behavioral
and biological effects of both brief and prolonged elevation of plasma prolactin
levels, are discussed. Possible risks of prolonged exposure to elevated plasma
prolactin levels are explored. Hypotheses on the impact of prolactin and dopamine
on sexual functioning are presented, and possible directions for future research are
suggested.




Schizophrenia, Sexual Functioning and Antipsychotic Treatment: a Review
Introduction
Over the past several years several patients on our research ward for people with
schizophrenia and related psychotic illnesses at the University Hospital in
Groningen began reporting sexual problems and amenorrhoea while undergoing
treatment and asked for consultation.  Turning to the literature, however, we
discovered there was surprisingly little to support clinical guidance.  Briefly put, it
was this glaring lacuna and, of course, the growing awareness that sexual
problems psychiatric patients are suffering may well be related to the treatment
they are receiving, that prompted us to undertake a number of research activities.
Among the questions raised are the following:
1. How is sexual functioning in patients with schizophrenia viewed from a
historical and social perspective? 
2. How important is sex for people with schizophrenia and to what extent are
their doctors aware of this?   
3. What weight do the sexual complaints of people with schizophrenia have
for the doctors that treat them?
4. How often do patients with schizophrenia experience sexual dysfunctions? 
5. What mechanism are involved in antipsychotic induced sexual
dysfunctions?  
6. In what way do antipsychotics influence individual aspects of a patient’s
sexual performance?
In this chapter these and other questions will be addressed in the following way.
First, the importance will be traced of social-related, disease-related and treatment-
related factors  with regards to sexual dysfunctions in patients with schizophrenia.
Next, psychopharmacological mechanisms involved in antipsychotic-related sexual
side effects will be discussed. Then, the focus will be on sexual dysfunctions
themselves and their relevance in clinical studies in schizophrenia.  Finally,
conclusions and clinical implications will be discussed.
How do sexual symptoms relate to schizophrenia?
In the early 20th century schizophrenia was thought to develop because of
deficiencies in sex hormones (Jacobs and Bobek 1991). Later psychoanalytic
theories suggested that psychosis might derive from unconscious homosexual
tendencies (Norman 1948). Erotic sexual behaviors were also seen as possible
causal factors in schizophrenia in pre-schizophrenic patients (Ariety 1967).  Mainly
theory-driven and not based on any empirical research, these ideas have been
abandoned in modern research. 
According to case reports, patients sometimes do experience cenesthesic
hallucinations of sexual nature, erotomanic delusions, delusions related to sexual
identity and hypersexuality during an acute psychotic episode (Akhtar and
Thomson 1980; Connolly and Gittleson 1971). But such psychotic manifestations
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are uncommon and usually disappear after the start of antipsychotic medication
(Fortier et al. 2000). 
Viewed from a social perspective, sexuality for people with schizophrenia was
restricted in many ways before the 1950’s. Given that extramarital sexual
intercourse was socially frowned upon (Hilger et al. 1983), institutionalization
reinforced sexual inactivity by discouraging or even prohibiting sexual
relationships. In the United States, for example, illegitimate pregnancies did occur
in psychiatric facilities, but only at one-fifth of the rate found among the general
population (Wignall and Meredith 1968).
When oral contraceptive medications became available, psychiatric institutions
started to change their regulations, allowing more sexually mixed social activities
and home passes (Wignall and Meredith 1968). Especially in the United States,
England and Italy, de-institutionalization accelerated after the 1960’s. In North
America beds in public psychiatric hospitals had decreased with 80 percent within
ten years (Appleby et al. 1993). In parallel with de-institutionalization, relative
fertility of women with a major mental illness increased (Ødegärd 1980), as living in
the community yielded more opportunities for sexual encounters (Nicholson et al.
1996).
According to Skopec et al. most patients with schizophrenia do not differ from
controls in terms of actual sexual behavior (Skopec et al. 1981). Though relatively
rare, some patients show a lack of inhibition in their sexual behavior as a direct
result of psychotic symptomatology, i.e. schizophrenia can be associated with
altered sexual behavior. Moreover, patients with schizophrenia can become
preoccupied with sex in seemingly distorted and bizarre ways. Preoccupations and
delusions may center on the sexual act and pregnancy, but they are seldom acted
upon (Jacobs and Bobek 1991). In fact, most sexual activity is expressed in either
fantasy or masturbation. According to earlier studies, male patients practice
masturbation two to three times more frequently, albeit less pleasurable than men
in the general population (Skopec et al. 1981). In a population with institutionalized
patients, both males and females with chronic schizophrenia showed diminished
interest in sexual activity, decreased frequency of intercourse, and loss of
satisfaction from sexual interactions, compared with controls (Lyketsos et al. 1983).
The lower frequency and lesser degree of satisfaction with sexual intercourse was
related to the severity of psychopathology and the length of institutionalization.
Interestingly, sexual dreams and fantasies among these patients did not differ
significantly from dreams and fantasies in the control group. Moreover, a study by
McEvoy of chronically institutionalized women found that most of them had
continuing interest in sex and were indeed sexually active (McEvoy et al. 1983).
Patients with schizophrenia viewed institutionalization as an obstacle to sexuality, it
took them longer to have a first date, first kiss, first coitus and first marriage
(Raboch 1984). At the same time, the sex-life of patients who did live harmoniously
with a partner seemed to be no different from controls who were not mentally ill
(Raboch 1984).
It has been suggested that schizophrenia influences the sexual behavior in men
and women in different ways (Verhulst and Schneidman 1981). For example,
women with schizophrenia have better social outcome, as they date, have sex,
marry and raise children more often than men do (McGlashan and Bardenstein
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1990). McEvoy and colleagues studied the sexual activity and attitude in chronic in-
patients with schizophrenia (McEvoy et al. 1983). Some female subjects reported
to have increased sexual activity, while others reported alternating periods of
hyper-sexuality and hypo-sexuality. Female patients often considered their sexual
partners to be undesirable, while both male and female patients tended to feel
guilty about their sexual preoccupations. A majority of female patients with chronic
schizophrenia continued to be interested in sex, and about one half of them wanted
to become pregnant, many of them unaware of the limitations in their parenting
abilities. 
In another study of sexual problems in 20 male and 20 female outpatients suffering
from schizophrenia, 80% indicated that sexuality was important to them and 68%
indicated to long for sexual contact (Buddeberg et al. 1988).  More than one third
did have regular sexual contacts. On the other hand, inhibition of sexual desire was
also reported, with many men having erectile dysfunctions and women reporting
more general sexual dysfunctions. The authors concluded that sexual dysfunctions
seemed to be related to antipsychotic treatment and an impaired capacity for
maintaining interpersonal relationships. 
Summary: only a limited number of studies have evaluated sexual functioning in
schizophrenic patients. Whether or not schizophrenia is linked to problematic
sexual behavior has yet to be settled. Clear is that institutionalization impairs
sexual functioning. Psychotropic medication may be affiliated with the induction of
sexual dysfunction. Still, most patients with schizophrenia show an interest in sex
that differs little from the general population. Compared with men, women with
schizophrenia tend to have a better social outcome, as reflected not only in longer
lasting sexual relationships but also in more often having offspring. On the whole,
however, due to social and interpersonal impairments, patients with schizophrenia
are not frequently involved in long and stable sexual relationships. 
How do patients and doctors weigh the burden of sexual complaints?
In a study of Finn et al. 41 patients with schizophrenia were asked to compare the
subjective burden caused by their psychotic symptoms with that caused by other
symptoms or side effects (Finn et al. 1990). The burden of symptoms could be
rated from 1 (mild) up to 5 (most serious). Patients rated prosecutory hallucinations
as heavy burden (frequency in patients reporting the symptom 66%, and the
corresponding burden 4.34). Significantly, the burden of impotence (frequency
34%, burden 4.5) and absence or painful ejaculation (frequency 12%, burden 4.0)
were rated in the same range. 
More recently, a survey of over 2000 mental health service users published by the
English National Schizophrenia Fellowship showed that a large proportion of
people experienced side effects from their antipsychotic medication and that sexual
side effects were deemed to be the most troublesome (Smith et al. 2002).
 It has also been shown that sexual side effects are of high importance to patients
and that they have a great influence on compliance (Finn et al. 1990). Still, patients




Strauss and Gross interviewed 86 psychiatrists on the importance of sexual side
effects of psychopharmacological treatment (Strauss and Gross 1984). Most
psychiatrists considered sexual side effects to be clinically relevant in two out of
three patients. Also many of the psychiatrists felt that these side effects were likely
to influence treatment compliance in a negative way. Moreover, a majority was
convinced that most patients would not discuss sexual items spontaneously. Yet,
only 10% of the psychiatrists had actually asked their patients about sexual side
effects. Why the other 90% refrained from doing so remained unexplained in this
study. Importantly, in their opinion antipsychotic drugs in general influenced sexual
functioning and about half of these psychiatrists asked actually used these side
effects for the clinical management of abnormal sexual behavior. 
In a large study of Lingjaerde et al. on antipsychotics medication, patients indicated
that neurological, psychic, autonomous and sexual side effects contributed to the
global side effects rating, all more or less to the same extent (Lingjaerde et al.
1987). On the other hand, doctors judged the neurological and psychological side
effects to correlate most with the overall global side effects rating. This suggests
that doctors tend to underestimate the impact of sexual side effects for the
patients.  
Summary: patients with schizophrenia consider sexual problems to be relevant to
them. However, both clinicians and patients seem to be reluctant to discuss these
side effects. Therefore, in clinical practice frequency and impact of sexual
problems may be widely underestimated.
How often do people with schizophrenia experience sexual dysfunctions?
Adequate evaluation of sexual dysfunctions in patients with schizophrenia is
hampered by the fact that alterations in sexual performance patients experience
may result from their primary illness, the way it is being treated as well as the
social consequences that adhere in being schizophrenic (Nestoros et al. 1981).
Clinical trials assessing sexual side effects of antipsychotics are rare; comparative
studies are virtually absent (Nestoros et al. 1981; Peuskens et al. 1998;
Knegtering et al. 2000). The studies we were able to identify as relevant in the
literature are listed in tables 2-4. Studies using spontaneous accounts of patients
report low incidences of sexual dysfunctions related to treatment with
antipsychotics, actually less than 10% of the patients report sexual dysfunctions
spontaneously when asked for side effects (Knegtering et al. 1999). On the other
hand, studies using structured interviews or questionnaires tend to report high
incidences of sexual side effects related to treatment with antipsychotics. In such
studies, 30% to 60% of the patients with schizophrenia report sexual dysfunctions
(Lingjaerde et al. 1987;  Sullivan and Lukoff 1990). 
Lingjaerde and colleagues interviewed 2,391 patients treated with antipsychotics,
using the Udvalg for Klinische Undersøgelser (UKU). This scale evaluates a wide
range of side effects including sexual side effects. The study was a cross-sectional
study including patients of all ages and varying duration of treatment, 58% of them
suffering from schizophrenia. The most reported side effect was libido reduction in
37% of male and female patients. Orgasmic dysfunction was found in 19% of
female and 16% of male patients. Sexual side effects seemed to be less
Schizophrenia, sexual functioning and antipsychotic treatment, a review
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pronounced for high-potency antipsychotics. Even years after treatment initiation,
the sexual side effects did not seem to subside. 
In a study by Pfeiffer et al. sexual dysfunction was evaluated in 103 outpatients
during long-term treatment with psychotropic medication (Pfeiffer et al. 1991).
Fifty-three percent of the patients using antipsychotics reported sexual
dysfunctions versus 10% of the patients using antidepressants and 31% of the
patients using lithium.
Aizenberg et al compared sexual functioning in 122 male subjects: 20 drug-free
patients with schizophrenia, 51 neuroleptic-treated (depot form) patients with
schizophrenia and 51 normal controls (Aizenberg et al. 1995). A high frequency of
sexual dysfunction was reported by both schizophrenic groups of patients. The
treated patients in particular reported impairments in arousal items (erection) and
orgasm during sex. Desire parameters (libido) were reduced in both groups of
patients, but reduction in the frequency of sexual thoughts was confined to the
untreated one. Treated patients reported dissatisfaction with their sexual function.
Aizenberg concluded that treatment with antipsychotics might be associated with
restoration of sexual desire while impairing erectile, orgasmic, and sexual
satisfaction problems.
Ghadirian et al. examined a random sample of 55 schizophrenic outpatients.
Selected from a long-term follow-up clinic (26 men and 29 women) were treated
with classical neuroleptics. The patients rated their current sexual functioning on
specially designed scales. Fifty-four percent of male and 30% of female patients
reported impaired sexual functioning during neuroleptic treatment. Men reported
mainly erection disturbance (Ghadirian et al. 1982a).
Teusch and coworkers compared sexual dysfunctions in male and female patients
with schizophrenia, opiate addiction, neurosis and normal controls (Teusch et al.
1995). We restrict our discussion to patients with schizophrenia (N=45, 30 male,
15 female) and normal controls (N=41, 22 male, 19 female). Eleven patients used
a phenothiazide derivates, 11 clozapine, 19 other antipsychotics, 4 no medication
(2 male, 2 female patients). Male patients with schizophrenia reported in 88% of
the cases sexual dysfunctions versus 27% of the controls (p=0.00). Female
patients with schizophrenia reported in 93% of the cases sexual dysfunctions
(including menstrual disorders) versus 63% of the controls (p=0.01).
Although comparative studies are rare, the majority of the literature suggests that
antipsychotics might differ in the type and frequency of sexual dysfunctions they
cause (Ghadirian et al. 1982b; Knegtering et al. 1999). For instance, thioridazine
seems to cause more sexual dysfunctions (erection and ejaculation) compared
with other classical antipsychotics (Kotin et al. 1976). 
In a study by Smith et al. 101 patients using conventional antipsychotics were
compared with 57 normal controls and 55 patients attending a sexual dysfunction
clinic. Sexual dysfunctions were found in 45% of the patients using conventional
(classical) antipsychotics, 17% of normal controls and 61% of controls attending a
sexual dysfunction clinic. Male patients reported normal libido, but were highly
likely to report erectile and ejaculation dysfunction. In women, thioxanthenes
substitutes, benzamides, and aliphatic phenothiazines were more likely to be




Clozapine is an “atypical” antipsychotic that causes no extrapyramidal side effects
and virtually no prolactin elevation. In addition, Crenshaw stated that clozapine
also had a lower liability for sexual dysfunctions (Crenshaw and Goldberg  1996).
However, Hummer et al. did a comparison study between clozapine and
haloperidol  in which patients were treated for six weeks with either clozapine or
haloperidol and sexual dysfunctions were evaluated weekly using the UKU
(Hummer et al. 1999). At week 6 more than 50% of the patients had reported
sexual side effects, but no differences were found between patients using
haloperidol versus clozapine (Hummer et al. 1999). Hummer then continued the
assessments on a monthly basis. Both treatment groups improved on sexual
dysfunctions from week 6 till week 18  (male patients from 53% sexual
dysfunctions and in female patients from 23% to 0%). At the same time it should
be noted, that over-time no subsiding sexual dysfunctions were found in several
other studies reporting continuation of sexual side effects even after years of
treatment (Lingjaerde et al. 1987; Pfeiffer et al. 1991).
In a recent study on sexual side effects 60 outpatient men using long-term
classical antipsychotics were randomly assigned to either continue classical
antipsychotics treatment or switch to clozapine (Aizenberg et al. 2001). They
concluded that maintenance therapy with the atypical neuroleptic clozapine was
associated with a lower degree of sexual dysfunction than classical antipsychotics.
Moreover, sexual side effects did continue over longer treatment periods, albeit
with possibly fewer sexual side effects in patients treated with clozapine
(Aizenberg et al. 2001).  
Summary: studies using questionnaires suggest that 40 to 60% of the patients
report sexual dysfunctions, possibly related to the use of antipsychotics. Some
problems in sexual functioning of people with schizophrenia mainly occur as a
direct result of their primary psychotic symptoms and impaired social skills that
complicate contacting potential partners. Libido reduction often seems, at least
partly, to be associated with schizophrenia itself. It is suggested that this
decreased libido in patients with schizophrenia might be linked to the general
reduction of initiative patients experience, often referred to as negative symptoms.
Still, most sexual problems seem to be related to the treatment with
antipsychotics. Although not all studies agree, there may be no tolerance for
sexual side effects when patients use these antipsychotics for a long time. There
is some evidence that antipsychotics might differ in the frequency and kind of
sexual dysfunctions being induced but there is a lack of well-controlled
comparative studies. 
 
Which mechanisms are involved in antipsychotic induced sexual
dysfunctions?
Introduction
All available antipsychotic drugs exert their antipsychotic effect through dopamine
antagonism. However, these drugs vary strongly with respect to, among others,
biochemical structure, receptor binding profile and pharmaco-kinetics. In addition,
impairment of sexual performance can be due to a variety of factors. The clinically
most important mechanisms through which antipsychotics may induce sexual side
Schizophrenia, sexual functioning and antipsychotic treatment, a review
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effects will be summarized here (Segraves 1989; Meston and Gorzalka 1992;
Meston and Frohlich 2000). 
Antipsychotics interact with many different neurotransmitter systems in the brain
and other parts of the body. Affinity for the dopamine system is a property shared
by all of these drugs, but the affinity for the serotonergic, noradrenergic, histaminic
and cholinergic neurotransmitter systems may differ among the various groups of
antipsychotics (table 1) (Leysen 1981; Leysen et al. 2000). 
Table 1. Receptor binding affinity profiles of most antipsychotics discussed in this thesis
D1 D2 5HT2a Alfa1 Alfa2 H1 M1
Chlorpromazine ++ ++ +++ +++ +
Clozapine + + ++ + + ++ +
Haloperidol +++ + + 0 0
Olanzapine ++ ++ +++ ++ + ++
Pimozide +++ + + 0 0
Quetiapine 0 + + + + + 0
Risperidone +++ ++++ +++ ++ ++
Sertindole ++ +++ +++ +++ + 0 0
Thioridazine ++ ++ +++ ++ +
Ziprasidone ++ +++ +++ ++ 0
Affinity for receptor: + low, ++ moderate, +++high, ++++ very high; 0 absent.
This table represents global ratings based on data of Leysen
(Leysen, J. E. 1981; Leysen, J. E. et al. 2000) 
Since all antipsychotics are dopamine antagonists, the question raises as to how
and to which extent dopamine blockade may contribute to libido loss, erectile
disorders and orgasm disturbance (Giuliano and Allard 2001).
Dopamine is an important neurotransmitter in experiencing motivation and
rewards, probably including sexual motivation (libido) and sexual reward (orgasm)
(Feldman et al. 1997). Studies in animals and reports in humans suggest that
dopamine can increase sexual desire and behavior (Deelen van et al. 2002;
Fibiger et al. 1992; Giuliano and Allard 2001; Pfaus et al. 1995). The role of
dopamine in female sexual functioning is less well understood. Low dosages of
dopamine agonists increase receptivity in female rats with low receptivity, while
high doses have the opposite effect in rats exhibiting high receptivity (Giuliano and
Allard 2001). In healthy men with normal erectile capacity apomorphine, a
dopamine-D1/D2 agonist, facilitates erections. In patients with Parkinson’s disease
levo-dopa treatment can provoke sexual hyperactivity (Deelen van et al. 2002; Uitti
et al. 1989). Of importance, the effects of dopamine-induced erection in male rats
can be blocked by dopamine antagonists like haloperidol. Taken together, there is
a growing body of evidence that dopamine is involved sexual arousal and orgasm
(Giuliano and Allard 2001).
In addition to its central role in reward and motivation, dopamine inhibits the
release of prolactin from the pituitary gland. On the other hand, prolactin
modulates dopaminergic transmission in the brain. Binding sites of prolactin have
been identified in the hypothalamus and substantia nigra (Sobrinho 1993).
Hyperprolactinemia stimulates dopamine turnover in several areas of the brain,
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including the nucleus accumbens, and reduces turnover in other regions, e.g. the
substantia nigra. Thus, complex interactions between prolactin and dopamine take
place.
On the level of actual behavior, prolactin is involved in a sexual behavior feedback
system. Serum prolactin levels raise during orgasm, while conversely sexual
behavior is reduced after orgasm for as long as plasma prolactin levels stay
elevated (Exton et al. 2000; Haake et al. 2002).
As stated above, the release of prolactin takes place under tonic inhibitory control
by dopamine in the tuberoinfundibular system. Therefore, an ensuing effect of
dopamine blockade by antipsychotics is a diminished inhibition of the prolactin
output. As a result, serum prolactin levels raise, at least temporarily, when
antipsychotic treatment is initiated. Indeed, prolactin elevation is an indirect
indicator of dopamine blockade (Kapur et al. 2001). However, the regulation of
prolactin release is clearly subject to a variety of factors. For example, interference
with serotonin receptor subtypes, i.e. the 5HT1A- or 5HT2C receptors, can modulate
the inhibitory effect of dopamine on prolactin release (for more details, see chapter
2). As to antipsychotic-induced Hyperprolactinemia, at least in men,  worsening of
sexual dysfunctions correlates with serum prolactin elevation (Ghadirian et al.
1982a; Burke et al. 1994; Segraves 1989). Although some authors suggest here a
causal relationship between prolactin elevation and sexual side effects, this is still
under debate (Arato et al. 1979; Kleinberg et al. 1999; Petty 1999a). Other
mechanisms associated with prolactin elevation contain a wide range of changes
in the levels of other hormones, including a decrease in serum testosterone level,
that might diminish sexual performance in men as well as in women (Rinieris et al.
1989). 
Although prolactin is the most widely studied hormone in sexual dysfunctions,
other hormone systems might also be involved. Some authors found a reduction of
LH levels, during treatment with antipsychotics like chlorpromazine, in both men
and women. Mechanisms suggested are dopamine blockade or noradrenalin
blockade by chlorpromazine (Rinieris et al. 1988; Praag van and Korf 1975). Some
studies found high LH levels correlating with normal sexual activity without
detecting a clear correlation between sexual dysfunction and prolactin levels
(Arato et al. 1979).
Sedating properties of antipsychotics also have an influence on sexual
performance. Histamine-H1 receptor blockade is related to the sedating properties
of antipsychotics (Leysen et al. 2000). And, of course, sedation itself might be
responsible for diminishing sexual performance. 
Many antipsychotics have α-blocking properties. The α1-blocking properties
possibly contribute to a diminishing ability for erection, vaginal lubrication and
ejaculation. These noradrenergic (α1) effects seem (partly) to be in balance with
(anti-)cholinergic effects leading to final effects on erection that might turn into
erection disturbance (often) or priapism (rare) and/or ejaculation disturbance. For
instance, antipsychotics like thioridazine or sertindole with α1-antagonistic
properties are associated with priapism (central α1-antagonism?) or ejaculation
disturbance (diminished semen volume) (Thompson Jr et al. 1990). Some
antipsychotics have α2-blocking properties. Linked to sexual dysfunctions in
treatment with antipsychotics this has hardly been described. In theory, as in the
α2-blocking yohimbine, it may stimulate erection (Linnankoski et al. 1992; Smith et
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al. 1987; Tallentire et al. 1999). The role of serotonin in sexual behavior is highly
complex and shows sex differences (Rosen et al. 1999). The clinical importance of
the serotonergic system becomes evident in patients treated with Selective
Serotonin Re-uptake Inhibitors (SSRIs) (Waldinger 1999). Treatment with SSRIs is
frequently associated with sexual dysfunctions, such as ejaculatory disorders and
anorgasmy (Lane 1997). Activation of 5-HT2 receptors seems to act in an inhibiting
manner on sexual stimulation and activity in men, while precisely the opposite
occurs in the case of women (Wilson 1993). Cyproheptadine, a 5-HT2 receptor
antagonist, is capable of eliminating SSRI-induced sexual dysfunction in men
(Baldwin et al. 1997). Since many antipsychotics are 5HT2a and some 5HT2c
antagonists, no important influence on sexual functioning might be expected from
these receptor systems. Antidepressants, like mirtazepine, with 5HT2c antagonistic
aspects are thought to compensate for serotomimetic aspects, reducing the
inhibitory effects on sexual behavior (Gelenberg et al. 2000). For antipsychotics
one might expect these complex interactions in compounds like ziprasidone, that
combines 5HT2a, 5HT2c antagonistic properties with 5HT1a agonistic aspects.
Today no studies are known to us on the influence of ziprasidone on sexual
behavior. 
Summary: Many different mechanisms may contribute to the effects of
antipsychotics on sexual functioning. Dopamine is involved in almost all aspects of
sexual behavior and dopamine blockade induced by antipsychotics seems to play
a role in the inhibition of all stages of sexual performance. Associated with
dopamine blockade is prolactin elevation, which may interfere with erection as well
as with possibly other aspects of sexual performance in a dose dependent way.
Some antipsychotics induce noradrenergic blockade, which appears to be
associated with disturbances in ejaculation and possibly lubrication. In addition
serotonergic, histaminergic and hormonal effects may contribute to the actual
sexual performance.     
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In what way do antipsychotics influence  individual aspects of sexual
performance?
In the first part of this review was focused on sexual dysfunctions in general. This
part of the review concentrates on the frequency of specific sexual dysfunctions in
schizophrenic patients with antipsychotic treatment. In the following subsections
first dysfunctions involving libido will be discussed, then those related to erection,
and finally ones reported for lubrication. For each definitions, physiology,
underlying pathophysiological mechanisms and relevant findings in clinical studies
will be presented. 
Libido
Physiology
Libido is a term often used as the equivalent for sexual desire, the latter commonly
defined as interest in sexual objects or sexual experiences. There is no objective
physiological criterion for desire. It is generally inferred from the self-reported
frequency of sexual thoughts, fantasies, dreams, wishes and interest in initiating
and/or engaging in sexual experiences (Meston and Frohlich 2000).  Libido is
closely connected with sexual arousal. Sexual arousal is defined both in subjective
(feeling sexually excited) and objective physiological terms (e.g. genital
vasocongestion, erection). 
There is a good deal of evidence showing that mechanisms in the brain involved in
motivation and initiating of behavior in general are, at least partly, the same as
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those involved in sexual motivation, in the context of this chapter called libido
(Pfaff 1999). Cerebral mechanism involved may be analyzed in terms of e.g.
endocrine influences, brain centers or brain-circuitries involved.
Although uncontested, it is generally assumed that the preoptic region and
possibly other regions of the hypothalamus are involved in thermoregulation,
aggression and sexual motivation (Robbins and Everitt 1999). Hypothalamic nuclei
contain high concentrations of steroid receptors (e.g. for prolactin, estradiol,
progesteron and testosteron), especially in the medial preoptic region and the
ventromedial hypothalamus. Individual hormones (progesterone, estrogen,
progesterone and testosterone) and the interaction of these hormones with each
other can at least in theory have influence on libido (Yen and Jaffe 1999).  This is
nicely illustrated by the way progesterone administration, after estrogen priming,
provokes a release of prolactin and Luteinizing Hormone (LH) in animal models
and women (Robbins and Everitt 1999). In rodents this is expressed in behavior
seen as a equivalent of libido in humans (Pfaff 1999). In line with these rodent
studies, in human sexual behavior there seems to be a peak in arousability (libido)
and sexual behavior in women in the late follicular phase of the menstrual cycle,
observations (Yen 1999). 
When focusing on brain circuitry, it is important to realize that neurological and
endocrine systems are closely intertwined, with for instance the dopaminergic
system having inhibiting influences on prolactin elevation and prolactin elevation
influencing dopaminergic transmission.  
The dopamine system, especially the mesolimbic and mesocortical dopaminergic
projections, plays an important role in the appetitive aspects of motivational
behavior probably including libido (Feldman et al. 1997).  
Pathophysiology
The mechanisms of libido-reduction during treatment with antipsychotics are as
yet not well understood. As dopaminergic systems are involved in experiencing
motivation, a blockade of the dopaminergic transmissions especially in the
mesolimbic pathways may be related to a diminished initiation of behavior
possibly, including sexual behavior. The subjective experience linked to the
inhibition of sexual initiative is libido reduction. Indeed, drugs like antipsychotics
that diminish dopamine transmission are generally correlated to libido-reduction.
On the other hand dopamimetic drugs, like L-dopa or apomorphine, may initiate an
increase in libido (Martin-Du Pan 1978; Bowers et al. 1971; Hyyppa et al. 1975;
Uitti et al. 2002). 
It is unclear to what extent libido reduction may also be affected by secondary
effects of dopamine blockade by antipsychotics, like prolactin elevation, reduction
of serum-testosterone, FSH or LH, or a diminished subjective well-being (Siris et
al. 1980;  Kruger et al. 2002).
There is some suggestion in the literature that, as a consequence of dopamine
blockade induced prolactin-elevation, the capability to have sexual fantasies is
diminished (Carani et al. 1996). Loss of libido is also seen in patients with
prolactinomas. This suggests that loss of libido in patients treated with




Findings in clinical studies
Un-medicated patients with schizophrenia often report libido reduction. This
disease-related libido reduction might be induced by an unknown underlying
process, the patients psychotic symptoms or as part of the general loss of initiative
and activity level (often called negative symptoms). Libido reduction then occurs
as a consequence of these negative symptoms. In addition the social
consequences concomitant with schizophrenia can be contributory to a decrease
in libido.
In early studies on sexual dysfunctions related to schizophrenia or antipsychotic
medication, libido was touched upon. In a review on drug therapy and sexual
dysfunction in men, Mitchell and Popkin (1982) quoted nine case reports indicating
libido reduction related to the use of antipsychotics, but cases with normal libido
were also reported. In a study by Aizenberg (1995) libido was found to be more
reduced in both groups of male patients with schizophrenia being treated with
antipsychotics compared with patients not using antipsychotics. Patients with
schizophrenia reported significantly more frequent libido reduction versus
unaffected controls. Reduction in the frequency of sexual thoughts was confined to
the untreated patients.  Patients being treated with antipsychotics were less easily
sexually aroused.
As we saw, in the study of Lingjaerde et al. using the UKU of 2391 patients treated
with antipsychotics 37% of male and female patients reported libido reduction.
Interestingly, 20% reported an increase of libido (Lingjaerde et al. 1987). Although
some patients studied were being treated with antipsychotics for up to 10 years,
about the same frequencies of libido reduction were reported irrespective of the
duration or the dosage of treatment.  Libido reduction was rated in half of the
cases as probably drug related while libido increase was considered to be drug
related in one out of four. 
Teusch et al. showed that 60% of male patients with schizophrenia report a libido
reduction versus 14% of the controls (Teusch et al. 1995). Of the female patients
in this study 60% reported libido reduction versus 26% of the controls. 
In the study by Hummer, quoted above, libido reduction was reported in more than
50% of the male patients treated with either haloperidol or clozapine and in about
30% of the female patients (Hummer et al. 1999). Patients treated with haloperidol
versus clozapine did show comparable frequencies of libido reduction. 
Summary: libido reduction in patients with schizophrenia seems to be related to
their psychotic illness as well as to antipsychotic medication. During treatment with
antipsychotics, some patients experience a restoration of libido, but the majority
experience libido reduction. Inhibition of dopaminergic pathways as well as
interference with endocrine functioning are probably the main reasons why
antipsychotics induce a general inhibition of initiative, including sexual initiative.
Literature suggests, but remains inconclusive about, the possible involvement of
other mechanisms like Hyperprolactinemia in antipsychotic induced loss of libido. 




Erection describes the non-flaccid state of the penis and is in most cases the
physiological expression of sexual arousal. Impotence refers to the inability of men
to achieve and/or maintain erection. In clinical practice patients often report
problems in case of a delayed, shortened or diminished ability to reach full
erection. It is these aspects of erectile dysfunction that we will discuss in the
following, grouping them all together under the heading of impotence. Although
erections often co-occur with the subjective feelings of sexual excitement, it can
also occur without arousal, for instance during Rapid Eye Movement (REM) sleep.
Erection begins with smooth muscle relaxation in the sinusoidal spaces of the
penis, mediated by noradrenergic-noncholinergic autonomic nerves, together with
the vascular endothelium release nitric oxide (NO) into the corpus cavernosum
(Creed et al. 1991; Meston and Frohlich 2000). The smooth muscle relaxation
reduces vascular resistance so that erectile bodies can fill with blood.
Detumescense occurs with the release of catecholamines during orgasm and
ejaculation.
Pathophysiology
The possible mechanisms for antipsychotic induced erection disturbances are
unclear. From patients with Hyperprolactinemia induced by prolactinomas we learn
that prolactin elevation can be correlated with erectile dysfunction (Thorner et al.
1998). Schwarz et al. refer to studies in which up to 90% of male patients with
Hyperprolactinemia, mostly within the context of a hypophysis adenoma, complain
to some extent of sexual dysfunction, especially of erection disorders (Schwartz et
al. 1982). In fact, impotence is sometimes the first symptom of a prolactinoma. Still,
it is unclear whether prolactin has a direct effect on erectile functioning. Prolactin
elevation may also have secondary effects through inducing the lowering of plasma
testosterone, TSH and LH levels and/or changes in mental attitudes (Tuomisto and
Mannisto 1985). It has been suggested that, as a consequence of prolactin-
elevation, there is no change in nocturnal (REM sleep linked) erections but the
capacity to have sexual fantasies are diminishes (Carani et al. 1996). So erection
disturbance in patients using antipsychotics may well be secondary to the libido
reduction, next to having a primary affect primary effect on erectile mechanisms. 
Findings in clinical studies
In many studies assessing arousal, questionnaires are used evaluating quantitative
(duration, frequency) and qualitative (rigidity) aspects of erection and in women
sometimes lubrication. More objective ways to study erection include for instance a
mechanical strain gauge that measures the penile circumference. Such objective
evaluations are complex and given the taboos surrounding sexuality not readily
excepted in routine clinical practice or clinical trials evaluating side effects of these
drugs. This explains why studies evaluating sexual side effects in patients using
antipsychotics on the whole relied on questionnaires.   
Aizenberg et al. found that erection in patients with schizophrenia, who had a
sexual partner, was slighter during coitus (Aizenberg et al. 1995). Patients using
antipsychotics experienced significantly more erection disturbance, during sexual
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intercourse as well as during masturbation compared with patients without
antipsychotics. At the same time, no change occurred in waking erections (an
expression of REM sleep correlated erections) in these patients. Weizman
evaluated sexual performance in 13 men treated with sulpiride (6 patients
schizophrenia, 7 anxiety disorder). Sulpiride (dose range 100-600 mg/day) was
associated with a dose dependent significant prolactin increase (35-190 ng/ml) and
induced in 5 patients erectile dysfunctions that correlated with dose and prolactin
levels (Weizman et al. 1985).  Lingjaerde et al. evaluated erection disturbance in
1259 men being treated with antipsychotics using the UKU (Lingjaerde et al. 1987).
They found in 22% of the patients erectile dysfunctions. As in libido, the
percentage of patients with erectile dysfunction hardly changed during prolonged
treatment with antipsychotics, i.e. for up to 10 years and more. Half of the cases of
erectile and ejaculatory dysfunctions were rated as probably drug induced. In the
study of Teusch et al. 33% of 30 inpatients with schizophrenia being treated with
antipsychotics reported erection disturbance versus 9% in healthy controls (Teusch
et al. 1995). Hummer et al. did not find significant differences in patients being
treated with haloperidol versus clozapine, both groups reporting around 25%
erectile dysfunctions (Hummer et al. 1999). Smith et al. found that men using
antipsychotics were 3.73 times more likely to complain about erectile dysfunction
than controls. Anticholinergic side effects and medication correlated with erectile
dysfunction (Smith et al. 2002).
The scant literature available suggests that erectile dysfunctions might be related
to schizophrenia as well as to antipsychotic medication. Dopamine and prolactin
are closely intertwined through feedback mechanisms. Apart from prolactin,
dopaminergic mechanisms are probably involved in all stages of sexual
performance, so dopamine may well be involved directly and indirectly in
influencing erection.  Which, in turn, might explain why apomorphine (a dopamine
agonist) is effective in treatment of erectile dysfunction (Uitti et al. 1989).
Summary: Erectile dysfunction or impotence has been reported to be related to the
use of antipsychotics. The incidence may be 20 to 30% of the patients. Dopamine




Priapism is a protracted and often painful erection of the penis (Compton and
Miller 2001). On the whole, priapism induced by antipsychotics seems to be a rare
but serious complication, especially as many different antipsychotics may be at
play here, those with strong α2-antagonistic properties apparently heading the list
(Compton and Miller 2001). 
How priapism results from the treatment of antipsychotics remains unclear. One
suggestion is through a lack of balance between noradrenergic and cholinergic
effects, whose final effects on erection may then turn into priapism (Patel et al.
1996; Compton and Miller 2001; Thompson et al. 1990). Priapism, of course, also
has numerous alternative etiologies. Obviously, the onset can be sexual
stimulation, but the condition itself persists long after sexual excitement has
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subsided. If untreated, impotence is a common sequela. In other words, it ought to
be viewed as a medical emergency requiring immediate attention. Urological
consultation and, sometimes, surgical intervention may prove necessary.
Findings in clinical studies
Priapism is a rarely occurring effect of antipsychotics initially observed with
thioridazine and chlorpromazine (Goff and Shader 1995; Mitchell and Popkin
1982). Priapism related to the treatment with antipsychotics has shown up only in
case reports, which relate priapism to many different antipsychotics, such as
risperidone (Emes and Millson 1994; Raja 1999), haloperidol (Morera et al 1988),
clozapine (Bongale et al. 2001; Thompson Jr et al. 1990; Seftel et al. 1992;
Moinfar et al. 1994), quetiapine (Pais and Ayvazian 2001) and olanzapine
(Kuperman et al. 2001; Deirmenjian et al. 1998; Gordon and de Groot 1999).
However, in most case reports in the literature it is chlorpromazine and
thioridazine  that come to the fore (Compton and Miller 2001). I should add that
besides the references mentioned, no other detailed or comparative studies
appear to be available on priapism related to the treatment with antipsychotics. 
Summary: Priapism is a medical emergency, occasionally reported in case studies
as being induced by antipsychotics. The incidence of antipsychotic-induced
priapism is unknown. Priapism is a potentially destructive side effect and should
be treated as soon as possible. 
Vaginal lubrication
Physiology
Vaginal lubrication is the excretion of a lubrifying fluid by the vaginal wall that
facilitates penetration of the penis during sexual intercourse, and is one of the
physiological responses in women associated with sexual arousal. 
It is unclear which neurotransmitters are involved in arterial smooth muscle
dilatation and lubrication. Animal studies suggest that adrenergic nerves induce
contraction and α-adrenergic receptors mediate contraction in both clitoral
cavernosal and vaginal tissue (Meston and Frohlich 2000). Vasoactine Intestinal
Peptide (VIP) may play an important role in the relaxation of vaginal tissue (Levin
1992).
Pathophysiology
Lubrication has hardly been studied in patients treated with antipsychotics. No
pathophysiological considerations were found in the literature, scanned for this
research, other than the suggestions that lubrication disturbance (dry vagina) may
well be an equivalent of impotence in men, having the same causes including




Although vaginal lubrication in women may be viewed as a physiological
equivalent of erection, it has hardly been studied in relation to schizophrenia or
antipsychotic medication. Lubrication can be evaluated indirectly by measuring
vaginal bloodflow using for instance photopletysmography, or by indirect
measures of heat dissipation and Doppler techniques. As they  require insertion by
a tampon shaped device into the vagina, these instruments are to intrusive to be
used in routine clinical practice or clinical research (Meston and Frohlich 2000).
Only in some surveys patients indicated that psychotrophic medication had an
impairing impact on lubrication (Miller 1997).  Traditional questionnaires evaluating
side effects of medications developed before 1999 almost never contain items
evaluating lubrication during sexual arousal or other possible side effects that
might be especially relevant for women, such as painful sexual intercourse. An
exception is the UKU that has one item for vaginal lubrication (vaginal dryness)
(Lingjaerde et al. 1987). Only recently have questionnaires become available that
include specific items for women like the Dickson Glazer Scale of Sexual Function
(DGSF) (Dickson et al. 2001) or the Antipsychotics and Sexual Functioning
Questionnaire (ASFQ) (Knegtering and Castelein 2001).  
To our knowledge, besides the validation-studies of the UKU, only one other study
included lubrication as an item. This study, by Teusch et al., compared sexual
dysfunctions in patients with schizophrenia (n=45), opiate addiction (n=37),
neurotic patients (n=50) and normal controls (n=41). Although only 15 women with
schizophrenia were included, a group too small to reach statistical significant
results, 33.3 % of them reported reduced lubrication versus 10% of the control
group (Teusch et al. 1995). In the UKU studies, 9% of the patients using
antipsychotics reported dryness of the vagina, with the highest frequency after 6 to
12 months of treatment. Nevertheless, lubrication did not show a clear relation to
duration of treatment (Lingjaerde et al. 1987). 
Summary: although physiologically comparable to erection in men, vaginal
lubrication has hardly been studied in relation to the use of antipsychotics. What
we have, primarily, are some hints in the literature that antipsychotics may
diminish lubrication in about 8-10% of the patients. 
Orgasm
Physiology
Orgasm is characterized by a peak in sexual pleasure accompanied by rhythmic
contractions of the genital and reproductive organs, cardiovascular and respiratory
changes and a release of sexual tension (Meston and Frohlich 2000). As
discussed earlier, dopaminergic systems are involved in attention, motivation, as
well as initiation of behavior and reward (Feldman et al. 1997). As a consequence,
dopamine is thought to be involved in all stages of sexual functioning including
experiencing orgasm (Giuliano and Allard 2001).
To what extent central neurophysiological events are related to the intensity or
experience of orgasm is unknown (Meston and Frohlich 2000). While orgasm is
generally the result of both genital and psychological stimulation, evidence
Schizophrenia, sexual functioning and antipsychotic treatment, a review
17
suggests that central stimulation alone may trigger orgasm (Levin 1992; Schiavi
and Segraves 1995). 
Pathophysiology
As dopaminergic systems are heavily involved in experiencing rewards, including
orgasm, the dopaminergic blockade of antipsychotics is most probably the reason
for inhibiting orgasm or decreasing the quality of a persons orgasmic experience.
But not all antipsychotics show the anti-dopaminergic activity in the same intensity.
For instance, quetiapine and clozapine only temporary block the dopamine system,
unlike many classical antipsychotics which bind more firmly to the dopamine
receptors (Kapur and Seeman 2001; Kapur et al. 2001). This suggests that
antipsychotics may differ in inducing sexual side effects, including orgasm.
Unfortunately, not only are comparative studies rare, they are also often
contradictory and thus inconclusive. 
Clinical studies
In studies evaluating sexual dysfunctions, orgasm is evaluated as an individual
item in questionnaires. Most studies assess the agree to which the patient
indicates he or she is capable of experiencing an orgasm (Teusch et al. 1995). In
the study of Teusch et al. 53,5% of the men and 26,7% of the women treated with
antipsychotics reported difficulties in achieving an orgasm, versus 9,1% of the male
controls and 10,5% of the female controls.
In the study of Lingjaerde et al. 19% of women and 16% of men reported orgasmic
dysfunction, it was recorded as probably drug induced in one third of those
affected. Some studies also noted a disturbance in the quality of the orgasm. In
some case-reports, patients using thioridazine mentioned a change in the quality
of their orgasm (Haider 1966; Kotin et al. 1976; Ying 2002) . In the study of
Ghadarian 58% of the male patients reported a decrease in ability and change in
quality of orgasms related to the antipsychotic medication they used. In female
patients 22% reported a decrease in the ability to experience an orgasm while
33% reported a change in quality (Ghadirian et al. 1982a).  
In the study of Aizenberg patients using clozapine reported the quality of their
orgasm had improved, unlike patients using classical antipsychotics (Aizenberg et
al. 2001).
Summary: treatment with classical antipsychotics, and possibly to a lesser degree
clozapine, have been associated with anorgasmia or an alteration in the quality of
orgasm in 16 to about 50% of the patients. Central dopaminergic blockade is




Ejaculation is the emission of semen during orgasm in men. Ejaculation
disturbances consist of a change in consistence or volume of the ejaculate. Most
commonly reported in patients treated with antipsychotics is a decreased
ejaculatory volume (DEV). Terms in the literature related to DEV are aspermia or
retrograde ejaculation. Shader states that retrograde ejaculation and aspermia or
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often used wrongly as synonyms (Shader and Elkins 1980). Aspermia can be
defined as the absence of ejaculate in the presence of erection, muscular
ejaculation and orgasm (Girgis 1968).  Retrograde ejaculation refers to ejaculate
being released into the bladder during orgasm as can be shown by analyzing the
urine for the presence of semen after orgasm. Aspermia does not always imply
retrograde ejaculation. 
The emission state of orgasm is thought to be under thoracolumbar control.
Seminal fluid is propelled into the bulbar urethra via the release of norepinephrine
that acts on α-adrenergic receptor and controls smooth muscles of the vas
efferens, prostate and seminal vessels.  During the ejaculatory phase, which is
mediated by a sacral spinal reflex, semen is released through the urethra via
constrictions of the striated muscles that surround the bulbar urethra (Schiavi and
Segraves 1995). 
Pathophysiology
The mechanism of a reduction in ejaculation volume during treatment with
antipsychotics is as yet not precisely known. Various antipsychotics with α1-
antagonistic properties are presumed to alter the sympatic tonus of the bladder or
urethral sphincter, allowing semen to pass retrogradely into the bladder during
ejaculation (Shiloh et al. 1999). The diminished semen volume during orgasm in
patients using thioridazine might be caused by retrograde ejaculation (Pollack et
al. 1992). Still, such explanations do not cover all observations. For instance, dry
ejaculation in patients using sertindole, an antipsychotic having α1-adrenergic
antagonistic properties, has been observed frequently, but this probably does not
involve retrograde ejaculation as no semen could be detected in the urine after
orgasm (Kammen van et al. 1996). Shader expresses doubts as to the
mechanisms involved in DEV, showing that indeed many antipsychotics with α-
antagonistic are associated with DEV, but that this side effect often does not seem
to correlate with other signs of α-antagonistic side effects (Girgis 1968; Shader
and Elkins 1980).  
An alternative mechanism has been suggested involving calcium channels on the
vas deferens. Contractions of the vas deferens are known to be affected in vitro by
calcium channel antagonists. Some antipsychotics show dose dependent calcium-
blocking features. Chlorpromazine and thioridazine are calcium blockers, so this
may contribute to DEV (Gould et al. 1984). 
Clinical studies
Some patients treated with antipsychotics report the complete absence of
ejaculate (dry ejaculation) during an orgasm. DEV and dry ejaculation are
reportedly related to the use of several antipsychotics like thioridazine,
chlorpromazine or sertindole (Girgis 1968; Shader and Elkins 1980; Patel et al.
1996). 
Kotin reported retrograde ejaculation in 49% of the patients (n=57) using
thioridazine, but in none of the patients treated with other antipsychotics (n=64)
(Kotin et al. 1976; Schiavi and Segraves 1995).
Ghadirian reported a decreased quantity of ejaculate in 46% of the patients, the
vast majority using fluphenazine (n=55) (Ghadirian et al. 1982a; Schiavi and
Segraves 1995). Lingjaerde et al. using the UKU found that 19% of patients
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treated with antipsychotics indicated ejaculation dysfunction (Lingjaerde et al.
1987; Schiavi and Segraves 1995). This finding seems to be in line with the study
of Hummer also using the UKU. Where Hummer et al. 20% of the patients treated
with haloperidol and 23 % of the patients treated with clozapine indicated
ejaculatory dysfunction (Hummer et al. 1999). According to the study of Lingjaerde
et al. ejaculatory dysfunction occurred more frequently in patients using high
dosages of antipsychotics (26%) versus patients using low dosages (11%)
(Lingjaerde et al. 1987). In this study the duration of treatment with antipsychotics
up to 10 years did not influence the frequency of ejaculatory dysfunction. 
In the registration studies of the antipsychotic sertindole, about 20% of the patients
treated with sertindole reported DEV versus 8% of patients treated with
haloperidol. DEV in patients using sertindole was not associated with an increase
in other sexual dysfunctions nor with prolactin elevation (Kammen van et al. 1996).
In the study of Smith and coworkers patients using antipsychotics were 16.4 time
more likely to complain of DEV than controls. Anti-adrenergic (noradrenergic) side
effects were associated with abnormal ejaculation (Smith et al. 2002).
Summary: decreased ejaculatory volume (DEV) is frequently (8-40%) reported in
patients treated with antipsychotics. Although the mechanisms are not completely
known, antipsychotics with α-blocking properties and possibly also calcium
channel blockers are thought to be most likely to induce DEV.
Other aspects of sexual functioning
Apart from the more or less detailed aspects of sexual functioning discussed
above, some studies have tried to evaluate the subjective judgment of the patients
about the overall quality of their sexual experience. Aizenberg included such items
in his questionnaire as ‘enjoyment of sex’ and ‘sexual satisfaction’ (Aizenberg et
al. 2001). As mentioned in the section on orgasm the study of Ghadarian et al.
include one item about change in the quality of orgasm (Ghadirian et al. 1982a).
Aizenberg found that ‘enjoyment with sex’ and ‘sexual satisfaction’ was
significantly higher in patients treated with clozapine than in those treated with
classical antipsychotics (Aizenberg et al. 2001) 
Some studies mention pain during orgasms. For instance, in the study of
Ghadirian 2 out of 27 female patients experienced mild pain during orgasm
(Ghadirian et al. 1982a). Berger reported painful ejaculation, also called
ordynogasmia, being a possible consequence of treatment with haloperidol or
trifluoperazine (Berger 1979; Donnellan et al. 2001). But on the whole pain during
orgasm as item is absent in most studies and the patho-physiological mechanisms
in relation to treatment with antipsychotics remains unclear. 
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Menstruation disturbance, galactorrhoea and gynecomastia
Although menstruation disturbances, gynecomastia and galactorrhea are not by
themselves sexual dysfunctions, they do tend to coincide with some of the sexual
dysfunctions since, at least partly, they originate from the same source: high serum
prolactin levels. The focus of this study is, of course, on sexual side effects, but as
in following chapters these subjects are discussed here briefly so as to have
covered all possible aspects.
Definitions   
Menstruation disturbance can be divided into menorrhagia and amenorrhea.
Menorrhagia (hypermenorrhea) is defined as a excessively prolonged or profuse
menstruation. Amenorrhea is the absence or abnormal cessation of the menses.
Amenorrhea is mostly defined as a cessation of the menses for at least half a year.
In case of cessation of the menses for shorter periods one speaks mostly of a
“missed period”. Galactorrhea is a flow of milk from the breasts other than from
normal lactation. Sometimes this flow is spontaneous, sometimes it only shows
when squeezing the nipples. Gynecomastia is the excessive development of the
mammary glands. 
In discussing the physiology of menstruation and lactation we will restrict our scope
to information that is directly relevant in the context of treatment with
antipsychotics. Before pregnancy prolactin levels are more or less stable, showing
some daily and seasonal variation (see next chapter). Prolactin levels rise during
pregnancy, peaking till shortly after labor (Barbieri 1999). As estrogen and prolactin
prepare them for lactation, the breasts enlarge mainly due to ductal proliferation
with periductal oedema.
Having risen further immediately after childbirth, prolactin levels stay high during
the first few months. During this period prolactin levels peak further shortly after the
initiating of each breastfeeding, returning to prior levels about two hours later. After
several months, even with continued breastfeeding, prolactin levels will come down
to the values they had before pregnancy. Breastfeeding in this period can continue
without elevated prolactin levels. 
During the rise of prolactin after childbirth, amenorrhea continues and is thought to
be related to the elevated prolactin levels. Suckling itself can inhibit the release of
gonadotrophin releasing hormone (GnRH) through many different systems,
reinforcing to amenorrhoea. Generally, several months after childbirth and after
prolactin levels have normalized, the monthly GnRH, LH and FSH cycle, estrogen
and progesterone cycle will return resulting in the resumption of the menstruation
cycle. For the majority of cases the menstruation cycle will have resumed within 6
months after delivery.  
Pathophysiology
Serum prolactin elevation is probably an important factor not only in causing
sexual side effects but also in inducing galactorrhea and gynecomastia (Halbreich
et al. 1995; Maguire 2002). Prolactin elevation may also influence the menstrual
cycle in patients with schizophrenia, though this may not be the only cause
(Canuso et al. 2002).
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In response to elevation of prolactin above a certain threshold, LH, estrogen and
progesteron will lower and stop showing a cycling plasma level pattern through the
month, corresponding with amenorrhoea (Oseko et al. 1988).
Elevation of prolactin levels by itself, but even more so in collaboration with
estrogen, provokes ductal growth in the breasts: gynecomastia (Barbieri 1999).
This is often followed by the production of milk. As prolactin levels during
treatment with antipsychotics are not as high as shortly after childbirth, there is
often only minimal milk production. The latter often shows only after squeezing the
breaths or nipples but sometimes also appears spontaneously.  
Although only a few studies are known, switching from a prolactin elevating
antipsychotic to a prolactin sparing antipsychotic or lowering serum prolactin levels
by co-administering a dopamine agonist, will in most cases correct these side
effects (Matsuoka et al. 1986; Gazzola and Opler 1998; Kim et al. 2002).
Clinical studies
Classical antipsychotics frequently increase serum prolactin levels (Dickson and
Glazer 1999). Increased prolactin levels are associated with amenorrhea,
galactorrhea and sexual dysfunctions (Windgassen et al. 1996). Some new
(atypical) antipsychotics like clozapine, olanzapine or quetiapine, hardly influence
prolactin levels at all (Crawford et al. 1997; Hamner et al. 1996).  For that reason,
these antipsychotics are sometimes called prolactin sparing antipsychotics. Other
new antipsychotics like risperidone and amisulpride increase prolactin levels
significantly and are denominated prolactin elevating antipsychotics (Grunder et al.
1999; Petty 1999b).
Systematic studies on amenorrhea, gynecomastia, and galactorrhea induced by
antipsychotics are scarce. Most information that is available consists of case
reports suggesting that antipsychotics which induce prolactin elevation indeed
may lead to amenorrhoea, gynecomastia and galactorrhoea (Gingell et al. 1993;
Kim et al. 1999). From these studies it is unclear how these possibly antipsychotic
induced side effects behave over time. The only systematic, and also most
informative, study is that of Lingjaerde (1987).  In this study in patients treated with
(prolactin elevating) classical antipsychotics, menorrhagia, amenorrhoea,
galactorrhoea and gynecomastia were rated. Menorrhagia was reported in 13%
and amenorrhea in 22% of the women. Galactorrhea was reported in 5% of the
women and in 3% of men. Gynecomastia was reported in 3% of the women and in
6% of the men. These symptoms were seldom considered by the patients
themselves to be drug related. Menstruation disorders and gynecomastia showed
in the age category below 60 little relation to age. At the same time, menstruation
disorders, galactorrhea and gynecomastia showed an uncertain relation to
treatment duration, although galactorrhea had a vague peak between 3 and 6
months of treatment.
Not all data point in the same direction. Canuso et al. compared the menstruation
in 8 patients treated with prolactin elevating classical antipsychotics or risperidone
and 8 patients treated with prolactin sparing olanzapine or clozapine. After weekly
blood sampling, 6 patients turned out to have Hyperprolactinemia. No difference
was found in rates of menstrual dysfunction or ovarian hormones (estradiol,
progesterone) between patients with or without prolactin elevation. Irrespective of
medication type or prolactin status, most subjects had peak estradiol levels below
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normal reference values for the preovulatory phase of the menstrual cycle. The
authors conclude that antipsychotic induced Hyperprolactinemia alone may not
adequately explain the observed ovarian dysfunction in women with schizophrenia
Summary: treatment with antipsychotics inducing significant prolactin elevation
may be associated with amenorrhea, gynecomastia and galactorrhea. There is not
enough information to estimate the incidence during short and long-term treatment
with antipsychotics. The limited literature that is available suggests that lowering of
prolactin levels with a dopamine agonist or by switching to a prolactin sparing
antipsychotic will often be successful in treating these side effects. 
Conclusions and clinical implications
There are only few studies, each with its own methodological limitations that deal
with sexual dysfunctions related to psychotic illnesses and treatment with
antipsychotics. As randomized comparative trials with validated evaluating
instruments are absent so to date only tentative conclusions are justified.
Studies using semi-structured questionnaires evaluating sexual dysfunctions
suggest that libido reduction is often reported in patients with schizophrenia, but
even more so in patients being treated with antipsychotics. Treatment with
antipsychotics might induce several sexual dysfunctions, amenorrhoea and
galactorrhoea. Most of these side effects are unlikely to subside during prolonged
treatment. Although comparative controlled studies are lacking, it can be
hypothesized that antipsychotics differ in their propensity to induce these effects.
Factors probably involved in inducing sexual side effects are dopamine blockade
and, linked to this, prolactin elevation. Serotonin, histamine or noradrenalin
blockade might also be of importance as well as sedative properties of
antipsychotics. Prolactin elevation might also induce other side effects like
galactorrhea and amenorrhea.  
Notwithstanding the absence of good clinical evidence, some clinical conclusions
are justified. Doctors and patients seem to be reluctant to discuss these issues
despite their high relevance in the motivation of patients to continue the
medication. In this respect, educating physicians, providing tools (questionnaires)
and encouraging them to discuss sexual side effects appears highly important.
Dose reduction should be tried as a first step to reduce these side effects. An
alternative strategy may be switching to another antipsychotic. Although hardly
investigated, a prolactin sparing antipsychotic, in theory, may induce less sexual
side effects and less amenorrhoea and galactorrhoea. In other words, switching
from a prolactin elevating antipsychotic to a prolactin sparing antipsychotic may be
advisable as a treatment option (Bunker et al. 1997; Gazzola and Opler 1998; Kim
et al. 2002). An alternative can be adding a prolactin agonist like amantadine or
bromocripitine to antipsychotic treatment with a prolactin elevating antipsychotic
(Matsuoka et al. 1986; Correa et al. 1987; Smith, S. 1992). Although some authors
feel that treatment with amantadine or bromocriptine may be a safe treatment
alternative, others warn for a possible increase of psychotic symptoms (Rego and
Giller Jr. 1989).
Given the virtual absence of comparative studies about sexual dysfunctions in
patients being treated with antipsychotics, there is a clear and urgent need for
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research.  Data of new studies should provide significant novel information to help
improve evidence based clinical guidance as well as enhance our understanding of
sexual pathophysiology.
Table 3. Main studies on antipsychotics and sexual side effects 
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Summary
Classical antipsychotic drugs increase the level of serum prolactin. The atypical
antipsychotic clozapine barely increases prolactin levels. An open naturalistic
study at the University Hospital of Groningen suggests that treatment with
risperidone in comparison to classical antipsychotics seems to increase the risk of
erectile and ejaculatory disorders in male patients and to menstrual disturbances
in female patients. In the literature reviewed, risperidone is associated with higher
prolactin levels in comparison to classical antipsychotics. It is still unclear which
mechanism is responsible for the increase of serum prolactin levels and sexual
dysfunctions in patients using risperidone. Dopaminergic and serotonergic





On the basis of a recent study in the Groningen University Hospital involving 95
patients who use antipsychotic drugs, it was found that 10% of the patients report
spontaneous sexual dysfunctions. However, 55% of the patients are found to
experience sexual function disorders, which they relate to the use of antipsychotic
drugs, for a specifically directed anamnesis by means of a semi-structured interview
or questionnaire (Knegtering et al. 1998). In many patients, prolactin levels are
found to increase strongly via antipsychotic drug usage, and this is correlated with
sexual function disorders, such as loss of libido and erection disorders. In our study,
the antipsychotic drug risperidone, which is frequently indicated as being atypical, is
found to cause sexual function disorders significantly more frequently (67%) than
classical antipsychotic drugs (50%), and is found to cause higher prolactin levels as
well (Knegtering et al. 2000). This was an unexpected finding, especially since the
atypical antipsychotic drug clozapine allegedly causes fewer sexual function
disorders, and hardly increases the prolactin levels at all. 
We decided to carry out a survey of the literature regarding what is known about
sexual function disorders and prolactin elevation when using classical antipsychotic
drugs and risperidone. In addition, a literature survey was carried out regarding
possible mechanisms for prolactin elevation and its relationship to sexual function
disorders.
Method
For this literature study, a literature search was done starting from 1980, with the
help of Medline and Index Medicus. The keywords were risperidone, schizophrenia,
neuroleptics, adverse effects, side effects, prolactin, Hyperprolactinemia,
endocrinological effects, neuroendocrine, serotonin, 5-HT2, dopamine D2,
galactorrhea, sexual dysfunction, gender differences.
Within the context of this article, we understand sexual dysfunctions to mean loss of
libido, erection disorders, orgasm disorders, ejaculatory disorders, galactorrhea and
menstrual disorders.
Results
Risperidone, Classical Antipsychotic Drugs, Prolactin level, and Sexual Functioning 
Table 2.1 reports all the (uncontrolled) studies that were found in which the
relationship between the use of risperidone and prolactin concentrations and/or
sexual dysfunctions is examined. In the studies by Gelders, Van den Bussche,
Mesotten and Bersani, a distinct and enduring  increase in prolactin levels is found
to occur during the use if risperidone (Bersani et al. 1990; Bussche van den et al.
1988; Mesotten et al. 1989). From the studies by Huang et al., the increase in
prolactin in people who use risperidone is found to be almost two times higher than
when using haloperidol (Huang et al. 1993). Sexual dysfunctions were reported in
only one of these publications. In a group of five women, Dickson found amenorrhea
in all of these persons and, in addition, galactorrhea in three of them, whereby this
is related to the use of risperidone (Dickson et al. 1995). In addition, this study found
that prolactin levels returned to their original level after stopping risperidone.
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Table 2.1. Non-comparative studies on risperidone, prolactin concentrations, and sexual
dysfunctions






6 healthy men: 0.5 and 1
mg risperidone on a single
occasion
Increased with a peak after 1
hour. Mean: 0.5 mg: 49.1






et al.  1988
15 schizophrenic patients:
risperidone in increasing
dose levels up to 25
mg/day. Duration: 4 weeks
Increasing 7x after 1st
administration. Increase







17 psychotic patients :
risperidone dose levels up




remained until the end of the
experiment. Men: from 4.5 to
36.7 µg/L (day 29).








dose levels up to 6 mg/day.
Durations: 4 weeks
Determined in 12 patients:
mean increase from 15.6






12 healthy men: 1 mg
risperidone intravenously,








with risperidone: dose and
duration not reported; 1
patient used damazal (sic;
possibly danazol)
Increased to a mean value of
124 µg/L. Decrease to a mean







in 3/5 women after
stopping risperidone
Peuskens found more erection disorders and ejaculatory disorders during treatment
with 12 mg risperidone in comparison to 10 mg haloperidol. Marder and Meibach
reported a higher frequency of dysmenorrhea and vaginitis (10 and 16 mg
risperidone per day compared to 20 mg haloperidol). In an open study involving
people who were using risperidone (median dose 3.2 mg/day; n = 28), Knegtering et
al. found 78% sexual function disorders versus 46% among patients who were
using classical antipsychotic drugs (median dose: 6.0 mg haloperidol
equivalents/day; n = 27) (Knegtering et al. 1998). Prolactin concentrations were
significantly higher in people who were using risperidone (median: 1235 mU/L)
compared to patients who were using classical antipsychotic drugs (median: 638
mU/L); the highest prolactin levels were found in women. In a regression analysis 
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Table 2.2. Comparative studies on risperidone versus classical antipsychotics in relation to




Double-blind study: 12mg/day risperidone (18 schizophrenic patients)




Double-blind study, schizophrenic patients:placebo (66 patients) versus
20 mg/day of haloperidol (66 patients), versus 2,6,10 and 16 mg/day
risperidone (63,64,65 and 64 patients respectively)
Peuskens
1995
Double-blind study, schizophrenic patients: 
 1 mg/day risperidone (229 patients)
vs 4 mg/day risperidone (227 patients)
vs 8 mg/day risperidone (230 patients)
vs 12mg/day risperidone (226 patients)
vs 16mg/day risperidone (224 patients)




Open study, 55 patients with functional psychosis after 6 weeks of
antipsychotic drug usage. 28 patients, median dose 3.2 mg risperidone
versus 27 patients, median dose 6.0 haloperidol-equivalent classical
antipsychotic drugs. Study with semistructured questionnaire
* Risp. = risperidone, Halo = haloperidol
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“No abnormal laboratory results that are clinically significant” ¼ dysmenorrhea if using 10 mg/day risperidone.






























Not reported in absolute values. However, mention 
is made of an increase, which is proportional to the 
dose, when using risperidone. No concluding 
statement made regarding prolactin level in the 
case of treatment with Haldol
Percentages relate to the increase in symptoms
relative to the baseline
Median prolactin level in the risperidone group: 
40.7 µg/L; significantly higher than the group using 
classical antipsychotic drugs with a median level of 
22.4 µg/L
78% of patients using risperidone and 46% of
patients using classical antipsychotic drugs report
sexual function disorders. Significantly more
sexual function disorders, namely erection
disorders and orgasm disorders, for men in the
risperidone group versus men in the classical
group
Table 2.2 contains all the controlled studies which deal with increased prolactin concentrations and/or the
occurrence of sexual function disorders. Marder and Meibach do not make any numerically substantiated
concluding statements regarding effects on prolactin concentrations (Marder and Meibach 1994).
Peuskens found a dose-related increase in prolactin that was related to risperidone and haloperidol, but
he makes no comparative statements (Peusken et al. 1998). Claus et al. found a significantly larger
increase in prolactin concentrations after six weeks in men who were treated with risperidone, compared
to a group that was treated with haloperidol (Claus et al. 1992).
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of the data for the men from this study (n=37), the prolactin level explained one third
of the sexual function disorders (R2 =0.30, p=0.001), especially erection disorders
(R2=0.15, p=0.02) (Knegtering et al. 1998).
Summarizing: little research has been carried out regarding the frequency of sexual
function disorders when using risperidone in comparison to classical antipsychotic
drugs. The studies reported here exhibit methodological shortcomings that prevent
unambiguous concluding statements being made. In clinically used dosages,
risperidone probably causes higher prolactin levels than is the case with haloperidol
or other classical antipsychotic drugs. In comparison to classical antipsychotic
drugs, moreover, risperidone appears to cause more sexual function disorders,
such as loss of libido, orgasm disorders, erection disorders and, possibly, menstrual
disorders as well. In light of the fact that this profile of side effects deviates from that
for the prototype of an atypical antipsychotic drug, clozapine, a discussion follows
below regarding possible mechanisms for prolactin increase when using
antipsychotic drugs, and the relationship between increased prolactin and sexual
function disorders.
Possible effects of increased prolactin on sexual function disorders
Prolactin elevation above physiological values leads to loss of libido and orgasm
disorders, whereby this is more so in men than in women. Schwarz et al. refer to
studies from which it is found that up to 90% of male patients with
Hyperprolactinemia – mostly within the context of a hypophysis adenoma –
complain to some extent of sexual dysfunction, and especially of erection disorders
(Schwartz et al. 1982). Gynecomastia is seen incidentally in men. Amenorrhea and
galactorrhea occur particularly in the case of women with Hyperprolactinemia
(Pollack et al. 1992). Improvement occurred in all cases after treating the
Hyperprolactinemia. It is unclear why an increase in prolactin leads to sexual
function disorders. An explanation could be that Hyperprolactinemia leads to
hypogonadotrophy and a reduction in the plasma concentrations of testosterone
and estrogens. However, sexual function disorders remained for men in whom the
reduced testosterone concentrations had been corrected. Moreover, it is found that
nocturnal erections are not influenced by Hyperprolactinemia, but sexual cognitions,
such as the capacity to have sexual fantasies, are affected in this way in particular
(Carani et al. 1996). Other mechanisms that are suggested are a reduction of
luteinizing (hormone)-releasing hormone (LH-RH) levels and a direct effect on the
hypothalamus (Hermanns and Hafez 1981). However, none of these theories is
well-substantiated.
Mechanisms for the regulation of prolactin secretion
Role of the dopaminergic system on prolactin secretion
Prolactin is a polypeptide hormone that derives from the adenohypophysis. Prolactin
plays an important role in the induction of lactation, in reproduction and in
osmoregulation. Dopamine, synthesized by tubero-infundibular neurons, is released
to the portal hypophysal circulation. Upon arrival in the adenohypophysis, dopamine
is designed “Prolactin Inhibiting Factor” (PIF) (Tuomisto et al. 1985). Blockade of D2
receptors in the tubero-infundibular system by classical antipsychotic drugs causes
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the disappearance of the inhibiting action of dopamine on prolactin secretion, and
this leads to Hyperprolactinemia as a consequence (Gitlin 1994; Green and Brown
1988). The influences of dopamine, serotonin and hormones are summarized in
figure 2.1.
Role of the serotonergic system on prolactin secretion 
The role of the serotonergic system on prolactin secretion is complex. Serotonin
(5-hydroxytryptamine, 5-HT) has a stimulating action on prolactin secretion,
probably via an inhibiting effect on the secretion of dopamine in the portal system
(Saller et al. 1990). Blockade of 5-HT receptors causes a decrease in prolactin
secretion. Thus, for example, ketanserin (a 5-HT2a antagonist) blocks the
pregnancy-induced increase in prolactin in rats. In humans, serum prolactin can be
increased with D-fenfluramine; this substance increases the release of serotonin
and blocks its re-uptake). A serum prolactin increase that is caused by D-
flenfuramine can be blocked by 5-HT2a/2c receptor blockade, e.g. with ritanserin or
amesergide (Coccaro et al. 1996).
Microinfusions of serotonin in the mediobasal hypothalamus of rats increase
prolactin levels, whereby this is an effect that can be blocked by metergoline, a 5-
HT1a antagonist (Mulroney et al. 1994).
Manipulation of the nipple leads to an increase in prolactin secretion via the so-
called nipple reflex, whereby this is a process that is partially mediated by
serotenergic mechanisms, and it can be blocked by 5-HT1a and, inter alia, other
serotonin antagonist (Kar van de  et al. 1996). Prolactin is then released in a
“pulsating” manner in accordance with a circadian rhythm, i.e. with higher levels in
the afternoon and during sleep. This frequency is regulated in part by 5-HT3 en 5-
HT1 receptor –mediated mechanisms (Thorner et al. 1998; Ulrich et al. 1994).
Other systems for regulating prolactin secretion
Three “releasing factors” promote prolactin secretion: thyreoid releasing hormones
(TRH), vaso-intestal peptide (VIP), and PHM-27, a peptide that is structurally similar
to VIP. It is not known which factor had the greatest physiological effect (Reichlin
1992). Estrogens increase the number of prolactin-secreting cells in the
hypothalamus. In addition, estrogens increase sensitivity to TRH which promotes
prolactin secretion. Estrogens also decrease the number of hypophysial dopamine
receptors. These three mechanisms all lead to an increase in prolactin secretion.
The physiologically higher level of prolactin in women, in comparison to men, are
possibly ascribable, in part, to effect by estrogens.
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 Figure 2.1. The regulation of serum prolactin levels
 
Serum prolactin levels may change through many mechanisms. The main mechanisms are
summarized. Dopamine has inhibiting effects on lactotroph cells of the anterior pituitary through the
tubero-infundibular pathway. This dopaminergic inhibition of prolactin secretion can be modulated
through several different serotonergic pathways leading to prolactin elevation during nipple
manipulation, pregnancy and early in the morning. Vasoactive intestinal peptide (VIP), thyrotrophin
releasing hormone (TRH) and estrogen also influence prolactin secretion. Higher physiological
prolactin levels in women in comparison to men are thought to be the result of higher estrogen levels
in women. Diminished dopaminergic input may have direct effects impairing sexual performance and
also through prolactin elevation. It is unclear if other hormones play an additional role in diminishing
sexual performance.
Serum prolactin levels and sexual dysfunctions in antipsychotic medication
39
Figure 2.2. The influence of classical antipsychotics on serum prolactin levels and possible
secondary effects of serum prolactin elevation.
 
All classical antipsychotics block, at least to some extend, post synaptic dopamine 2 receptors
(big arrows). Disruption of the dopamine tubero-infundibular neuronal pathway des-inhibits the
dopamine mediated prolactin release in the anterior pituitary. This leads to prolactin elevation
with possible effects on other hormones, sexual functioning, amenorrhea and galactorrhea.
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Figure 2.3. The influence of new antipsychotics on dopaminergic and serotonergic pathways, the
possible consequences for serum prolactin levels and other effects  
 
The new antipsychotics like clozapine, olanzapine quetiapine and risperidone block, at least to
some extend, post synaptic dopamine 2 receptors like classical antipsychotics. Disruption of the
dopamine tubero-infundibular neuronal pathway des-inhibits the dopamine mediated prolactin
release in the anterior pituitary. This leads to prolactin elevation with possible effects on other
hormones, sexual functioning, amenorrhea and galactorrhea.
Serotonin inhibits through dopaminergic pathways the physiological inhibition of prolactin in the
tubero-infundibular pathways. In theory 5HT2a blockade of new antipsychotics could result in
modulation of prolactin elevation induced by the dopamine-blockade. This could in theory correct
prolactin elevation, especially in cases when dopamine blockade is not to strong. This theory
would predict that the final effect of an antipsychotic on serum prolactin levels and sexual
functioning would depend on the balance between dopamine and serotonine blockade.
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Other non-prolactin related mechanisms of sexual function disorders
In addition to prolactin-related sexual function disorders, antipsychotic drugs can
also cause sexual function disorders via other mechanisms. Without going into all
these mechanisms in detail, mention is made here of the most important ones to the
extent that they are of importance in this article. Dopaminergic systems are involved
in experiencing pleasure and sexuality. Blockade of dopamine causes the libido to
decrease, while over-stimulation leads to increased libido and sexual activity in
some cases (Gitlin 1994). An erection is produced via the interaction of the
parasympathetic and sympathetic systems. Stimulation of the sacral
parasympathetic nerves, or blockade of peripheral sympathetic innervation of the
penis, leads to an erection via reduced venous drainage. The erection is terminated
by peripheral sympathetic domination over the parasympathetic influence.
Sympathetic influence takes place, inter-alia, via the α-adrenergic receptors of the
cavernosa. Stimulation of the α(2) -receptors can cause impotence, and blockade
can lead to priapism (Patel et al. 1996) (See also chapter 1).
Treatment with selective serotonin re-uptake inhibitors (Selective Serotonin Re-
uptake Inhibitors: SSRI’s) is frequently associated with sexual dysfunctions, such as
ejaculatory disorders and anorgasmy (Lane 1997). Activation of 5-HT2 receptors
should act in an inhibiting manner on sexual stimulation and activity in men, while
precisely the opposite occurs in the case of women (Wilson 1993). Cyproheptadine,
a 5-HT2 receptor antagonist, is capable of eliminating SSRI-induced sexual
dysfunction in men (Baldwin et al. 1997).
The receptor-binding profile of risperidone
In vitro, risperidone is found to be primarily an antagonist of the serotonergic 5-HT2a
receptors, dopaminergic D2 receptors, adrenergic aplha1 and aplha2 receptors, and
histaminergic H1 receptors. The binding affinity for these receptors is as follows: 5-
HT2a  > alpha1 > H1 > D2 (Grant and Fitton 1994; Leysen et al. 1992). The affinity for
D2  receptors is 20x lower than for 5-HT2a  receptors (Kar van de et al. 1996).
Risperidone binds to serotonergic receptors, particularly to 5-HT2a  receptors. The
affinity for this subtype is 100x higher than for the other 5-HT receptors. Compared
to haloperidol, in vitro binding of risperidone is 170x stronger to 5-HT2a receptors,
and 2-3x weaker to D2 receptors. Compared to clozapine, risperidone in vitro binds
20x more strongly to 5-HT2a receptors and 50x more strongly to D2  receptors
(Tuomisto et al. 1985) . In vivo, risperidone occupies the 5-HT2, D2 and α1 receptors
in particular (Bussche van den et al. 1988) 9-hydroxyrisperidone , the active
metabolite that is formed by risperidone, has a pharmacological profile that
corresponds, in an overall way, to that of risperidone, but it is 4-6x weaker (Leysen
et al. 1994). In a positron emission tomography study (PET) involving three healthy
male test persons, it was found that 60% of the 5-HT2 receptors in the frontal cortex
are occupied, and that 50 % of the D2 receptors in the stratium are occupied after
four hours and also seven hours following the oral administration of 1 mg
risperidone (Nyberg et al. 1993). It can be surmised in this connection that the
degree of occupancy will be greater at therapeutic dosages (usually 4-6 mg/day).
A high degree of D2 receptors occupancy was indeed found in a 123I-IBZM single
photon emission computerized tomography study (SPECT) for one patient who was
diagnosed as being schizophrenic and who was being treated with 12 mg per day
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risperidone, and (the same result was also found) in 123I-IBZM single photon
emission (computerized) tomography studies (SPECT) involving six patients who
were diagnosed as being schizophrenic or schizo-affective and who were being
treated with 4-12 mg per day risperidone (Bursatto et al. 1995; Bursatto and
Pilowsky 1993). D2 blockade of between 75 and 80% was found in a PET study
involving patients who had been using approximately 6 mg risperidone per day for
some time (Farde et al. 1995). The binding of risperidone to D2 receptors in SPECT
and PET studies can be compared to the binding which takes place in patients who
are being treated with classical antipsychotic drugs (70-89%), and is higher than for
treatment with clozapine (38-63%) (Boer den  et al. 1996; Farde et al. 1992).
Discussion
Research into the occurrence of sexual function disorders is complicated by the fact
that little is reported spontaneously in this regard. Direct questions by means of
questionnaires show much higher frequencies of sexual function disorders than is
the case with spontaneous reporting (Riley and Riley 1993). Women are found to be
still less inclined to speak about sexual problems than men (Shen and Sata 1990).
This explains why sexual function disorders are reported only to a small extent in
standard (pre)clinical research, while it is found that sexual function disorders occur
very frequently on the basis of research with (semi)structured interviews or
questionnaires, both for classical antipsychotic drugs and still more with risperidone.
It is found from out own research that, in comparison to the classical antipsychotic
drugs, risperidone causes a more intense increase in prolactin, whereby this is
associated with a significantly more frequent occurrence of erection disorders (50%)
and orgasm disorders (56%) for men (p < 0.05).
Interpretation of the data needs to be considered within the perspective of the fact
that, even without medication, people with schizophrenia possibly have reduced
sexual desire, though without erection disorders and orgasm disorders (Aizenberg
et al. 1995). An interaction between the effect of medication and the symptoms of
schizophrenia possibly plays a role in loss of libido, in particular. It is likely from the
literature, which is designated above, that risperidone causes higher prolactin levels
than classical antipsychotic drugs and clozapine. It is in risperidone probably not a
transient increase in prolactin at the beginning of the treatment, as is the case with
clozapine. From our own observations it is suggestive that prolactin elevation is still
present after many years of treatment. The reason why this is so remains unclear.
In light of the 5-HT2 blocking properties of risperidone, rather, a reduction in
prolactin levels would be expected when using risperidone. PET and SPECT
studies show high striatal D2 receptor blockade for clinically effective dosages of 6
mg risperidone per day, though this is not higher than with classical antipsychotic
drugs in clinically effective dosages. However, striatal D2 receptor occupation by
both classical antipsychotic drugs and by risperidone in clinically effective dosages
is significantly higher than with clozapine. Nevertheless, risperidone – in relatively
low dosages (3.2 mg/day) – causes significantly higher prolactin levels in
comparison to classical antipsychotic drugs. An explanation could be that
risperidone exhibits a higher affinity for D2 receptors in the tubero-infundibular
system. However, no references to this are found in the literature. In our own PET-
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study, this area was found to be inadequately imaged in standard recordings (Boer
den et al. 1996).
The fact that prolactin levels are more elevated in women than in men, if using
classical antipsychotic drugs and risperidone, can be explained by an interaction
with estrogens. The disorders in sexual function that are found in men who use
risperidone (erection disorders and orgasm disorders) may be linked, in part, to an
increase in prolactin; however, a direct effect via D2 blockade, can contribute to
these effects. As was to be expected, risperidone causes menstrual disorders and
galactorrhea in women, it has not been demonstrated that this occurs more
frequently than with classical antipsychotic drugs. Evaluation of menstrual disorders
is impeded by the fact that many women use oral contraceptives, which possibly
can mask menstrual disorders.
More research is necessary attempting to find better explanations for the findings
designated here. Thus it is important to have more information regarding the nature
and frequency of sexual function disorders and prolactin elevations for other new
antipsychotic drugs, such as olanzapine or quetiapine. It is important in this regard
that the same method always be used with the help of standardized questionnaires
and/or semi-structured interviews. Comparative studies are being conducted at the
moment at the University Hospital of Groningen. Regarding clinical practice, it is
important to know that sexual function disorders occur very frequently, that they are
rarely reported spontaneously. Sexual dysfunctions can be a reason for the patient
to stop taking his/her medication. Medication-induced sexual function disorders are
almost always reversible, so that dose reduction, or possibly stopping the
medication for several days, or changing over to another antipsychotic drug, can
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Summary
A literature review was made of questionnaires that evaluate the sexual side effects
of antipsychotics. As none of the questionnaires found was suitable for studying
sexual side effects in patients with schizophrenia, a new questionnaire, the
Antipsychotic and Sexual Functioning Questionnaire (ASFQ) was developed.
Preliminary studies on the validity and reliability of the ASFQ are presented here.
Although the number of patients in these studies is still small, the data suggest that
the ASFQ has an acceptable test-retest validity, modest concurrent validity, and
good sensitivity for therapeutic changes with regard to most important items of
sexual functioning. The ASFQ was chosen as the main instrument in the studies




Six years ago, when we began to study sexual side effects of antipsychotics on
schizophrenic patients, validated instruments (questionnaires or interviews designed
to evaluate sexual dysfunctions) were scarcely available. Reviews about validated
instruments have become available only recently; these still do not provide
information about their suitability for the assessment of sexual functioning in
patients with schizophrenia, or about sensitivity to treatment effects (Derogatis and
Laban 1998;  Meston and Derogatis 2002). 
Most authors reporting on the sexual side effects of antipsychotics have developed
their own instruments, and do not provide information about the reliability or validity
of the scales they use (Teusch et al. 1995; Aizenberg et al. 1995; Aizenberg et al.
2001). In some studies, the validated UKU side effects rating scale has been used
(Hummer et al. 1999; Lingjaerde et al. 1987). The UKU is a semi-structured
questionnaire designed to assess psychological, neurological, autonomic and other
side effects of antipsychotics. The UKU has reliable scorings rules but no
standardized questions. The UKU indicates subjects in a checklist; these subjects
are to be discussed until sufficient information is obtained to score an item
according to the criteria specified. The fact that the UKU does not indicate how the
questions are to be asked leaves a lot of room for interviewer bias.
Burke et al (1994) published a pilot study on a 15-item Sexual Functioning
Questionnaire (SFQ) inquiring about habitual and actual sexual functioning in men
on antipsychotic medication (Burke et al. 1994). Questions could be answered as
true or false. Sexual functioning was rated for the past two years, the past two
weeks, and the present. Patients were asked whether their present medication
changed the frequency of sexual thoughts, frequency of sexual activities, or the
quality of their sexual functioning. In addition, a general question was posed,
whether patients’ present sexual functioning was better or worse than previously.
The authors concluded that in their sample of 20 chronically hospitalized patients
with schizophrenia, patients could respond consistently to simple inquiries about
concrete events such as erections or masturbation, but experienced difficulties in
reporting about sexual thoughts and fantasies, or reporting about overall
impairment. The authors concluded that a repeat study with a larger sample-size
and more rigorous statistical testing was needed.
A recent study by Smith et al. (2002), called the Sexual Functioning Questionnaire,
presents 38 questions. This questionnaire is a modified version of Burke’s SPQ;
Smith’s study will here be referred to as SPQ-S. The SPQ-S contains sub-scales for
different areas of sexual functioning; items for women were also added. The
questions can be answered true or false, and the time frame is the past month.
Some information is available about the reliability of this instrument (Cronbach’s α =
0.90, Guttman’s split half reliability = 0.86); no information is available about the
reliability of the SPQ-S. Both questionnaires, the SPQ and the SPQ-S, lack scoring
possibilities for improvement on individual items of sexual functioning.
The lack of validated or standardized instruments makes it difficult to give a good
interpretation or to compare the results of studies evaluating sexual dysfunctions in
patients being treated with antipsychotics. This may partly explain why the results
between studies vary a great deal. In most pre-marketing registration studies of
antipsychotics, assessment of side effects is restricted to specific areas such as
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extra-pyramidal side effects and acathisia, while other side effects are mainly
assessed by spontaneous reports. Side effects are reported in studies using
spontaneous reports, clinical interviews using questionnaires, or self-rating versions
of the same questionnaires, the latter source identifying the most side effects
(Lindstrom et al. 2001). As both patients and clinicians are often reluctant to discuss
sexual side effects, these side effects are seldom found in general studies, whereas
high frequencies are found in studies specially designed to measure sexual side
effects (Knegtering et al. 2003; Peuskens et al. 1998). 
When we started studies on sexual side effects of antipsychotics at the University of
Groningen, we needed an instrument to assess the different phases of sexual
activity: libido, arousal (erection, lubrication), orgasm and ejaculation. The
instrument had to be easy to apply to clinical practice, reliable, able to detect sexual
dysfunctions and changes in sexual performance, and suitable for patients with mild
cognitive or psychotic symptoms.
We tried a Dutch translation of the Clayton Sexual Functioning Questionnaire
(CSFQ), originally a pencil and paper questionnaire (Clayton et al. 1997). The
CSFQ turned out to be too complicated for many patients with schizophrenia, as
illustrated by the fact that some female patients filled in items for men. Another
problem was that the questionnaire did not include a clear time frame, or items
pertaining to libido. For these reasons, the CSFQ was not included in the analysis of
our data.
In the course of our studies, the Dickson and Glazer Sexual Functioning
questionnaire (DGSF), a computerized questionnaire designed to evaluate
antipsychotic-induced sexual dysfunctions, became available (Dickson et al. 2001).
We translated it into Dutch in collaboration with the authors of the DGSF
(Knegtering and Castelein 2001). Although this computerized questionnaire has
many advantages in terms of reliability and excludes interviewer bias, two important
problems limited its usefulness: 1 If a patient indicates s/he has no partner and no
sexual activity, further questioning is stopped, leading to a loss of information; 2
Items for libido and orgasm are lacking, while items on thinking about sex and
satisfaction with sexual performance have been added. These additions did not
correspond well with items about libido or orgasm as defined in the UKU and ASFQ.
The DGSF also includes an item about overall sexual functioning, asking the patient
to report changes in sexual symptoms probably linked to treatment with
antipsychotic medication. In conclusion, although the DGSF has many advantages,
it does not cover all phases of sexual functioning (Meston and Frohlich 2000), and
the structure of the questionnaire leads to loss of data. 
The items in the UKU turned out to be the most appropriate ones for our studies,
and using them made it possible to compare data with other studies. However,
some problems became evident during pilot studies in our clinic using the sexual
side effects items on the UKU:
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1. Clinicians/interviewers experienced difficulties interviewing the patients.
Some of them found it difficult to introduce sexual topics to the patient and
some missed guiding questions needed for an optimal interview. 
2. Often interviewers asked questions in different ways; although not formally
investigated, this probably affected the inter-rater reliability of the data.  
3. Although the vast majority of patients reported impairments in sexual
functioning, some did report improvement. However, apart from libido, the
wording of the items of the UKU did not permit ratings for improvement.
4. The time frame of the questions (the past three days) was too short.
The antipsychotics and sexual functioning questionnaire (ASFQ)
In order to keep the advantages of the UKU but to eliminate its disadvantages, we
developed a questionnaire based on the UKU items for sexual functioning, the
Antipsychotics and Sexual Functioning Questionnaire (ASFQ) (Knegtering, H. and
Castelein, S. 2001). The objective was to design a questionnaire specifically aimed
at discovering the sexual side effects of antipsychotics in patients with
schizophrenia and related psychotic disorders. To reduce interviewer bias, a semi-
structured interview was included. Questions were to be phrased in a non-leading
and understandable way. Patients with (mild) psychotic symptoms ought to be able
to complete the interview. Items for men and women were to be included, covering
the main areas of sexual functioning, and enabling both improvement and
worsening to be scored. The questionnaire was intended to help clinicians be able
to discuss sexual side effects.
Structure of UKU and ASFQ 
The items in the UKU relating to sexual side effects are the following: increased
sexual desire, diminished sexual desire, erectile dysfunction, ejaculatory
dysfunction, orgasmic dysfunction, insufficient vaginal lubrication. Each item can be
scored as 0 (no or doubtful side effect); 1 (mild side effects that do not interfere with
sexual functioning); 2 (side effects that interfere moderately with the patient’s sexual
functioning); or 3 (side effects that interfere markedly with sexual functioning). The
time frame in the UKU is the past three days. In conclusion, the interviewer is asked
to estimate the likelihood of a causal relationship between the side effects reported
and the medication used, to be scored as follows: improbable; possible; probable. 
The ASFQ guides interviewers in introducing the subject of sexual side effects to
the patient in a normal and non-directive way. At the beginning of the interview,
some basic clinical and demographic information is solicited. After a general
introduction to the questionnaire, preliminary questions are provided for each item.
The interviewer is instructed to continue asking questions until the answers are
clear enough to permit a scoring. Rules for scoring are presented along with each
individual item. The time frame of the interview is the past month.
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The items and scores
In order to give the ASFQ a consistent structure, increased or decreased sexual
desire is considered as one item, libido. This makes it possible to handle all items in
the same way, offering scoring possibilities for improvement or worsening of
symptoms. Each item can be scored as 0 –absent, or if present, not related to
antipsychotic treatment; 1 -much decreased (severe); 2 -decreased (mild); 3 -
unchanged; 4 -increased (improved); 5 -strongly increased (much improved). Items
on the ASFQ included sexual desire (libido), orgasm, erectile dysfunction,
ejaculatory dysfunction, and vaginal lubrication. Also included, but not within the
scope of this pilot study, were amenorrhoea, dysmenorrhea, galactorrhea,
gynaecomastia.  
Psychometric properties of the ASFQ, a pilot study
We conducted a pilot study on the reliability and the validity of the ASFQ.  Reliability
and validity are important concepts for assessing a questionnaire. Test-retest
reliability, inter-rater reliability, concurrent reliability, and sensitivity to change are
important criteria in evaluating questionnaires like the ASFQ (Derogatis and Laban
1998; Kluiter and Ormel 1999). Validation studies of the ASFQ are ongoing.
Preliminary data are presented on main items of the ASFQ: libido, orgasm, erection,
ejaculation and a sum score indicating the presence of any sexual side effect
related to the use of antipsychotics. The last category offers possibilities of
comparison to the general description of sexual dysfunctions in other
questionnaires. In addition, interviewers and patients were asked about their
experiences with the ASFQ. Test-retest, concurrent reliability and sensitivity to
change were determined.
Method
Test-retest reliability was determined by twice interviewing a group of 17 patients
with an interval of one week, using the ASFQ. The criteria for inclusion were using
an antipsychotic for at least six weeks, and not changing medication during the
study period of six weeks, being between 17 and 42 years old, and suffering from
schizophrenia, or a schizophrenia spectrum disorder. Concurrent reliability was
determined by interviewing 51 patients with the ASFQ and the DGSF after six
weeks of treatment with antipsychotic medication. Items with the same wording
were selected for comparison. The presence of any sexual dysfunction according to
the ASFQ was compared with sexual side effects experienced by patients according
to the DGSF. Sensitivity for change was determined by interviewing 18 patients who
experienced sexual side effects when being treated with a prolactin-elevating
antipsychotic and then switched to a prolactin-sparing antipsychotic. Patients were
interviewed after six weeks’ treatment with the antipsychotic medication tested. Our
impression based on a collective database suggested that about 70% of the
patients would improve in sexual functioning (Knegtering et al. 2003). For test-retest
reliability and concurrent validity, Phi (ϕ) was used as a regulating function. In these





The face validity appeared to be good. Interviewers and patients did not experience
problems understanding and completing the questionnaire. The average time for
completing the questionnaire was 15 minutes. Clinicians found the interview helpful
in discussing sexual side effects with patients. Test-retest reliability was assessed in
17 patients with dichotomised scores of individual items: Libido ϕ= .627, p=. 01;
Orgasm ϕ=. 522, P=. 070; Erection ϕ=. 542, P=. 072; Ejaculation ϕ=. 316, P=. 343;
Any sexual dysfunction ϕ=. 633, P=. 009. Because only three women were
included, vaginal lubrication could not be assessed.
Concurrent validity was gauged in 51 patients with dichotomized items of the DGSF:
Erection ϕ=. 472 P=. 01; Ejaculation ϕ=. 289 P= .197 and Any sexual dysfunction
ϕ=. 524 P=. 000 (Dickson et al. 2001). The conceptual differences regarding libido
and orgasm hindered the comparisons of these items. Not enough women were
included to evaluate the vaginal lubrication item.
To examine the sensitivity of the ASFQ to changes in antipsychotic medication, 18
patients who had reported sexual dysfunctions while on prolactin-elevating
antipsychotics were changed to a prolactin-sparing antipsychotic. In 14 patients,
one or more items of the ASFQ were evaluated as having improved (Chi-
square=5.556, df=1, p=. 012). These findings were in line with our expectation that
in about 70% of the patients sexual performance would improve when switching
from a prolactin-elevating to a prolactin-sparing antipsychotic. These results suggest
that the ASFQ is sensitive to clinical change.
Conclusion
The ASFQ has good face validity, and offers interviewers and patients supportive
guidance. Inter-rater reliability data, while important, are not yet available. The test-
retest reliability is modest on the level of individual items, and acceptable on the
final item (any sexual dysfunction). For concurrent validity, apart from the item on
erection, the data are not convincing on individual items, and modest for the overall
scores. Here the main problem was a lack of overlap between the definitions of
items on the ASFQ and DGSF. The sensitivity to changes in treatment is promising. 
Although the number of patients in these studies is still small, preliminary data
suggest that the ASFQ has an acceptable test-retest reliability, modest concurrent
validity and good sensitivity for therapeutic changes for most important items of
sexual functioning. 
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Introduction
The main aim of this questionnaire is to study the effects of antipsychotics on the
sexual functioning of patients to enable a comparative study of different
antipsychotics. Please fill in this questionnaire if you have been taking
antipsychotics for 4 to 6 weeks, are younger than 45, and are not pregnant or
lactating. The questions in bold in this questionnaire are obligatory. The interviewer
may alter the phrasing of the questions, or add questions so as to clarify the
meaning as desired.
__________________________________________________________________
- Name       :
- Patient number :
- Name of hospital :
- Date of birth :
- Sex :
- Length and height :           
 (Note length/height, in a doubtful case, measure length!) 
- DSM-IV diagnosis :
- Date  :
- Psychiatrist / physician :
__________________________________________________________________
Reason for prescribing the current antipsychotic:
…………………………………………………………………………………………………
……………………………………………………………………………………………
Please list here all medications taken, with dosages, prior to the current
antipsychotic (note also non-antipsychotics):
…………………………………………………………………………………………………
……………………………………………………………………………………………
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For how long did the patient use the previous antipsychotic?
1. The patient has not used any antipsychotic in the past month
2. Less than a week
3. 1-2 weeks
4. 2-6 weeks
5. 6 weeks to 3 months




What was the main reason for stopping the previous antipsychotic?
1. Another psychotic episode
2. Previous antipsychotic was not effective








Can you describe the effects of the antipsychotic medication you use at
present (name of medication)?
(Result of treatment. The score is based on the opinion of the patient in
comparison with four to six weeks ago and the general clinical impression
made on the interviewer during the conversation).   









What side effects did you experience from this antipsychotic? Have you
experienced any other undesirable effects from this medication?
(Describe all side effects mentioned by the patient that may be related to the
antipsychotic used over the past four weeks. Do not add side effects
mentioned by the patient in a later phase of the interview.)
…………………………………………………………………………………………………
……………………………………………………………………………………………
Some patients notice changes in their sexual desires and functioning after
using antipsychotics. Sometimes changes are noted during sexual
intercourse with a partner or during sexual self-stimulation. Some patients
relate an improvement in sexual functioning, others a worsening. 
Did you notice a change in your sexual desire or interest in the past 4 to 6
weeks, for example more or less interest in sex?
(Continue questioning until the answer is clear or no further clarification can
be obtained.
Score changes in sexual functioning that may be related to the use of this
antipsychotic over the past four weeks.)
Unknown will be scored if patients are not willing or not able to answer the question,
or if no clear answer can be obtained in spite of thorough questioning.
Much worse will be scored if the patient has hardly any spontaneous sexual
interests and/or is suffering from decreased sexual interest.
Worse will be scored if the patient has decreased sexual interest, but the patient
does not suffer from this too much. 
Unchanged will be scored if there is no change in sexual interest caused by the use
of antipsychotic medication, i.e. libido is normal. Some patients state they never had
sexual interests, and if this has not changed, score unchanged.  
Improvement will be scored if the patient mentions an improvement in sexual
interest in comparison with at any time previously.
Strong improvement will be scored if the patient mentions a strong improvement in
sexual interest/ desires in comparison with at any time previously, so that optimal
sexual functioning is possible.
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Do you think your current antipsychotic medication has affected your ability
to achieve orgasm (come) in the past four to six weeks? For example, have
you had difficulty achieving orgasm (coming) or have you had an orgasm
(come) sooner than  you wanted to?
(Continue questioning until the answer is clear or no further clarification can
be obtained. Score changes in sexual functioning that may be related to the
use of this antipsychotic over the past four weeks.)
Unknown will be scored if patients are not willing or not able to answer the question
or if no clear answer can be obtained in spite of thorough questioning.
Much worse will be scored if the patient has hardly had any orgasms and/or is
suffering because of being unable to ejaculate (come).
Worse will be scored if the patient’s ability to ejaculate is reduced (but not absent),
for example coming later than desired.
Unchanged will be scored if the use of the antipsychotic has no effect on the ability
to have an orgasm. Some patients state that they never have orgasms; if this has
not changed, score unchanged.  
Improvement will be scored if the patient describes an improvement in the ability to
have an orgasm in comparison with at any time previously.
Strong improvement will be scored if the patient describes a strong improvement in
the ability to have an orgasm in comparison with at any time previously, so that
optimal sexual functioning is possible.






Men (women, go to page 6)
Do you think that your current antipsychotic medication affects your ability to
have an erection? For example, has the time required to obtain and maintain
an erection changed, or has the stiffness of the penis during an erection
changed (worsened or improved)? 
(Continue questioning until the answer is clear or no further clarification can
be obtained. Score changes in sexual functioning that may be related to the
use of this antipsychotic over the past four weeks.)
Unknown will be scored if patients are not willing or not able to answer the question
or if no clear answer can be obtained in spite of thorough questioning.
Much worse will be scored if the patient can hardly obtain an erection and/or is
suffering a lot from a reduced ability to have an erection.
Worse will be scored if the ability to obtain an erection is reduced (but not absent),
for example it takes longer to get an erection, there is a problem maintaining it, or if
the stiffness of the penis during an erection is reduced.
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Unchanged will be scored if the use of the antipsychotic seems to have no effect on
the ability to have an erection. Some patients mention a problem with erection
caused by a somatic problem not related to the use of the current antipsychotic, if
this continues as before score unchanged.
Improvement will be scored if the patient describes an improvement in the ability to
have an erection in comparison with at any time previously (faster and/or longer
duration and/or improved stiffness).
Strong improvement will be scored if the patient describes a strong improvement in
the ability to have an erection in comparison with at any time previously, so that
optimal sexual functioning is possible. 
Priapism is an unwanted erection that is painful and lasts for over one hour without
any stimulation (Note: priapism must be treated immediately).





 5. Strong improvement
6. Priapism
Did you notice a change in the volume of ejaculate (sperm) in the past four to
six weeks? For example, was the volume of ejaculate less or more than
usuaI? Or was ejaculation absent?
(Continue questioning until the answer is clear or no further clarification can
be obtained. Score changes in sexual functioning that may be related to the
use of this antipsychotic over the past four weeks.)
Unknown will be scored if patients are not willing or not able to answer the question
or if no clear answer can be obtained in spite of thorough questioning. Score
unknown if the patient did not come (ejaculate) in the last six weeks.
Much worse will be scored if there is hardly any sperm during an orgasm and/or the
patient is suffering a reduced ability to produce sperm.
Worse will be scored if there is a decline (but not absence) in volume of ejaculate
during an orgasm.
Unchanged will be scored if the use of the antipsychotic medication seems to have
no effect on the volume of ejaculate. 
Improvement will be scored if the patient describes an increase in the volume of
ejaculate during an orgasm in comparison with at any time previously.
Strong improvement will be scored if the patient mentions a strong improvement in
the volume of ejaculate during an orgasm in comparison with at any time previously,
so that optimal sexual functioning is possible. 





5. Strong improvement 
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Women
Are you taking birth control pills?




If yes, name of birth control pill………………………………
Was your menstrual period absent during the past four to six weeks?
Absence of menstrual period:            
0.    Unknown
1. Yes
2. No
3. Yes, I am probably pregnant
Date of last menstruation                       ……/……../…………
In the past four to six weeks, have you had milk leak from your breasts? Or
did you leak milk when you squeezed your nipples? 




Have you noticed a swelling of your breasts and/or nipples in the last four to
six weeks?
Swelling of breasts and/or nipples:           
0.    Unknown
1. Yes
2. No
Do you think that your current antipsychotic medication has affected the
amount of vaginal lubrication (wetness) in the last four to six weeks? For
example, have you noticed during sexual intercourse or during sexual self-
stimulation that the amount of vaginal lubrication has increased or
decreased? 
(Continue questioning until the answer is clear or no further clarification can
be obtained. Score changes in sexual functioning that may be related to the
use of this antipsychotic over the past four weeks.)
Unknown will be scored if patients are not willing or not able to answer the question
or if no clear answer can be obtained in spite of thorough questioning.
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Much worse will be scored if there is hardly any vaginal lubrication during sexual
stimulation and/or if the patient is suffering because of a decrease in vaginal
lubrication.
Worse will be scored if the amount of vaginal lubrication has decreased. 
Unchanged will be scored if there is no change in the amount of vaginal lubrication
or if the problem already existed and is probably not related to the use of the current
antipsychotic.
Improvement will be scored if the patient mentions an improvement in the amount of
lubrication or becomes lubricated more easily in comparison with six weeks ago.
Strong improvement will be scored if the patient mentions a strong improvement in
the amount of lubrication in comparison with six weeks ago, so that optimal sexual
functioning is possible. 
Change in vaginal lubrication 







Have you had sexual intercourse with a partner the last six weeks?
0. Yes, continue
1. No, go to page 8 (results of the laboratory research)
Did you have pain during sexual intercourse in the last four to six weeks?
(Continue questioning until the answer is clear or no further clarification can
be obtained. Score changes in sexual functioning that may be related to the
use of this antipsychotic over the past four weeks.)
Unknown will be scored if patients are not willing or not able to answer the question
or if no clear answer can be obtained in spite of thorough questioning.
Worse means that having sexual intercourse is painful, and that this is probably
related to the present antipsychotic medication.
Unchanged means the present antipsychotic medication did not result in painful
sexual intercourse or painful sexual intercourse was already present before using
this antipsychotic medication.
Improvement will be scored if painful sexual intercourse in the past has clearly
diminished since the present antipsychotic medication.
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To compare sexual functioning in patients treated with olanzapine or risperidone. 
Method: 
This open–label trial included 46 patients randomized to olanzapine (5-15 mg/day)
or risperidone (1-6 mg/day) for 6 weeks.  Sexual dysfunction was assessed by a
semi-structured interview based upon the items of the UKU.  
Results:  
Three olanzapine-treated patients (12.0%) compared to 11 risperidone-treated
patients (52.4%) reported sexual dysfunctions (p=.008) in the semi-structured
interview.  Only 4 patients (8.7%) spontaneously reported sexual dysfunction.  The
mean dose was 9.4 mg/day for olanzapine and 3.4 mg/day for risperidone.  The
mean (± SD) prolactin levels (ng/mL) in olanzapine- and risperidone-treated
patients were 25.1 (± 23.5) and 43.5 (± 26.1), respectively.  
Conclusion:  
Less sexual dysfunction occurred in the group treated with olanzapine compared to
risperidone.  Direct questioning about sexual functioning is necessary to avoid
underestimating the frequency of sexual side effects in patients with schizophrenia




Sexual dysfunction in patients with schizophrenia seems to be related to the
disease itself, psychosocial factors, medical health, as well as to the use of
psychotropic medications (Aizenberg et al. 1995; Dickson and Glazer 1999). Many
of the conventional or typical antipsychotics have been associated with sexual
dysfunction, such as decreased libido, erectile dysfunction, anorgasmia, delayed or
retrograde ejaculation, oligomenorrhoea, and amenorrhoea (Dickson et al. 2000;
Ghadirian et al. 1982; Segraves 1989; Sullivan and Lukoff 1990). 
The prevalence rate of sexual dysfunction in persons with schizophrenia is thought
to be high.  However, sexual dysfunction is rarely reported spontaneously by
patients (Rubin 1987); therefore, clinical trials of antipsychotic medications that rely
on spontaneous reporting by patients to assess side effects report low incidences
of sexual dysfunction.  In contrast, those studies using structured interviews or
questionnaires result in 30 - 60% of the patients with schizophrenia reporting
sexual dysfunctions (Sullivan and Lukoff 1990).
Although comparative studies are rare, the literature does suggest that
antipsychotic medications differ in both the type and frequency of associated
sexual dysfunction.  For instance, a significantly greater percentage of patients on
thioridazine report sexual dysfunctions versus patients treated with other typical
antipsychotics (Kotin et al. 1976).  The atypical antipsychotics (clozapine,
olanzapine, quetiapine) are reported to cause less sexual dysfunction than the
typical antipsychotics and risperidone (Aizenberg; et al. 1995; Aizenberg et al.
2001; Arvanitis and Miller 1997; Canuso et al. 1998; Currier and Simpson 1998;
Dickson and Glazer 1999; Gazzola and Opler 1998; Madhusoodanan and Brenner
1996;  Shiwach and Carmody 1998; Tran et al. 1997). 
The pathomechanisms of antipsychotic-associated sexual dysfunction in patients
with schizophrenia remain poorly understood (Tran et al. 1997). Most of the typical
antipsychotics, as well as risperidone, can cause sustained elevation of the
anterior pituitary hormone, prolactin (Ghadirian et al. 1982; Rubin 1987).
Neuroleptic-induced Hyperprolactinemia (NIHP) has been associated with a
number of side effects including galactorrhea, menstrual disturbances,
amenorrhea, and sexual dysfunction (Ghadirian et al. 1982; Dickson and Glazer
1999).  Interestingly, antipsychotic medications have also been reported to cause
priapism and ejaculation disturbances (Kuperman et al. 2001; Meston and Frohlich
2000; Nicolson and McCurley 1997; Patel et al. 1996; Sirota and Bogdanov 2000).
However, the mechanism is probably associated with α-adrenergic blockade rather
than increased levels of prolactin (Hansen et al. 1997; Patel et al. 1996). 
The atypical antipsychotics, other than risperidone, do not appear to cause
sustained elevated levels of prolactin, and the limited reports available, suggest
that patients prescribed these antipsychotics have lower rates of sexual
dysfunction.  Clozapine, which does not induce significant prolactin elevation
(Meltzer et al. 1979), in a recent study was reported to cause fewer sexual side
effects than classical antipsychotics (Aizenberg et al. 1995), although Hummer and
colleagues reported comparable frequencies of sexual dysfunctions in patients
treated with clozapine or haloperidol (Hummer et al. 1999).  Quetiapine-treated
patients have been shown to experience prolactin levels similar to placebo and a
A randomized open label comparison of the impact of olanzapine versus risperidone
63
low incidence of sexual dysfunctions (Borison et al. 1996; Dev and Raniwalla 2000;
Small et al. 1997).  Olanzapine has been shown to cause significantly less
prolactin elevation than both haloperidol (Beasley et al. 1996;  Crawford et al.
1997) and risperidone (Tran et al. 1997); the mild elevations of prolactin that may
occur are usually transient (Crawford et al. 1997).   At risperidone’s recommended
dose range of 3-6 mg/day, significant and sustained prolactin elevation has been
reported (Claus et al. 1992). 
In a previous open-label naturalistic study, we found a higher incidence of sexual
dysfunctions and significantly higher prolactin levels in patients treated with
risperidone compared to patients treated with typical antipsychotics or olanzapine
(Knegtering et al. 1998).  However, in this study, selection-bias could have
influenced the results, thus the need for the blinded randomized assignment to
medication in the present study. 
Material and methods
Study participants included inpatients and outpatients with schizophrenia who were
to be switched to a new antipsychotic for clinical reasons as determined by the
attending psychiatrists.  Written and oral consent were then given by patients in
accordance with the local ethical committee for research.  Patients could be taking
any antipsychotic before entering the study except depot neuroleptics, olanzapine
or risperidone.   Patients were randomized to either open-label olanzapine (starting
dose 10 mg) or risperidone (starting dose 1 mg).  For both groups, the dosage
could be adjusted as deemed necessary on a weekly basis by the clinician
(olanzapine, 5-15 mg/day; risperidone, 1-6 mg/day).  The patients were informed
that effects of the switch would be assessed but they were blinded in regard to the
hypothesis to be tested.  
Sexual dysfunction was assessed at 6 weeks post-randomization by a semi-
structured interview based upon the items of the UKU (34) administered by 6
trained physicians.  This interview was used in our previous studies and includes
items assessing sexual side effects (libido, erection, ejaculation, orgasm), and
galactorrhoea.  Baseline sexual functioning was not recorded because most of the
patients were psychotic and considered too ill at study entry to participate in
assessment of sexual functioning.  Prolactin levels were measured 6 weeks but not
at baseline.  The clinicians were also asked to assess efficacy of the treatment for
psychotic symptoms using the Clinical Global Impressions- Global Improvement
(CGI-I) scale.
The chi-square test was applied to categorical outcomes.  The chi-square value
was corrected for continuity because the sizes of the tables were all two by two.
The Students t-test was used to analyze continuous outcomes including age and
prolactin levels.  Prolactin levels were normalized by converting to their natural




Forty-six patients (olanzapine, N=25; risperidone, N=21), including 7 women and
39 men, agreed to participate in this trial (Table 1). The mean age (mean ± SD) of
the olanzapine group (27.2 ± 7.2) was comparable to the risperidone group (26.0 ±
6.3).  The patients’ age ranged from 19 to 40 years.  Clinical diagnoses, according
to DSM-IV were brief psychotic disorder (N=2), schizophreniform disorder (N=4),
schizophrenia (N=31), schizoaffective disorder (N=1), delusional disorder (N=3),
and psychosis NOS (N=5). 
Prolactin levels could not be obtained in 13 patients because they refused blood
sampling.  At 6 weeks, the mean dosage of olanzapine and risperidone was 9.4
mg/day (range, 5-15 mg/day) and 3.4 mg/day (range, 2-6 mg/day), respectively. 






Age (years, mean ± SD) 27.2 ± 7.2 26.0 ± 6.3 .52
Sex (%)
Male 80.0 90.5 .43
Female 20.0 9.5
Diagnosis (%) .60
Brief Psychotic Disorder 4.0 4.8 nsa
Delusional Disorder 8.0 4.8 ns
Psychotic Disorder NOS 12.0 9.5 ns
Schizoaffective Disorder 4.0 0   ns
Schizophrenia 64.0 71.4 ns
Schizophreniform Disorder 8.0 9.5 ns
a There were no statistically significant differences (ns) for any specific 
disorder between the treatment groups.
The CGI-I (rated as much worse, worse, unchanged, improved, or much improved)
was used to assess treatment results by the attending physician.  Both
antipsychotics were considered effective: 75% of the patients were rated by their
physician as being clinically significantly improved (improved and much improved)
after 6 weeks. Although numerically more patients on risperidone were rated as
improved in comparison to the olanzapine group, this difference was not significant
(Mann-Whitney U 118.0; z=-645; p=.52).
Some patients could not reliably answer certain questions because they felt
embarrassed or because it was difficult to be sure of the correct interpretation of
the answer. Therefore, we report the number of patients with clearly specified
sexual dysfunctions, which they attributed to the use of the antipsychotic
medication. Unless indicated, the reported sexual dysfunctions exclude
amenorrhoea.  
A severity score was created for sexual dysfunctions. Each dysfunction could be
rated as absent, giving some problems or giving many problems, and scored as 0,
1 or 2 points, respectively. Using this global rating, patients using risperidone
experienced more serious problems in comparison to patients using olanzapine
(Mann-Whitney U 121.0; z=-3.072; p=0.002).  Of the 46 patients who completed
the trial, only 4 (8.7%) reported sexual dysfunction spontaneously.  In response to
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the semi-structured interview, 14/46 (30.4%) reported sexual dysfunctions (mild or
severe).  Only 3 of 25 olanzapine patients (12.0%) reported sexual dysfunction
compared to 11 of 21 patients (52.4%) treated with risperidone (chi-square=7.13;
df=1; p=0.008).  The nature and frequency of the sexual dysfunctions are
summarized in Table 2. 
The mean (±SD) prolactin concentration was 25.1 ng/mL (± 23.5) in the olanzapine
group and 43.5 ng/mL (± 26.1) in the risperidone group (t-test (natural log), t=2.49;
df=26; p=.052).  






Prolactin (ng/mL, mean ± SD) 25.1 ± 23.5 43.5 ± 26.1 .02
Type of sexual dysfunction (%)
   Decreased libido 12.0 33.3 .13
   Decreased orgasm 0 19.0 .09
   Any sexual dysfunction 12.0 52.4 .008
Sexual dysfunction and prolactin levels in men 
As the majority of patients were men, their data were analyzed separately.
Ten male patients (25.6%) reported sexual dysfunction attributable to their
antipsychotic medication (Table 3).  Sexual dysfunction was more commonly
reported in men treated with risperidone (9/19; 47.4%) compared to men treated
with olanzapine (1/20; 5%) (Chi-square=6.65; df=1; p=0.01).  Using the severity
score described above, risperidone-treated patients experienced more serious
problems in comparison to olanzapine-treated patients (Mann-Whitney U 79.0; z=-
2.947; p=.003).
The mean (±SD) prolactin levels were significantly higher in male patients treated
with risperidone (41.5 ± 19.5 ng/mL) compared to olanzapine-treated patients (15.9
± 5.3 ng/mL) (t-test (natural log)=3.90; df=19; p=0.001). 







Prolactin (ng/mL, mean ± SD) 15.9 ± 5.3 41.5 ± 19.5 .001
Type of sexual dysfunction (%)
   Decreased erection 0 31.6 .04
   Decreased libido 5.0 31.6 .15
   Decreased orgasm 0 21.1 .14
   Ejaculation dysfunction 0 16.7 .27
   Any sexual dysfunction 6.3 47.4 .01
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Sexual dysfunction and serum prolactin levels in women 
Two of 7 women reported having a missed period and both had high prolactin
levels (> 48.6 ng/mL).  One patient was taking olanzapine (10 mg/day) and the
other receiving risperidone (6 mg/day).  However, there were not enough female
patients to perform a separate analysis. 
Discussion
As has been found in previous studies, (Lingjaerde et al. 1987) reliance on
spontaneous reports underestimates the prevalence of sexual dysfunction in
patients treated with psychotropic medications.  The male risperidone-treated
group reported significantly more sexual side effects compared to the olanzapine
group. Prolactin levels were higher in patients using risperidone compared to
patients using olanzapine.  The findings of this prospective open-label randomized
study of olanzapine and risperidone are consistent with prior studies and case
reports of Hyperprolactinemia occurring in risperidone-treated patients  (Chung and
Eun 1998; Claus et al. 1992; Dickson et al. 1995; Tran et al. 1997) and associating
risperidone treatment with sexual dysfunction  (Gupta et al. 2001; Hardan et al.
1996; Kim et al. 1999; Madhusoodanan and Brenner 1996; Shiloh et al. 2001).
These findings of increased risk and greater severity of sexual dysfunction in
risperidone-treated patients are also consistent with those of our naturalistic study
on typical antipsychotics, olanzapine and risperidone (Knegtering et al. 1999).
Unfortunately, given the low number of female patients in each group, a separate
analysis was not possible.
The few reports of sexual side effects in olanzapine treated patients include only
cases of priapism, which is not etiologically attributable to Hyperprolactinemia
(Gordon and de Groot 1999; Kuperman et al. 2001). Olanzapine generally reverses
the effects of risperidone, and other antipsychotics, on prolactin levels and may in
some case reverse sexual dysfunction (Canuso et al. 1998; Gazzola and Opler
1998). 
Clearly, medication is not the only reason for patients to experience sexual
dysfunction. Patients suffering from schizophrenia experience more sexual
dysfunction, with or without medication (Aizenberg et al. 1995; Teusch; et al.
1995).  The difference in the incidence of sexual side effects between patients
treated with olanzapine and risperidone is likely related to the pharmacological
properties of these drugs.  However, given the lack of baseline ratings and the
relatively small numbers, we cannot exclude differences in function that predate
randomization.  Nevertheless, significant differences in such a small sample size
are considered important by many clinicians.  Future studies should be randomized
and double-blind.  
Olanzapine doses used in this trial are probably associated with a relatively low D2
occupancy of about 60% (Kapur et al. 1998; Nyberg et al. 1997), while risperidone,
in doses of 2-6 mg/day, is associated with a higher D2 occupancy (Busatto and
Pilowsky 1993; Busatto et al. 1995).  Since the dopamine system is involved in
sexual arousal and the ability to experience pleasure, the blockade of this system
might be one of the reasons for decreased libido (Segraves 1989). 
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Prolactin elevation in patients with a prolactinoma is associated with amenorrhea,
galactorrhea, erectile dysfunction, and possibly decreased libido (Pollack et al.
1992; Schwartz et al. 1982).  However, the mechanism of sexual dysfunctions
caused by prolactin elevation is not known. There is some evidence that prolactin
elevation is related to a reduced capacity to create sexual fantasies, while
nocturnal penile erections are not influenced (Carani et al. 1996).  Another
mechanism known to influence sexual dysfunction is α-adrenergic blockade
(ejaculation disturbance), probably in balance with cholinergic functioning
(Segraves 1989).  Risperidone has α-adrenergic blocking properties that might
contribute to sexual side effects. Olanzapine has a lower affinity for the α-
adrenergic system compared to risperidone.  Indeed, olanzapine appeared to have
no effect on ejaculation or other sexual dysfunctions in this study. 
A limitation of this study was that we could not show a relationship between
prolactin levels and sexual side effects because of the small sample size and
missing prolactin data (N=13).  However, in a pooled analysis of several small
studies, Knegtering and colleagues found a clear correlation between elevated
prolactin levels and an increased incidence of sexual dysfunctions (Knegtering,
Moolen, et al. 2003). 
During this brief study, all patients initially randomized to receive either risperidone
or olanzapine continued on their assigned medications for the 6 week study period,
but medication compliance was not formally assessed. In our clinical experience,
drug-induced sexual dysfunction is often cited by patients as the reason for
medication discontinuation or request for treatment alternatives.  We are not aware
of any studies on the correlation between compliance and sexual side effects due
to antipsychotic drugs, but studies suggest that clinicians do underestimate the
frequency and importance of sexual side effects in patients with schizophrenia
(Finn et al. 1990) and other psychiatric disorders (Singh and Beck 1997).  Although
further research is required on the relationship of specific side effects on
compliance with prescribed psychotropic medications, physicians should be aware
that sexual dysfunctions occur commonly in patients with psychotic disorders and
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Summary
Objective: 
To compare sexual functioning in patients treated with quetiapine or risperidone.
Method: 
This open-label study included patients with schizophrenia or a related psychotic
illness who were randomised to quetiapine (200-1200 mg/day) or risperidone (1-6
mg/day) for 6 weeks. Sexual dysfunction was assessed by a semi-structured
interview, the Antipsychotics and Sexual Functioning Questionnaire (ASFQ), based
upon the Utvalg for Kliniske Undersogelser (UKU).
Results: 
Four of 25 quetiapine-treated patients (16%) and 12 of 24 risperidone-treated
patients (50%) reported sexual dysfunction (Chi-squared=6.4; df=1; p=0.006) on
the ASFQ. Six patients (11.7%; 4 on risperidone, 2 on quetiapine) spontaneously
reported sexual dysfunction. The mean ± SD dose was 580±224 mg/day for
quetiapine and 3.2±1.3 mg/day for risperidone. Mean ± SD prolactin levels in
quetiapine- and risperidone-treated patients were 13.8±17.9 ng/ml and 57.7±39.7
ng/ml, respectively. Conclusion: Sexual dysfunction was less common in patients
treated with quetiapine than with risperidone. Direct questioning about sexual
functioning is necessary to avoid underestimating the frequency of sexual side




Sexual dysfunction in patients with schizophrenia seems to be related to the
disease itself, psychosocial factors, medical health, and to the use of psychotropic
medications (Aizenberg et al. 1995; Dickson and Glazer 1999; Peuskens et al.
1998). Many of the conventional or typical antipsychotics have been associated
with sexual dysfunction, such as decreased libido, erectile dysfunction,
anorgasmia, delayed or retrograde ejaculation, oligomenorrhoea, and
amenorrhoea (Dickson et al. 2000; Ghadirian et al. 1982; Segraves 1989; Sullivan
and Lukoff 1990). 
Sexual dysfunction is rarely reported spontaneously by patients (Riley and Riley
1993); therefore, clinical trials of antipsychotic medications that rely on
spontaneous reporting by patients to assess side effects, report low frequencies of
sexual dysfunction. In contrast, studies using structured interviews or
questionnaires result in 30-60% of patients with schizophrenia reporting sexual
dysfunctions (Dickson et al. 2000; Knegtering et al. 2003; Sullivan and Lukoff
1990). The National Schizophrenia Fellowship in the United Kingdom conducted a
survey of over 2000 mental health service users, and found that amongst many
side effects patients experience, sexual side effects were deemed to be the most
troublesome (Smith et al. 2002).
The pathomechanisms of antipsychotic-associated sexual dysfunction in patients
with schizophrenia remain poorly understood (Meston and Frohlich 2000). All
antipsychotics can cause elevation of the anterior pituitary hormone prolactin,
although they differ in the magnitude of this effect (Alexiadis et al. 2002; Ghadirian
et al. 1982; Kaneda 2001; Kapur et al. 1998; Kapur et al. 2000; Kapur et al. 2001;
Kapur and Seeman 2001). Neuroleptic-induced Hyperprolactinemia (NIHP) has
been associated with a number of side effects including galactorrhoea, menstrual
disturbances, amenorrhoea, and sexual dysfunction (Dickson and Glazer 1999;
Ghadirian et al. 1982). Although comparative studies are rare, antipsychotics may
differ in type and frequency of associated sexual dysfunction (Kotin et al. 1976;
Smith et al. 2002).
The atypical antipsychotics, other than risperidone and amisulpride, do not appear
to cause sustained elevation of prolactin levels, and the limited reports available
suggest that patients prescribed these agents might have lower rates of sexual
dysfunction than with conventional antipsychotics (Aizenberg et al. 1995;
Aizenberg et al. 2001; Arvanitis and Miller 1997; Dickson and Glazer 1999;
Knegtering et al. 2003).Quetiapine-treated patients have been shown to exhibit a
lack of increase in prolactin levels, or a reduction to levels similar to those
observed with placebo, and might have a low incidence of sexual dysfunction
(Borison et al. 2002; Dev and Raniwalla 2000; Small et al. 1997). At risperidone’s
recommended dose range of 3-8 mg/day, significant and sustained prolactin
elevation has been reported (Claus et al. 1992; Knegtering et al. 2000).
In previous studies, we found a higher incidence of sexual dysfunction and
significantly higher prolactin levels in patients treated with risperidone compared
with those treated with typical antipsychotics and olanzapine. Here we present an
open-label randomised study, comparing the effects of risperidone and quetiapine
on sexual dysfunction and serum prolactin levels were compared in patients with
schizophrenia or related illnesses.
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Patients, assessments and statistics
Patients
Study participants included in- and out-patients with schizophrenia or a related
psychosis like schizophreniform, schizo-affective or brief psychotic episode, who
either needed for the first time treatment with antipsychotics or were to be switched
to a new antipsychotic for clinical reasons as determined by the attending
psychiatrists. These clinical reasons were an untreated psychotic episode,
insufficient response to treatment with antipsychotic medication, or serious side
effects during treatment with the previous antipsychotic. To exclude the effects of
aging on sexual performance, only patients between 16 and 40 years could enter
the study (Smith et al. 2002).
Written and oral consent were given by patients in accordance with the local ethical
committee for research. Patients could be taking any antipsychotic before entering
the study, except depot neuroleptics, quetiapine or risperidone.
Patients being treated with other medications with known effects on sexual
functioning, such as selective serotonin re-uptake inhibitors, could not participate in
the study (Rosen et al. 1999. Patients were randomised to treatment with either
open-label quetiapine (dosage increased from 50 mg/day to 400 mg/day over 3
days) or risperidone (starting dose 1 mg). In case previous to the study
antipsychotics were used, the dosage was tapered down within the first three
weeks of the study. In both groups, the dosage of the studied antipsychotics could
be adjusted as deemed necessary by the clinician on a weekly basis (quetiapine
200-1200 mg/day; risperidone 1-6 mg/day). The patients were informed that effects
of the switch would be assessed but they were blinded in regard to the hypothesis
to be tested.
Assessments
Sexual dysfunction was assessed 6 weeks post-randomisation using a semi-
structured interview: the Antipsychotics and Sexual Functioning Questionnaire
(ASFQ), based upon the items of the Utvalg for Kliniske Undersogelser (UKU)
administered by 6 trained physicians (Lingjaerde et al. 1987; Knegtering and
Castelein 2001). The ASFQ was used in our previous studies and includes items
assessing sexual side effects (libido, orgasm, and galactorrhoea. For men, it
includes erection and ejaculation, and for women it includes vaginal lubrication and
menstruation). Baseline sexual functioning was not assessed at Week 1, because
many patients were psychotic and some were considered too ill at study entry to
participate in the assessment. For both men and women, a severity score was
created for libido and orgasm according to the ASFQ. Each dysfunction could be
rated as absent (0 points), giving some problems (1) or giving many problems (2).
Severity scores could theoretically vary from -4 (much improved on libido and
orgasm) to +4 (most serious sexual dysfunction). A second severity score was
developed including libido, erection, orgasm, and ejaculation (range -8 to +8). For
women a severity score including libido, vaginal lubrication, and orgasm was
developed (range -6 to +6).
At Week 6, premorbid social and sexual functioning were evaluated using a
subscale of the Dickson-Glazer Scale for Assessment of Sexual Functioning of
Patients on Antipsychotic Medications (DGSF) (Dickson et al. 2001). In this
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subscale most important aspects of social and sexual functioning are assessed on
a lifetime bases. Medication compliance was assessed by interviewing the patients
for compliance, and by plasma antipsychotic level monitoring. Antipsychotic,
prolactin and testosterone serum levels were measured at week 6 in the morning,
but not at baseline, as carry-over effects from previous antipsychotic therapy would
obscure interpretation of these data. By excluding patients treated with long-acting
(depot) antipsychotics, the influence of carry-over effects from previous
antipsychotics at Week 6 were minimised. Symptom severity was also assessed by
independent raters using the Positive and Negative Syndrome Scale (PANSS) at
baseline and Week 6 (Kay et al. 1987).
Statistical analysis
From previous studies it was hypothesised that patients treated with risperidone
would report more sexual dysfunctions and higher prolactin levels than patients
treated with quetiapine. The students t-test was used to analyse continuous
outcomes including age, PANSS efficacy data, and prolactin levels, at the 2-sided
α level of 0.05. Pearson’s chi-square test, if needed corrected for continuity, was
applied to categorical outcomes. Prolactin level values were first normalised by
converting them to their natural logarithm. The chi-square test was applied to
categorical outcomes. The Mann-Whitney U test was applied for the severity
scores. Of all the analyses of sexual dysfunction, the effects were one-sided tested
with the significance-level at 0.05. For correlations between variables on the
interval-level of measurement Pearson’s r was used; significance-testing was two-
sided with α at 0.05. 
Results
Sixty-six patients were eligible for the study and randomised. Five male patients
randomised to risperidone treatment, and 3 to quetiapine never started medication,
and required further clinical guidance. One man on risperidone and 3 women on
quetiapine had second thoughts after giving informed consent. One male patient
on quetiapine stopped treatment after one week for side effects not related to the
study. One woman left the hospital for unknown reasons. One patient experienced
a new psychotic episode despite treatment with quetiapine 1000 mg/day: the
patient was withdrawn from the study, and the psychosis responded to treatment
with clozapine.
Fifty-one patients (quetiapine, n=25; risperidone, n=26), including 15 women and
36 men, agreed to participate in this study and their data could be analysed (Table
1). The mean (± SD) age of the quetiapine group (26.5±5.4) was comparable to the
risperidone group (25.2±7.3). Clinical diagnoses, according to DSM-IV were brief
psychotic disorder (n=3), schizophreniform disorder (n=8), schizophrenia (n=29),
schizoaffective disorder (n=2), delusional disorder (n=1), and psychosis not
otherwise specified (n=7).
In both the quetiapine- and risperidone groups, 11 patients were included because
of ongoing serious psychotic symptoms. Fourteen patients in the quetiapine group
and 13 in the risperidone group were included because of intolerance to their
previous antipsychotic medication. Eight patients in the quetiapine group and 7 in
the risperidone group had not used any antipsychotic within 6 weeks of the start of
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the study. In the quetiapine group, 9 patients had been treated with a conventional
antipsychotic, and 5 with olanzapine before the study. In the risperidone group, 6
patients had been taking a conventional antipsychotic, and 7 had been taking
olanzapine.
All patients initially randomised to receive either quetiapine or risperidone
completed the 6 week study period: all patients reported to have taken their
antipsychotic medication, and this was confirmed in all patients allowing blood
sampling (n=44). At week 6, the mean dosages of quetiapine and risperidone were
580 (range 200-1200) mg/day and 3.2 (range 1-6) mg/day, respectively.
Premorbid and present sexual activity information was obtained at week 6. Nine
patients reported being involved in an ongoing heterosexual relationship, 6 lived
together with a partner, and 45 were single. Eleven patients had an ongoing sexual
relationship with a partner, 26 reported to be sexually active through masturbation,
and 20 said they had no sexual activity during the previous month. There were no
statistically significant differences between patients treated with quetiapine or
risperidone.
At the end of the study, patients were asked if evaluation of sexual side effects was
important to them: 82% considered this an important assessment in a clinical trial.
Patients who had been using antipsychotics before entering the study were asked
if sexual side effects had been evaluated: 70% had never been asked for sexual
side effect information.
Treatment outcome of psychotic symptoms
In 18 quetiapine-treated patients and 15 risperidone-treated patients PANSS
scores (mean ± SD) were available for both Week 1 and Week 6. At start of the
study no significant differences were found in the PANSS total scores between
patients treated with quetiapine (65.2±23.0) or risperidone (65.3±21.1) (t=0.005;
df=31; p=0.99). The reduction in PANSS total score was modest in this study:
5.4±12.3 in the quetiapine group, and 8.4±11.2 in the risperidone group (t=0.807;
df=31; p=0.43), reflecting the fact that many patients switched to quetiapine or
risperidone for intolerance of a former antipsychotic treatment. There were no
significant differences in the PANSS total score, or in the positive, negative and
general psychopathology subscore measures between the treatment groups.
Treatment outcome of sexual side effects
Although the majority of patients answered questions on the ASFQ without any
difficulty, some could not reliably answer certain questions because they felt
embarrassed or because it was difficult to be sure of the correct interpretation of
the answer. The numbers show the number and percentage of the patients who
reported clearly about sexual functioning. Sexual dysfunction was included in the
calculation if patients reported dysfunctions that they attributed to use of the
antipsychotic medication. Of the 51 patients who completed the trial, only 6
(11.7%) (4 risperidone and 2 quetiapine) reported sexual dysfunction (libido and/or
orgasm) spontaneously. In response to the semi-structured interview (ASFQ),
16/49 (32.7%) reported sexual dysfunction (mild or severe). Only 4 of 25
quetiapine patients (16.0%) reported sexual dysfunction compared to 12 of 24
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patients (50%) treated with risperidone (Chi-squared=6.4; df=1; p=0.01). Four
patients on quetiapine (16%) and one on risperidone (4.1%) reported some
improvement in libido or orgasm. The nature and frequency of sexual dysfunction
is summarised in table 2. Using the severity scores, patients taking risperidone
experienced more serious problems (on libido and orgasm) than patients using
quetiapine (U=203.0; z=-2.2; p=0.01).
The mean (±SD) prolactin concentration was 13.6±17.9 ng/ml in the quetiapine
group, and 57.9±39.7 ng/ml in the risperidone group (natural log t=7.704; df=42;
p=0.000).
Sexual dysfunction and prolactin levels in men
The majority of patients were men. Twelve of 33 male patients (36.4%) reported
sexual dysfunction attributable to their antipsychotic medication used during the
study (Table 3). Sexual dysfunction (libido and/or orgasm) was more commonly
reported in men treated with risperidone (8/14; 57.1%) versus quetiapine (4/19;
21.1%) (Chi-squared=4.5; df=1; p=0.02). Dysfunction of erection and ejaculation
was also more commonly reported in men treated with risperidone (8/14; 57.1%)
versus quetiapine (5/19; 26.3%) (Chi-squared=3.2; df=1; p=0.04). Using the
severity score for men (including libido, erection, orgasm, ejaculation), risperidone-
treated patients experienced more serious problems than quetiapine-treated
patients (U=74.0; z=-2.3; p=0.01).
Mean (±SD) prolactin levels were significantly higher in male patients treated with
risperidone (47.1±24.1 ng/ml) than in quetiapine-treated patients (12.1±10.1 ng/ml:
natural log t=6.2; df=28; p = 0.000). In men, prolactin elevation was correlated with
the severity score for sexual dysfunction (libido, erection, orgasm, ejaculation)
(r=0.5; p=0.01) and with a decrease in orgasm (r=0.6; p=0.001). There was no
significant correlation between serum prolactin and testosterone levels, nor were
testosterone levels correlated with sexual dysfunction.
Sexual dysfunctions and serum prolactin levels in women
Female patients were a minority: 6 in the quetiapine group and 10 in the
risperidone group. Although the numbers are small, we present their data in detail
to enable further hypothesis development.
Four of 16 female patients (25%) reported sexual dysfunction attributable to their
antipsychotic medication (Table 3). Sexual dysfunction (libido and/or orgasm) was
only reported in women treated with risperidone (4/10; 40%) (Chi-squared=3.2;
df=1; p=0.04).
Evaluation of sexual dysfunction (libido, orgasm and lubrication) was also more
commonly reported in women treated with risperidone (4/10; 40%) versus
quetiapine (0/6; 0%) (Chi-squared=3.6; df = 1; p = 0.03). Using the severity score
(including libido, lubrication and orgasm), 3 risperidone-treated patients
experienced more serious sexual side effects compared with quetiapine-treated
patients (U=15.0; z=-1.8; p=0.04).
Mean (±SD) prolactin levels were higher in female patients treated with risperidone
(78.1±55.4 ng/ml) than in quetiapine-treated patients (18.0±21.5 ng/ml ) (natural
log t=4.0; df=12; p=0.001).
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In male patients treated with risperidone, plasma drug levels correlated with
ejaculation disturbance (r=0.77; p=0.02) and with the sum score for sexual
dysfunction (libido, erection, orgasm, ejaculation) (r=0.70; p=0.04). The 9-hydroxy-
risperidone metabolite and plasma prolactin levels did not show a significant
correlation with plasma risperidone levels, nor with any sexual dysfunction or sum
scores of these dysfunctions. In male patients taking quetiapine, no correlations
between plasma levels of quetiapine, prolactin or any sexual dysfunction were
found. For women, the sample size was too limited to do further statistical analysis.
Discussion
As has been found in previous studies, relying on spontaneous reports
underestimates the prevalence of sexual dysfunction in patients treated with
psychotropic medications (Lingjaerde, Ahlfors, et al 1987 76/id). With prescribed
psychotropic medications, physicians should be aware that sexual dysfunction
occurs commonly in patients with psychotic disorders and that active questioning is
required to elicit this sensitive information.
The risperidone-treated group reported significantly more sexual side effects than
the quetiapine group. Prolactin levels were higher in patients taking risperidone
than in those taking quetiapine. The findings of this prospective open-label
randomised study of quetiapine and risperidone are consistent with prior studies
and case reports of Hyperprolactinemia occurring in risperidone-treated patients,
associating risperidone treatment with sexual dysfunction (Knegtering et al. 2003).
The findings of increased risk and severity of sexual dysfunction in risperidone-
treated patients are also consistent with those of our naturalistic study on typical
antipsychotics, clozapine, olanzapine, quetiapine and risperidone (Knegtering et al.
2002).
Clearly, medication is not the only reason for sexual dysfunction: patients with
schizophrenia experience more frequent sexual dysfunction, with or without
medications (Aizenberg et al. 1995; Teusch et al. 1995). The difference in the
incidence of sexual side effects between patients treated with quetiapine and
risperidone is likely to be related to the pharmacological properties of these drugs.
However, given the lack of baseline ratings and the relatively small numbers, we
cannot exclude differences in function that predate randomisation. Nevertheless,
significant differences in such a small sample size are considered important by
many clinicians. 
The mechanisms of sexual dysfunctions induced by antipsychotics are not well
understood (Meston and Frohlich 2000). The quetiapine doses used in this study
(200-1200 mg/day) are probably associated with a relatively low D2 occupancy,
while risperidone (2-6 mg/day) is associated with greater and more sustained D2
occupancy (Alexiadis et al. 2002; Kapur et al. 1999; Kapur et al. 2000; Kapur and
Seeman 2001). Since the dopamine system is involved in sexual arousal and the
ability to experience pleasure, sustained blockade of this system might be one of
the reasons for decreased libido and orgasm (Segraves 1989).
A secondary effect of dopamine blockade in the anterior pituitary is prolactin
elevation. Prolactin elevation in patients with a prolactinoma is associated with
amenorrhoea, galactorrhoea, erectile dysfunction, and possibly decreased libido
(Pollack et al. 1992; Schwartz et al. 1982). However, the mechanism of sexual
Chapter 5
78
dysfunction caused by prolactin elevation is not known. There is some evidence
that prolactin elevation is related to a reduced capacity to create sexual fantasies,
while nocturnal penile erections are not influenced (Carani et al. 1996). Other
suggested mechanisms are the lowering of testosterone levels in response to
prolactin elevations (Rinieris et al. 1989). We could not find a correlation between
prolactin and testosterone levels.
Other suggested mechanisms of prolactin elevation being correlated with sexual
side effects are prolactin’s influence on multiple dopaminergic sites in the brain,
sometimes increasing and sometimes decreasing dopamine turnover, including
that in the substantia nigra (Sobrinho 1993). Recently, physiological prolactin
elevation has been found following orgasm in men as in women, correlated with
post-coital inhibition of sexual behaviour after orgasm. This suggests that prolactin
elevation might be involved in experiencing sexual satiety (Exton et al. 2000;
Haake et al. 2002).
Apart from the dopaminergic and prolactin-linked mechanisms, risperidone and
quetiapine both have α-adrenergic blocking properties (Leysen et al. 2000): α1-
adrenergic mechanisms may be involved in ejaculation disturbance (Segraves
1989; Shiloh et al. 1999). The volume of the ejaculate is reduced or absent while
experiencing an orgasm, a condition often referred to retrograde ejaculation or
aspermia (Girgis 1968; Shader and Elkins 1980). Indeed, some patients using
either quetiapine or risperidone reported in response to our questionnaire a
reduction in ejaculate volume: 14.3% versus 28.6%, respectively: the difference
was not significant.
Limitations of this study are the open design and, especially in women, the small
number of participants. Also the time frame of 6 weeks is short, considering that
patients are often advised to take antipsychotics for many years. Evaluating sexual
side effects and serum prolactin levels in long-term follow-up studies would provide
patients and clinicians with important information. An improved design for future
studies could be in stable patients with schizophrenia being switched to alternative
treatment options in a double blind study design allowing baseline assessment of
sexual and hormonal functioning.  Although in this brief study all participants took
their assigned medications, in our clinical experience drug-induced sexual
dysfunction is often a reason for medication discontinuation or requests for
treatment alternatives. We are not aware of any studies on the correlation between
compliance and sexual side effects due to antipsychotic drugs. Studies suggest
that clinicians tend to underestimate the frequency and importance of sexual side
effects in patients with schizophrenia (Finn et al. 1990; Peuskens et al. 1998) and
other psychiatric disorders (Singh and Beck 1997). Further research is required on
sexual side effects induced by antipsychotics, the possible mechanisms involved
and on the relationship of specific side effects on compliance.
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Age (years) 25.2±7.3 26.5±5.4 NS*
Sex (%)
Male 76 62 NS*
Female 24 38
Diagnosis (%)
Brief Psychotic Disorder 4.0 7.7
Delusional Disorder 4.0 0.0
Psychotic Disorder (NOS) 20 7.7
Schizoaffective Disorder 0.0 7.7
Schizophrenia 60 57.7
Schizophreniform Disorder 12.0 19.2
PANSS** scores week 1 (mean ± SD) 65.21±23.01 65.25±21.05 NS*
Mean improvement on the PANSS
improvement in week 6
5.39±12.34 8.37±11.22 NS*
NS = Not significant, * t-test, **PANSS= Positive and Negative Syndrome rating Scale







Prolactin (ng/ml) 13.8±17.9 57.9±39.7 0.000*
Type of sexual dysfunction (n (%))
Decreased libido 4/25 (16) 9/24 (36) 0.05**
Decreased orgasm 1/21 (5) 7/23 (30) 0.01**
Sexual dysfunction (libido and/or orgasm) 4/25 (16) 12/24 (50) 0.006**
* t-test ** Chi-square
Table 3. Prolactin levels (mean ± SD) and sexual dysfunction in male and female patients treated













12.1±10.1 47.1±24.1 0.000* 18.0±21.5 78.1±55.4 0.001*
Type of sexual dysfunction (n (%))
Decreased
libido
4/19 (21) 6/15 (40) 0.12** 0/6 (0) 3/10 (30) 0.07**
Decreased
erection




0/5 (0) 3/9 (38) 0.05**
Decreased
orgasm
1/16 (6) 4/15 (27) 0.05** 0/5 (0) 3/8  (38) 0.06**
Ejaculation
dysfunction





4/19 (21) 8/14 (57) 0.02** 0/6 (0) 4/10 (40) 0.04**
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The atypical antipsychotic risperidone significantly increases plasma prolactin
levels in patients, whereas clozapine, olanzapine and quetiapine do not. The
difference in neuro-endocrine response can not readily be explained by their
affinity for the dopamine D2 receptor, but may be connected to their metabolism. To
gain insight in the contributory role of risperidone’s active metabolite 9-OH
risperidone, we measured the plasma concentrations of risperidone, 9-OH-
risperidone and prolactin. 
Blood samples were taken from twenty-five patients with a psychotic disorder (14
male, 11 female; mean age 25+ 7 yr (range 17-52)), after risperidone treatment for
at least 4-6 weeks. Risperidone was given at a dose ranging from 1-6 mg/day
(mean dose: 3 mg/day). Mean plasma concentrations for risperidone was 4.6
(range 1.0 - 36.2 µg/l) and for 9-OH risperidone 19.4 (range 1.0 -75.0 µg/l). Mean
prolactin concentrations were 985.5 (SD 721.7, range 106-3700 ME/L).
Dosages of risperidone (in mg/day) correlated significantly with plasma
concentrations of risperidone, 9-OH risperidone, active moiety and prolactin.
Statistical analysis did not reveal a correlation between plasma levels of
risperidone and plasma prolactin concentrations. Yet, plasma concentrations of 9-
OH-risperidone showed a positive correlation with prolactin concentration. Pearson
correlation 0.516, p=0.008. These data support an active role of 9-OH-risperidone
in risperidone’s high tendency to elevate prolactin levels. In addition, 9-OH





The atypical antipsychotics are characterized by a low propensity to induce extra-
pyramidal side effects (EPS). They differ, however, as regards weight gain, insulin
resistance and the induction of prolactin elevation.
Most classical antipsychotics are potent dopamine 2 (D2) antagonists and they
inevitably induce Hyperprolactinemia. In contrast, the atypical antipsychotics
olanzapine, quetiapine and clozapine induce only mild, transient prolactin
elevations. Surprisingly, the atypical agent risperidone produces profound and
lasting increases in plasma prolactin levels, that are similar or even greater than
those seen with haloperidol or other classical antipsychotics (Knegtering et al.
2000). This is an unexpected finding since risperidone is a considerably less potent
D2 receptor antagonist than haloperidol (Leysen 1981; Leysen et al. 1992; Leysen
et al. 1994).
Several ideas have been advanced to explain the differences between atypical and
typical antipsychotics with regard to their EPS liability (for review see Westerink
2002). Most important theories are:
1) A higher affinity for the 5HT2 receptor compared to the dopamine D2 receptor
2) A lower dopamine D2 receptor occupancy
3) Surmountable binding to dopamine receptors 
These theories on atypicality do not, or only partly, explain the lack of significant
prolactin elevation by clozapine, quetiapine and olanzapine. Recently, Kapur et al.,
proposed a poorer penetrability of the blood-brain barrier of risperidone to explain
its higher tendency for Hyperprolactinemia as compared to olanzapine and
quetiapine (Kapur et al. 2001; Kapur et al. 2002). 
All fore-mentioned theories have focused on the interaction of the antipsychotic
agents per se with dopamine neurotransmission at the level of the various
dopamine-D2 receptors. Relatively little attention has been directed to the
pharmacokinetic differences between the compounds with respect to their active
metabolites to account for their endocrinological profiles. Indeed, for most
antipsychotics the contribution of their metabolites is generally considered to be of
only minor importance (Baldessarini et al. 1993). An exception is risperidone. This
drug is extensively metabolised in the liver to 9-hydroxy-risperidone, an active
metabolite with similar receptor binding profile as risperidone (Beijsterveldt van et
al. 1994). Presumably, 9-OH-risperidone contributes to risperidone’s
pharmacological action (Aravagiri et al. 1998). Table 6.1 shows the major
metabolic pathways of risperidone discussed in this article.
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In this study, we propose that 9-OH risperidone considerably contributes to
risperidone’s higher tendency to prolactin elevation. To test this hypothesis we
have measured the plasma levels of risperidone, 9-OH risperidone and prolactin
from patients with schizophrenia, treated long-term with risperidone. In addition, we
have investigated whether measurement of 9-OH risperidone plasma levels should
be included when monitoring for compliance. 
Methodology 
The present study is part of a large survey at the University Hospital Groningen
into antipsychotic-induced Hyperprolactinemia and sexual dysfunctions. Inclusion
criteria for this subset included: age between 18 and 45 years, having a diagnosis
within the schizophrenic spectrum or other psychotic disorders and having received
risperidone treatment for at least 4 weeks. Informed consent was obtained from all
participating patients. The study was approved by the local ethical committee.
From each individual patient bloodsamples were taken simultaneously for
determination of risperidone, 9-OH-risperidone and prolactin concentrations. Blood
samples were collected between 8.30 - 9.00 a.m.  Reversed phase HPLC with UV-
detection was used to determine plasma risperidone and 9-OH-risperidone
concentrations in the blood samples. With this method plasma concentrations
down to 2µg/L for risperidone and 1µg/L for 9-OH-risperidone can be measured. To
determine prolactin levels the MAIA clone kit was used. With this method prolactin
concentrations over the range of 6.0-10,000 ME/L can be measured. Samples are
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reacted with a mixture of monoclonal antibodies to prolactin. By measuring the
bound fraction (Seperation Reagent pellet) of the sample in a gamma counter
calibrated to detect 125-Iodine, the concentration of prolactin in the sample can be
determined.
For statistical analysis the Pearson correlation coefficient for non parametric
variables was used. Prolactin levels, serum levels of risperidone and active moiety
were normalized by converting them to their natural logarithm. For all analyses, the
effects were tested at the 2-sided α level of 0.05. 
Results
Twenty-five patients treated with risperidone (14 male, 11 female; mean age 25
years, range 17-52, SD 7 years) had plasma assessments available of the three
compounds under study. All these patients had a psychotic disorder according to
DSM-IV criteria (20 with a diagnosis within the schizophrenic spectrum and 5 with
other psychotic disorders).  Subjects received risperidone treatment for a minimum
of four weeks, with a mean risperidone dosage of 3 mg/day (range 1-6 mg/day).
Mean prolactin concentrations were 985.5 (range 106-3700 ME/L). Plasma
concentrations of risperidone, 9-OH-risperidone, the active moiety of both and
serum prolactin are listed in table 6.1.
Table 6.1. plasma concentrations during 4 to 6 weeks treatment with risperidone mean dosage 3
mg/day (range 1-6 mg)
Compound Mean plasma concentrations(± SD)  Range
Risperidone       4.6 (±    7.4) µg/l  1.0 to 36.2 µg/l 
9-OH-risperidone   19.4 (±  16.7) µg/l 1.0 to 75.0 µg/l 
Active moiety    24.0 (±  18.7) µg/l 2.0 to 77.0 µg/l
Prolactin concentration 985.5 (±721.7) mE/L* 106-3700   mE/L*
* 1ng/ml ≅ 20 ME/L
In figure 6.2 the (Pearson) correlation coefficients are presented between the oral
daily risperidone dosage, plasma levels of risperidone, 9-OH risperidone and
serum prolactin. Oral risperidone dosage is significantly correlated with plasma
risperidone levels (r=0.521; p=0.008) as well as plasma 9-OH risperidone levels
(r=0.571; p=0.003) and plasma prolactin levels (r=0.445; p=0.026). In contrast to
plasma risperidone, only 9-OH risperidone correlates significantly with plasma
prolactin levels (r=0.516; p=0.008). No significant correlations were found between
plasma risperidone levels and plasma prolactin levels (r=0.234, p=0.260) nor
between plasma risperidone levels and 9-OH risperidone levels (r=0.293,
p=0.155).
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Figure 6.2. Correlations between daily oral risperidone dosage, plasma risperidone, plasma 9-OH

















r=Pearson correlation coefficient, NS= no significant correlation
In figure 6.3 plasma risperidone and 9-OH risperidone are presented together as
their active moiety. Oral risperidone dosage correlates significantly with the active
moiety of risperidone (r=0.764; p=0.000) and plasma prolactin levels (r=0.445;




Figure 6.3. Correlations between daily oral risperidone dosage, the active moiety (of plasma

















r=Pearson correlation coefficient, 
Active moiety is sum of plasma levels of risperidone and 9-OH risperidone
Discussion
In this study treatment with risperidone at therapeutic doses was associated with
profound Hyperprolactinemia. In addition, assessment of risperidone and its major
metabolite 9-OH-risperidone revealed plasma levels of 9-OH-risperidone
approximately 4 times higher than those of the parent compound. Risperidone
levels and that of its metabolite correlated significantly with the risperidone dosage.
In addition, a statistically significant correlation was found between the daily
dosage of risperidone and 9-OH-risperidone with plasma prolactin. No correlation
was found between plasma risperidone and plasma prolactin levels.
The Hyperprolactinemia found after 6 weeks of risperidone treatment is in
accordance with our previous findings, as well as with the data of large clinical
trials, showing prolactin levels higher than with classical neuroleptic-treatment
(Knegtering  et al. 1998; Kleinberg et al. 1999; Knegtering et al. 2000; Knegtering
et al. 2003). Clearly, risperidone contrasts with most of the other atypical
antipsychotics, which produce only transient prolactin elevation (Kapur et al. 2001;
Kapur et al. 2002; Kim et al. 2002). This difference in endocrine response has not
been fully clarified so far. There is however one important distinction between EPS
induction and prolactin elevation. The induction of EPS is mediated through
blockade of central dopamine D2 receptors in the striatum. Conversely,
antipsychotic-induced prolactin elevation is due to blockade of peripheral dopamine
D2 receptors, located in the anterior pituary outside the blood brain barrier (Kapur
et al. 2002). Here, the tonic inhibitory effect of dopamine on the release on
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prolactin is overruled by a blockade of the postsynaptic D2 receptors, resulting in
Hyperprolactinemia. To explain the high levels of prolactin associated with chronic
risperidone treatment, several mechanisms may be called upon. 
Drugs with a poor penetration of the blood brain barrier, are more active at the
peripheral D2 receptors as compared to the central D2 receptors. In an
experimental study, Kapur and coworkers, have compared the effects of
antipsychotics on peripheral D2 receptors in the tubero-infundibular tract and the
central D2 receptors in the striatum (Kapur et al. 2002). They thus calculated the
“central to peripheral ratio of D2 occupancy”. Risperidone displayed a higher
peripheral potency at a given level of functional central antagonism as compared to
quetiapine and olanzapine. In other words, risperidone’s central activity (i.e.
antipsychotic action) is paralleled by a relatively higher peripheral activity (i.e. a
higher prolactin elevation). 
Although clozapine, olanzapine and quetiapine are not associated with prolonged
prolactin elevation, Turrone et al., demonstrated that they do produce a short
transient prolactin increase immediately after dose administration (Turrone et al.
2002). In contrast, risperidone demonstrated a much higher transient increase of
prolactin, superimposed on a sustained elevation (Turrone et al. 2002). Since the
release of prolactin with the so-called prolactin sparing antipsychotics is of short
duration, accumulation does not come about with subsequent dosing of these
antipsychotics (Kapur and Seeman 2001). Indeed a drug must exert a prolonged
action to account for accumulation. Given the short half-life of risperidone (2-4 hr),
we therefore propose that the active metabolite 9-hydroxy risperidone (9-OH-
risperidone) is a relevant factor in cumulating prolactin elevation over time
(Heykants et al. 1994).  
Risperidone is preferentially metabolized to 9-OH risperidone by the P450 liver
enzyme CPY2D6 to 9-OH risperidone. This is the major active metabolite in
humans with a half-life of 20 hour (Caccia 2000). Notably, 9-OH risperidone
displays receptor affinities for the D2 and 5HT2 receptors similar to risperidone
(Beijsterveldt van et al. 1994). From a receptor occupancy study in healthy
subjects it was concluded that, 9-OH risperidone will substantially contribute to the
overall antipsychotic effect of risperidone (Nyberg et al. 1995). Moreover, 9-OH
risperidone counterbalanced the variability in the disposition of risperidone (Nyberg
et al. 1995). Importantly, early in vitro experiments have demonstrated a
comparable potency of risperidone and 9-OH-risperidone to stimulate prolactin
release (Bowden et al. 1992). Since both compounds have similar pharmacological
actions, the combination of risperidone and its active metabolite 9-OH risperidone
together are often referred to as the ‘active moiety’. There are however important
differences between risperidone and 9-OH-risperidone, with regard to their
distribution within the peripheral and central compartments, plasma and brain
respectively. 
Protein binding (mostly albumin and α-1-acid glycoprotein) of risperidone and 9-OH
risperidone is 90.0 and 77.4%, respectively (Mannens et al., 1994). This would
implicate a more than two times higher free fraction for 9-OH risperidone compared
to the parent compound. However, logP values (logarithm of the n-octanol/water
partition coefficient) for risperidone and 9-OH-risperidone are 3.04 and 2.32
respectively (Mannens et al. 1994). This indicates that the 9-OH metabolite is
approximately 5 times less lipophilic than risperidone. Combining these values for
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protein binding and logP with our measured plasma concentrations of risperidone
and 9-OH risperidone, we would expect brain levels of the metabolite to be twice
as high as those of the parent compound. This is broadly compatible with a study
in rats where a single dose of risperidone resulted in brain tissue concentrations,
which were comparable for the parent compound and its 9-OH metabolite
(Aravagiri and Marder 2002). Moreover, it supports the notion that the 9-OH
metabolite substantially contributes to the antipsychotic effect of risperidone.
LogP values of risperidone and its metabolite are lower than for most other
antipsychotics, indicating that risperidone and its metabolite are less lipophilic. This
implies that risperidone and even more so 9-OH-risperidone do not readily enter
the brain through the blood-brain barrier. Indeed, in a study comparing risperidone
and 9-OH-risperidone, concentrations in different tissues in rats after 15 days of
treatment with risperidone demonstrated relatively low brain/plasma ratios for
risperidone and 9-OH-risperidone (Aravagiri et al. 1998).  In a subsequent study,
they reported equal concentration for risperidone and 9-OH-risperidone in brain
tissue after a single dose of risperidone (Aravagiri and Marder 2002). However, the
levels of 9-OH-risperidone were 4.5 times higher in the plasma than the risperidone
levels, which is very similar to the ratio we found in our study. Although one must
be careful to extrapolate experimental studies to humans, taken together, these
data suggest that 9-OH-risperidone has an even lower ability to penetrate the brain
than risperidone. Therefore, while both compounds presumably contribute to a
similar extent to the central effects of risperidone, it can be argued that the
peripheral effects on prolactin release are dominated by the much higher plasma
concentrations of the 9-OH metabolite. These assumptions are supported by the
findings presented here. In addition plasma 9-OH-risperidone correlated highly
significantly with prolactin, where as risperidone plasma levels did not.
Clozapine, olanzapine, quetiapine and risperidone are potent serotonin receptor
antagonists. Interactions with serotonin system per se clearly modulate the release
of prolactin (Kar van de  et al. 1996). However, a large body of clinical and pre-
clinical evidence indicates the effect of serotonin receptor-antagonism on prolactin
release is overruled by the strong concurrent D2 blockade in the pituitary
(Knegtering et al. 1999). Clearly, in our patients a prolonged occupancy of D2
receptors in the pituitary is very likely, due to both the action of risperidone but
even more so of its active metabolite. 
There is an increasing awareness that compliance with antipsychotics is poor, and
that this probably also holds for the newer atypical antipsychotics (Perkins 2002).
However, monitoring risperidone blood-levels for compliance has not become
clinical practice today. 
In our study the dose of risperidone clearly correlated with 9-OH-risperidone but
not with the parent compound risperidone. Assessing risperidone levels without 9-
OH-risperidone levels can easily lead to misinterpretations of patients’ compliance.
Indeed, there was a wide range in the risperidone levels. The wide range or the
risperidone plasma levels found in this study may relate to two factors. A
methodological flaw in this study could be the variance in time between dosing and
moment of blood sampling. Given the short life-time of risperidone, such variance
may lead to the collection of inconsistent data. Indeed, large variations were found
in plasma levels of risperidone, but also in 9-OH-risperidone and prolactin.
Variations in 9-OH-risperidone and prolactin levels blood levels are probably much
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less sensitive to variations times of sampling, implying that, at least in part, this
should also be attributed to individual differences in metabolism. Consequently,
drug monitoring for clinical reasons should include preferable both, risperidone and
9-OH risperidone.
To conclude, we found high prolactin levels with chronic risperidone treatment.
Moreover, in our study oral dosage of risperidone and plasma concentrations of 9-
OH-risperidone, but not those of plasma risperidone correlated with prolactin
elevation. Taken into account that the active metabolite has similar D2 affinity, a
lower brain/plasma ratio and a long half-life-time, these data are in support of a
predominant role for 9-OH-risperidone in prolactin elevation, inducing prolactin
elevation. This explains why, although in absence of high incidences of extra
pyramidal symptoms, prolactin elevation related side effects like amenorrhea
galactorrhea and sexual side effects may occur frequently. Prolactin elevation
reflects peripheral D2-antagonism of risperidone and its metabolite and therefore it
is not a good index for central postsynaptic receptor occupancy by risperidone.
Finally, monitoring plasma levels for compliance is valid only when it includes both
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Summary
In a target population of about 200 patients treated with classical antipsychotics or
clozapine for more than half a year 35 patients (21 classical, 14 clozapine) could
be included in a cross-sectional study evaluating sexual side effects attributed to
the treatment of antipsychotics. Libido reduction was reported in 33% of the
patients in both treatment groups. There was a trend of less detrimental effects of
clozapine on erections orgasm and ejaculation in comparison to classical
antipsychotics. The sample-size of the study was small, the identified differences
between the groups did not reach statistic significance.  As the frequency of
reported sexual dysfunctions in this long-term study are in line with reports in short-
term studies, this studies supports the hypothesis that sexual side effects don’t
subside over time. Definite conclusions of clozapine inducing less sexual side
effects than classical antipsychotics can’t be drawn, due to the small sample-size




The prevalence of sexual dysfunctions that are related to the use of antipsychotics
is only infrequently. Only few studies have been published, estimating the
prevalence of sexual dysfunctions between 25 and 60% in patients using
antipsychotic drugs for six weeks (Knegtering et al. 2003). A few studies on the
prevalence of sexual dysfunctions after long-term use ranging from six months to
many years suggest that sexual side effects do not subside over time (Ghadirian et
al. 1982; Lingjaerde et al. 1987). Although the relative burden of sexual
dysfunctions is probably high it is only seldom investigated (Finn et al. 1990; Smith
et al. 2002). In the literature sexual dysfunctions in patients with schizophrenia are
often attributed to a combination of the disease process (schizophrenia) and the
effects of antipsychotics (Knegtering et al. 2003). There are suggestions in the
literature that prolactin-elevating antipsychotics are associated with more serious
sexual dysfunctions in comparison to patients using prolactin sparing
antipsychotics (Kim et al. 2002; Knegtering et al. 2002). In agreement with this
literature is the study of Aizenberg who switched 30 out of 60 patients from
classical antipsychotics to clozapine in a randomized study. Patients continuing
treatment with classical antipsychotics reported more sexual side effects than
patients switching to clozapine (Aizenberg et al. 2001). 
This was in contrast to the findings of Hummer et al, who compared the effects on
sexual functioning of haloperidol (prolactin-elevating) with clozapine (prolactin-
sparing) in an open, non randomized study (Hummer et al. 1999). Both haloperidol
and clozapine were correlated with the same frequency of sexual side effects after
six weeks with weekly evaluations. Not in line with other studies these sexual
dysfunctions seemed to subside during monthly follow-up in both treatment groups.
As the prevalence of sexual dysfunctions in patients treated with antipsychotics for
a long time has hardly been studied and the available findings are not consistent
we decided to examine sexual side effects in patients who were being treated for
more than six months with either classical antipsychotics or clozapine.  
Method
In- or out-patients being treated at the University Medical Center Groningen
(UMCG) or the Mental Healthcare Foundation Groningen (GGz Groningen) were
asked to participate in a study evaluating their experiences with antipsychotics.
The study has not been sponsored by any third party and the study design was in
agreement with the local ethical commission.
In order to reflect patients having more or less the same severity of illness, only
patients treated with depot antipsychotics or clozapine could enter the study. In
order to reduce selection bias, all patients who were being treated with depot
antipsychotics or clozapine were identified using information of the hospital
pharmacy database (GGz Groningen) and information of clinicians (GGz
Groningen and UMCG). An independent physician (second author) checked the
records of the identified patients for fulfilling inclusion criteria. Inclusion criteria
were a diagnosis within the schizophrenia spectrum (schizophreniform disorder,
schizophrenia, schizoaffective disorder) age between 18 and 65 years, being
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treated with only one antipsychotic, on stable for at least 6 months. Antipsychotics
could be either a classical depot antipsychotic or clozapine. No co-medication with
known influence on sexual functioning was allowed. Patients had to able to give
oral and written informed consent. Patients were asked to participate by their
therapists. Two independent raters performed the interviews and they scheduled
appointments with the eligible patients. Both interviewers were trained
psychologists. To reduce possible bias of the interviewers, they agreed not to be
informed about any study hypothesis. 
Socio-demographical information was gathered including diagnosis (information of
the treating physician), duration of illness, duration of using antipsychotics and the
duration of use of the present antipsychotic and other medication.  
The patients were interviewed using the Antipsychotics and Sexual Functioning
Questionnaire (ASFQ), an interview based upon the UKU side effects rating scale
(Lingjaerde et al. 1987; Knegtering and Castelein 2001). The ASFQ  includes semi-
structured items assessing improvement or worsening of sexual functioning
attributed to the use of antipsychotics. An open question about side effects in
general is followed by a semi-structured questioning about libido, orgasm and
galactorrhoea, for men erection and ejaculation and for women vaginal lubrication
and menstruation. 
Statistics
We did pair-wise comparisons to identify possible differences between
demographical data and between antipsychotics in inducing sexual side effects.
The statistical methods applied were: chi-square tests for pair-wise differences in
percentages patients with sexual dysfunction. Two sided t-tests were applied for
pair-wise differences in mean age, duration of illness and duration of treatment.      
Results
Two hundred patients were selected from the pharmacy database treated with
either depot antipsychotics or clozapine for more than six months. After checking
the medical files half of these patients had to be excluded for not fulfilling the
inclusion criteria for the study (other diagnosis, age, treated with more than one
antipsychotic or other co-medication possible influencing sexual functioning like
antidepressants or lithium, diabetes mellitus. Thirty patients did not want to
participate in the study, 20 patients were considered by their treating physician to
be to ill to be interviewed, Fifteen could not be traced or did not show up on their
appointment.  Finally thirty-five patients (24 men and 11 women) agreed to
participate and could be included. Demographical data of these patients as well as




Table 7.1. Demographical data of patients being treated with classical antipsychotics or




significant differences between the
groups
Number of men/women 11/3 13/8 NS
Mean age in years (range) 34.9 (20-44) 44.0 (26-61) t=-2.888
df=33
p=0.007
Being involved in a partner
relationship last year
5/14 (36 %) 6/21 (29%) NS
Presently having a partner
and living together 
2/14 (14%) 1/21 (  5%) NS
Having a partner not living
together
4/14 (29%) 4/21 (19%) NS
Never had a partner 8/14 (57%) 14/21 (66%) NS
Mean number of years
treated with antipsychotics
(range)
7.3 (2.5-15) 11 (2-25) t=-1.943
df=33
p=0.64
Mean number of years
treated with the present
antipsychotic (range)
4.7 (1-8) 5.6 (0.5-15) NS
In response to the open questions, 3 patients indicated to experience sexual side
effects; all treated with classical depot antipsychotics. In response to the semi-
structured questions 33% of the interviewed patients on depot antipsychotics and
33% of those using clozapine reported loss of libido. Reduction of the capacity to
experience an orgasm and erectile dysfunction were only reported by patients
treated with classical antipsychotics (22% and 25% respectively). 11% of patients
treated with clozapine and 36% of patients using classical antipsychotics reported
a reduction in the volume of ejaculate. There was a trend showing clozapine to be
associated with less negative effects on orgasm, erection and ejaculation although
this did not reach statistical significance (see table 7.2). 
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0/12 (0%) 4/18 (22%) Chi-square 2.836, df=1
p=0.09
Erection 0/9 (0%) 3/12 (25%) Chi-square 2.625
df=1
p=0.10
  Ejaculation 1/9 (11%) 4/11 (36%) Chi-square 1.111
df=1
p=0.29
In table 7.3 the data of this long-term treatment of antipsychotics are compared
with data from other studies performed by our group obtained in patients who were
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using either classical (oral) antipsychotics or clozapine for six weeks. The details of
these studies are described in chapter 9. Neither classical antipsychotics, nor
clozapine showed significant differences regarding the incidence of sexual
dysfunctions after six weeks or long-term treatment with the antipsychotics (Chi-
square NS).
Table 7.3. Number of patients experiencing sexual dysfunction versus the total number of
patients responded on that item and the percentage of patients with a sexual dysfunction
attributed to antipsychotic medication
Men and women Men
Libido Orgasm Erection Ejaculation









































Discussion and conclusions 
We had aimed at an epidemiological representative cross-sectional cohort study
comparing patients being treated for at least six months with classical (depot)
antipsychotics and clozapine. However we met many problems in including the
preferred number of patients. A great number of patients had to be excluded using
multiple antipsychotics or other co-medication. A further complication was the
significant difference between the long-term treatment groups in mean age. Higher
age may be a risk-factor for experiencing more sexual side effects (Smith et al.
2002). Still by excluding patients above 55 years from the database and eliminating
the statistical differences in age, did not change the results. In addition to the
limitations of this study we could not include enough women to examine their
sexual functioning in detail. 
Still the findings of this study are in line with previous studies. Only 3 patients (all
on classical antipsychotics) reported sexual dysfunctions without explicitly asking
for them. This is in line with our former studies, showing that about 10% of patients
treated with classical antipsychotics mention sexual side effects spontaneously
(Knegtering et al. 1998). In studies using semi-structured questionnaires between
30 to 50% of the patients report a reduction in libido or orgasm after six weeks
treatment with classical antipsychotics. The findings in this study are well within
these boundaries. This supports the hypothesis that sexual side effects do not
subside after continuation of classical antipsychotics. Also the findings in patients
treated with clozapine for more than 6 months are in line with earlier findings in
patients treated for six weeks. These preliminary results support the hypothesis
that sexual side effects do not subside over time, which is in line with the findings
of Lingjaerde (Lingjaerde et al. 1987).
The interpretation of the differential effects of classical depot antipsychotics versus
clozapine can only be tentative. Although the difference did not reaching statistical
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significance, patients treated with clozapine may experience less detrimental
effects on orgasm, erection and ejaculation. 
Libido reduction is known to be caused by schizophrenia itself as well as by
antipsychotic drugs. In contrast to orgasm, erection and ejaculation, libido is
difficult for the patient to judge or to attribute (Burke et al. 1994). The results from
comparing clozapine to classical antipsychotic could support the hypothesis that
serum prolactin elevation (classical) antipsychotics may contribute to the
occurrence high frequencies of reduction in erection, orgasm and ejaculation.
Prolactin sparing antipsychotics, including clozapine, may have a much lower
tendency to induce sexual side effects (Kim et al. 2002; Knegtering et al. 2002;
Knegtering et al 2003).
These are just preliminary data. A study with more power is likely to report
significant differences. Presently this study is being extended in other psychiatric
centers in order to include enough patients to confirm these preliminary findings
with enough power.
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Summary
The literature is reviewed and preliminary results of new studies are presented
showing that treatment with classical antipsychotics, as well as risperidone,
induces sexual dysfunctions in 30% to 60% of the patients. These antipsychotics
also frequently induce amenorrhoea and galactorrhoea. 
Although comparative studies are rare, it is likely that prolactin-sparing
antipsychotics, as recently shown in a randomized trial of olanzapine versus
risperidone, induce less sexual side effects.
From these studies, it becomes apparent that prolactin elevation induced by
classical antipsychotics and risperidone is probably a factor in inducing sexual
dysfunctions, amenorrhoea and galactorrhoea. The role of other factors inducing
sexual dysfunctions like sedation, ∝-blockade, testosterone, dopamine, and
serotonin is discussed. Finally, it is concluded that sexual and hormonal effects of
antipsychotics, although clearly important, are often neglected, in research as in
clinical practice. Lowering the dosage or switching to a prolactin-sparing




Chapter 8 has been published in psychoneuroendocrinology in 2002. The content
includes a review of the literature and recent findings of our studies, presented in
chapter 1, 2, 4. The data of the patients presented in chapter 2, 4 and from
ongoing open studies of patients treated for 6 weeks with antipsychotics are
analysed in a summative dataset allowing analyses in a broader context. In this
book chapter 8 overlaps in some aspects with chapter 9. The advantage of this
overlap is that each chapter can be read independently. 
Introduction
There is a growing awareness of sexual side effects and changes in endocrine
functioning induced by antipsychotics, a field of research that has been neglected
for a long time. We will combine a review of the literature with results of recent
studies from our research group. In conclusion, we discuss the findings and
reflect on possible pathogenetic mechanisms, clinical implications, and future
directions of studies.  
What are the effects of antipsychotics on sexual dysfunctions?
A problem in evaluating sexual dysfunctions in patients with schizophrenia is that
some patients with schizophrenia may experience alterations in sexual
performance as a result of their primary illness and the social consequences of
this illness (Nestoros et al., 1981). Others might experience problems in sexual
functioning primarily related to treatment with antipsychotic medication. Studies
show that most patients with schizophrenia are sexually active, often by
masturbation although many patients also have sexual contacts with a partner.
Studies evaluating sexual performance in unmedicated patients with
schizophrenia show that these patients tend to experience a reduced libido, but
no other sexual dysfunctions (Aizenberg et al., 1995). This decreased libido might
be linked to the general reduction of initiative, often referred to as negative
symptoms.  Another problem is that patients, as a consequence of their
symptoms, experience many social problems complicating contacting potential
partners.
Many pharmacological properties of antipsychotics may influence sexual
performance. Segraves and Meston et al. reviewed these mechanisms. The most
important ones will be mentioned here (Segraves 1989; Meston et al. 1992;
Meston and Frohlich 2000).
All antipsychotics are dopamine antagonists. Dopamine is involved in sexual
arousal and orgasm. Dopamine blockade might contribute to libido loss and
orgasm disturbance. A secondary effect of dopamine blockade, above a certain
threshold, in the tuberoinfundibular system of the brain is prolactin elevation. The
mechanisms are being discussed elsewhere in this journal supplement. As a
consequence of prolactin elevation, many changes in other hormone levels might
occur, including a decrease in serum testosterone levels that might influence
sexual performance in men as well as in women. The prolactin elevation itself as
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well as decreased levels of testosterone and possibly other hormones may
decrease some aspects of sexual behavior.
Many antipsychotics, partly from being histamin antagonists, have sedating
properties diminishing sexual performance. Some antipsychotics have alpha
blocking properties that might diminish erection, vaginal lubrification and
ejaculation. These noradrenergic effects seemed to be partly balanced with (anti-)
cholinergic effects leading to final effects on erection that might turn into erection
disturbance (often) or priapism (rare). The main mechanisms and effects of
antipsychotics on sexual performance are summarized in table 1.

































?= possible influence, but no consensus in the literature.
Studies that assess sexual side effects of antipsychotics are rare; comparative
studies almost absent (Nestoros  et al., 1981; Knegtering et al., 2000; Peuskens
et al., 1998). Studies using spontaneous reports of patients report low incidences
(10% or less) of sexual dysfunctions (Knegtering et al., 1999). In contrast, studies
using structured interviews or questionnaires tend to report high incidences of
sexual side effects related to treatment with antipsychotics. In such studies, 30%
to 60% of the patients with schizophrenia report sexual dysfunctions (Lingjearde
et al., 1987; Sullivan  and Lukoff  1990).
Classical antipsychotics frequently show a higher incidence of amenorrhoea,
galactorrhoea, and impotence in comparison to placebo (Ghadirian  et al., 1982).
These effects are associated with prolactin elevation.
According to Aizenberg et al, untreated male schizophrenic patients exhibit
decreased sexual desire. Their study suggests that antipsychotics might lead to a
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restoration of sexual desire while impairing erectile, orgasmic, and sexual
satisfaction problems (Aizenberg et al., 1995).
Ghadirian et al. examined a random sample of 55 schizophrenic outpatients (26
men and 29 women) treated with classical antipsychotics selected from a long-
term follow-up clinic. The patients rated their current sexual functioning on
specially designed scales. More than 58 %of the male (reduced erection and
orgasm) and 33% of the female patients (orgasm) reported impaired sexual
functioning during  treatment with antipsychotics. Ninety-one per cent of the
female patients reported changes in menstruation (Ghadirian et al. 1982).
Although comparative studies are rare, the majority of the literature suggests that
antipsychotics might differ in the type and frequency of sexual dysfunctions
(Knegtering et al., 1999). For instance, thioridazine seems to cause more sexual
dysfunctions (erection and ejaculation) in comparison to other classical
antipsychotics (Kotin et al., 2001). 
In a study by Smith et al. (2000), 101 patients using conventional antipsychotics
were compared with 57 normal controls and 55 patients attending a sexual
dysfunction clinic. Sexual dysfunctions were found in 45% of the patients using
classical antipsychotics, 17% of normal controls, and 61% of controls attending a
sexual dysfunction clinic. Male patients reported normal libido but were highly
likely to report erectile and ejaculation dysfunction. In women, thioxanthene
substitutes, benzamides, and aliphatic phenothiazines were more likely to be
associated with sexual dysfunction than with other antipsychotics.
Clozapine, which induces no significant and sustained prolactin elevation, causes
few sexual dysfunctions according to some authors (Crenshaw and Goldberg
1996). But according to a study by Hummer et al. (1999), the prolactin-elevating
classical antipsychotic haloperidol and (non prolactin-elevating) clozapine showed
comparable frequencies of sexual dysfunctions. In this study, 153 patients were
treated for six weeks with either clozapine (N=100) or haloperidol (N=53).  Sexual
dysfunctions were evaluated in weekly assessments. In the last week of their
study, there was a difference in sexual dysfunctions; haloperidol causing more
sexual dysfunctions in comparison to clozapine. In their final analysis carried out
on a last-observation-carried-forward basis, more than 60% of men and 30% of
women in both treatment groups, reported sexual dysfunctions, no statistical
significant differences were found between the treatmentgroups (Hummer et al.,
1999). In contrast Aizenberg et al. (2001) in a study with 60 outpatient men using
long-term classical antipsychotics, 30 being switched to clozapine, found that
maintenance therapy with the atypical antipsychotic clozapine may be associated
with a lesser degree of sexual dysfunction than the classical antipsychotics. 
In 1997 we initiated a research-program aiming at the evaluation of the effects of anti-
psychotics on sexual functioning and the (mediating) influence of endocrine functions
in bringing about eventual effects. 
In an open randomized clinical trial (RCT) we compared sexual dysfunctions in
patients treated with olanzapine versus patients treated with risperidone. Twenty-five
patients received olanzapine, mean dosage 9,4 (range 5-15) mg/day; 21 patients
received risperidone, mean dosage 3,4 (range 2-6) mg/day. Sexual functioning was
assessed by means of a semi-structured questionnaire based upon the UKU
(Lingjaerde 1987): the Antipsychotics and Sexual Functioning Questionnaire (ASFQ)
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(Knegtering and Castelein 2000). The ASFQ guides the interviewer in introducing the
subjects of the interview and provides more detailed scoring instructions than the
UKU. Patients were asked if they experienced a change in sexual functioning which
they relate to the medication used last month. Sexual dysfunctions most probably
related to the use of antipsychotics could be rated as much improved, improved,
unchanged, worse, much worse or in case the answer was not clear, unknown. As
almost no patient reported improvement in sexual performance during treatment with
antipsychotics, we converted the ratings into the dichotomized ratings unchanged or
worsened before some of the statistical analyses. Sexual dysfunctions were rated and
blood sampling was done after six consecutive weeks of treatment with anti-
psychotics. Patients received general information about side effects but were blind for
any specific hypothesis. No statistical significant differences were found between the
treatment groups in demographical data and diagnosis. Sexual dysfunctions (libido
reduction, problems achieving an orgasm, erectile dysfunction or ejaculatory
dysfunction) were reported by 3 out of 25 patients (12%) in the olanzapine-group, and
by 11 out of 21 patients (52%) in the risperidone-group. Statistical test-results: chi-
square value= 6.99; df= 1; p= .004; 95% confidence-interval for the difference: 16% -
65% (Knegtering et al.  2001).
We combined the dataset of this RCT with the dataset of an open study that started in
1997 and is still going on. The patients of the open study and of the RCT were from
the same population of patients with a first psychotic episode.
All patients were recruited from the inpatient or outpatient departments of our
university hospital. The main criteria for inclusion in the open study were: treatment
of the patients for a functional psychosis with anti-psychotic medication for four to
six weeks. No co-medication with known influence on sexual performance was
allowed. Sexual functioning was assessed by the same method as was used in the
RCT. Preliminary results on the first 95 patients were reported in 1999 (Knegtering
et al., 1999). Tentative conclusions were then: a) olanzapine had less detrimental
effects on sexual functioning than classical antipsychotics or risperidone, b)
olanzapine did better in this respect than classical antipsychotics, but not markedly
so, and c) patients reporting sexual dysfunctions had on average higher serum
prolactin levels than those without such dysfunctions.
The combined dataset now contains data of 199 patients (134 men, 65 women).
The current analysis is targeted at the pairwise comparison of a group of patients
using classical antipsychotic medications versus olanzapine versus risperidone.
Table 2a shows, for each medication (-group): the mean dosages of the
antipsychotics, the percentages of patients (men and women combined) who
reported sexual dysfunctions and the observed mean prolactin levels. We did
pairwise comparisons. The statistical methods applied were: chi-square tests for
pairwise differences in percentages patients with sexual dysfunction; two sided t-
tests for pairwise differences in mean prolactin levels (natural log transformed) in
addition 95% confidence intervals were calculated for all differences.  The corres-
ponding results of the statistical evaluation are shown in table 2b.
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                    N=40
40%  18% 43%   41.6 (SD 40.6)
Olanzapine  N=40 18%    3% 18%   18.2 (SD 17.4)
Risperidone N=82 50%  50% 64%   58.4 (SD 44.7)
Legenda table 1
Classical antipsychotics:  broomperidol N=1 (dosage 9 mg/day), haloperidol N=5  (Mean dosage 4
mg/day SD 2.5), perphenazine N=3 (mean dosage 77 mg/day SD 148), pimozide N=19 (Mean dosage
7 mg/day SD 5.2), sulpiride N=2 (Mean dosage 250 mg/day SD 71),  zuclopentixol N=10 (Mean
dosage 45 mg/day SD 90).
Olanzapine Mean dosage  10.2 mg/day SD 3.6
Risperidone Mean dosage 4 mg/day SD 2.0
Table 2b. Statistical results of pairwise comparisons between anti-psychotics: differences in
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df= degrees of freedom
Summarizing the data in tables 2a and 2b: sexual dysfunctions in men and women
(reduced libido and/or orgasm) were reported in 18% of the patients treated with
olanzapine, 43% classical antipsychotics and 64% risperidone. The results suggest
that olanzapine is significantly less detrimental to experienced sexual functioning than
risperidone. The classical antipsychotics used in this study induced significantly more
sexual dysfunctions than olanzapine but significantly less than risperidone. 
The three treatment groups differed significantly in prolactin elevation, olanzapine
induced only little prolactin elevation. Classical antipsychotics and even more (so)
risperidone induced significant prolactin elevation.
As the majority of the patients participating in our studies are men we analyzed their
data separately (tables 3a and 3b). The same variables as before are used supple-
mented with variables describing specific male sexual problems. The statistical tests
and techniques are the same.
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 44% 26.2 SD 19.6
Olanzapine
N=30
 20%  20%    4%   4%  28% 14.1 SD .2
Risperidone
N=55
 46%  42%  43%  36%  60% 38.1 SD 20.5
 
Classical antipsychotics  bromperidol N=1 (dosage 9mg/day), haloperidol N=4  (Mean dosage  4.25
mg/day SD 2.87 ), pimozide N=14 (Mean dosage  8.31 mg/day SD 5.78), sulpiride N=2 (dosage 300
mg/day ),  zuclopentixol N=6 (Mean dosage  65 mg/day SD 115.7).
Olanzapine Mean dosage  9.92 mg/day SD 3.97
Risperidone Mean dosage 4 mg/day SD 1.92






































































df= degrees of freedom
Chapter 8
108
Summarizing the data in tables 3a and 3b: sexual dysfunctions (libido, erection,
orgasm, ejaculation) in men were reported in 28% of the patients treated with
olanzapine, 44% classical antipsychotics and 60% risperidone. Patients treated with
olanzapine reported significant less frequently libido reduction, orgasm disturbance
and reduction of ejaculation volume in comparison to patients with risperidone. The
classical antipsychotics used in this study induced significant less frequently erection
disturbance and orgasm disturbance in comparison to risperidone. 
What are the effects of antipsychotics on the endocrine system?
The influence of prolactin elevation
Prolactin controls the lactation process, but it has also a gonadotrophic function
and regulates the libido and possibly some aspects of sexual behavior (Carani  et
al., 1996). Prolactin levels show daily and seasonal variation and might be
influenced by many factors like pregnancy, lactation, stress, sexual activity, and
nipple manipulation. 
Although many neurotransmitters might play a role in prolactin regulation,
modulation by dopaminergic mechanisms is probably the most important
neurotransmitter system involved. All antipsychotics are dopamine blockers, while
some antipsychotics are also serotonin blockers. Blockade of dopamine receptors
by antipsychotics in the tubero-infundibular tract releases the inhibition of
prolactin storage cells, resulting in elevation of prolactin levels. In contrast to
dopamine, serotonin acts to stimulate prolactin release by an inhibiting effect on
the dopaminergic influence on the tubero-infundibular tract. A consequence of this
mechanism is that serotonergic influences can modulate (dopamine-mediated)
prolactin release, but serotonin can only show this effect as long as the
dopaminergic influence is present.
Some atypical antipsychotics are antagonists of both, serotonin and dopamine, so
exerting opposing effects on prolactin release. The net effect would depend on
the relative strength of the two actions. 
Elevation of the prolactin level can have different consequences for male and
female antipsychotic users.  Luteinising hormone (LH) stimulates testosterone
production in men. If prolactin levels are raising, gonadotropin-releasing hormone
(GnRH) levels and consequently LH-levels will fall. This might result in a decrease
of testosterone levels, which might contribute to sexual function disorders. In
women, elevated prolactin levels can result in changes of pulse released GnRH,
which can induce inhibition of the menstrual cycle. If GnRH levels rise even more,
estrogen lack may occur and the ovarian function can stop. In short term, this can
lead to amenorrhoea, but long-term complications of lack of estrogen may result
in osteoporosis and cardiovascular diseases (Dickson and Glazer 1999). Chronic
Hyperprolactinemia decreases bone density in both men and women probably
caused by decreased gonadal functioning, but possibly also by a direct effect of
prolactin on bone (Thorner et al., 1998).
Much of the influences of prolactin elevation on other hormone systems are
learned from patients with prolactinomas. However prolactinomas are in general
associated with higher prolactin levels than patients using antipsychotics. 
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Only few studies are known to evaluate these hormonal effects in patients using
antipsychotics. Smith examined the influence of antipsychotics on several
hormones (Smith et al., 2000). They evaluated sex hormone profiles in 67
patients using classical antipsychotics. In men, prolactin, SHBG, FSH, TSH, LH,
and testosterone were evaluated. In women, prolactin, FSH, TSH, LH, oestradiol,
and progesterone were evaluated. In men, there was a significant positive relation
between antipsychotic dose and serum prolactin levels. In women, there was a
significant positive correlation between antipsychotic medication dose and
prolactin levels while there was a negative correlation between antipsychotic dose
and progesterone levels. In men, the mean prolactin levels were in the normal
range, although they correlated with the dosage. In women, there was
Hyperprolactinemia, mean estrogen and progesterone levels were below the
normal range. The authors concluded the classical antipsychotics induced in
women a hypogonadal state, possibly reducing fertility.
We examined the correlation between prolactin and testosterone levels in 38 men
who had been treated with risperidone for six weeks (mean dosage 4.1, range 3-5
mg/day). Mean prolactin levels were modestly elevated in most patients and in 11
patients prolactin levels were markedly elevated (mean 23.6 ng/ml, 
range 2.3-93.5 ng/ml). Testosterone levels stayed in the normal range in all
patients (mean 18.6 nmol/l, range 2.1-37 nmol/l) and no significant correlation
was found between prolactin levels and testosterone levels (Pearson correlation
0.181, p=0.277).  
This lack of predicted testosterone changes is in line with the study of Rinieris et
al. who examined prolactin levels and testosterone levels in 15 patients being
treated with a dose range of 7.5 to 60 mg haloperidol/day (Rinieris et al., 1989). A
significant decrease in serum testosterone levels was found in patients treated
with 30 to 60 mg/day but not in lower dose ranges.  The studies on the relation
between prolactin, testosterone and antipsychotics are comparisons between
individuals using different antipsychotics. It cannot be ruled out that within
individuals antipsychotic induced prolactin elevation might diminish testosterone
levels.  
Prolactin levels in unmedicated patients suffering from schizophrenia are normal,
with the possible exception that the circadian rhythm of prolactin, especially in
women, might be advanced by 1.0-1,5 hours compared to healthy controls, a
finding with unknown significance (Rao et al, 1994; Melzer et al., 1974). 
All classical antipsychotics, being powerful dopamine 2 antagonists, cause a
significant elevation of plasma prolactin levels (Green and Brown 1988). 
If antipsychotics induce major elevation of prolactin, the levels can rise up to 150
ng/ml and remain at a high level when continuing medication. Although elevation
is dose-dependent, dose reduction does not always give a decrease of prolactin
levels. Stopping medication tends to normalize prolactin levels (Santoni and
Saubuda 1995).  Amenorrhoea and galactorrhoea, as well as infertility in women
(caused by hypo-estrogenemia) usually completely recovers after normalisation of
serum prolactin levels.
Most atypical antipsychotics like clozapine, olanzapine, sertindol, or quetiapine
give less blockade of dopamine receptors in the tubero-infundibular pathway
(anterior pituitary) than most classical antipsychotics and risperidone. The amount
of dopamine blockade is partly related to a fast dissociation from the dopamine
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receptor (Kinon and Lieberman 1996; Kapur and Seeman 2001; Kapur et al.
2000; Kapur et al. 1999). Due to this mechanism, these antipsychotics generally
only give a short-lived and low elevation of prolactin level, which is completely
normalized after a few hours and will often be undetected in standard laboratory
control. 
Risperidone is an exception. It gives a significant elevation of prolactin, possibly
even more than some classical antipsychotics (Knegtering et al. 2000; Shiwach
and Carmody 1998). In the previously described randomized trial comparing sexual
dysfunctions in patients with olanzapine versus risperidone, prolactin levels were
significantly higher in patients using risperidone (Knegtering et al. 2001). The
antipsychotic amisulpride, often described as atypical, seems to elevate serum
prolactin levels as well (Stanniland and Taylor 2000).
 
What is the role of prolactin and other hormones in inducing sexual side
effects?
The association between the dosage of classical antipsychotics, degree of
prolactin elevation and sexual dysfunction suggests a possible causal
relationship. 
Prolactin elevation in patients with a prolactinoma is associated with amenorrhoea
and galactorrhoea in women. Prolactinoma is also associated with erectile
dysfunction in men and possibly with decrease of libido and orgasm in men as
well as women (Schwartz et al. 1982; Pollack et al. 1992). 
In antipsychotic-induced Hyperprolactinemia worsening of sexual dysfunctions
correlates with serum prolactin elevation (Ghadirian et al. 1982; Burke et al.,
1994).
Our dataset of 199 patients (men and women), combining open and controlled
studies, enabled us to compare patients using prolactin-elevating with patients
using non-prolactin-elevating antipsychotics (see data in tables 2a, 2b, 3a and
3b). 
Antipsychotics elevating prolactin (classical antipsychotics and risperidone)
(n=123) were associated with high frequencies of sexual dysfunctions (libido loss
(43,9%), orgasm disturbance (31,7%)). Antipsychotics that hardly elevated
prolactin (clozapine, olanzapine, quetiapine, sertindole) (n=76) were associated
with much lower frequencies of sexual dysfunctions (libido loss (11.8%), orgasm
disturbance (5.2%)). We compared summative scores of sexual dysfunctions in
both treatment-groups including libido and orgasm. The summative scores ranged
from 0 (libido and orgasm not changed) to 4 (libido and orgasm both much
worse). Prolactin elevating antipsychotics induced sexual side effects more
frequently and seriously in comparison to prolactin sparing antipsychotics (Mann
Whitney U, Z= –5.129, p=0.000).
Analyzing the data in a subgroup of 66 patients using risperidone, a clear
correlation is found between risperidone dosage and prolactin levels (Pearson
correlation 0.44, p=0.000). In men (n=50), the dosage of risperidone and the
prolactin levels correlated significantly with sexual dysfunction (Pearson
correlation 0.34, p=0.005).
However, not all studies find a relation between prolactin elevation and sexual
side effects. A review of Kleinberg et al. (1999) summarizes all data from
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randomized, double-blind studies of risperidone in patients with chronic
schizophrenia. The two largest studies (the North American and multinational
trials) included 841 patients (259 women, 582 men) with paired prolactin level
data and 1,884 patients (554 women, 1,330 men) with data on six adverse events
possibly associated with increased prolactin levels (amenorrhoea, galactorrhoea,
and decreased libido in women; erectile dysfunction, ejaculatory dysfunction,
gyneacomastia, and decreased libido in men). They concluded that among
women, the risperidone dose was not correlated with adverse events, nor were
the adverse events correlated with endpoint prolactin levels. Among men, the
incidence of adverse events was positively correlated with risperidone dose;
however, at risperidone doses of 4 to 10 mg/day the incidence of adverse events
was not significantly higher than that observed in patients receiving placebo.
Furthermore, adverse events in men were unrelated to plasma prolactin levels.
Risperidone-associated increase in serum prolactin levels was not significantly
correlated with the emergence of possible prolactin-related side effects.  The
study of Hummer et al. (1999) also suggests  a more limited role for prolactin in
inducing sexual dysfunctions. 
However, both the Kleinberg and Hummer studies have severe limitations. The
study of Kleinberg et al is not based on structured interviews or questionnaire
data. As mentioned earlier in this article spontaneous reporting of sexual
dysfunctions is rare and therefore the frequency of sexual dysfunctions is
probably heavily underreported. This makes it unlikely that  correlations between
prolactin and sexual dysfunctions could  be detected. A limitation of the study of
Hummer is the fact that any sexual dysfunction reported in any week during six
observations in six subsequent weeks was taken into account. But in the first
week, carryover effects of former antipsychotics, sedating, and ∝-blocking effects
of clozapine must have influenced the observations. So the final analysis should
have been made in the last week. In that week, clozapine indeed induced less
sexual dysfunctions than haloperidol.
The final conclusion from the majority of these studies seems to be that prolactin
might play an important role in inducing sexual dysfunctions, amenorrhoea, and
galactorrhoea.
By what mechanism prolactin elevation is correlated to sexual dysfunction is not
known. A reduced capacity to create sexual fantasies might be a contributing
factor (Carani et al. 1996). As mentioned earlier, reduction of testosterone levels
secondary to elevated prolactin levels is also a factor suggested to play a role in
Hyperprolactinemia-related sexual dysfunctions, but this effect might be occurring
only in high dose ranges. 
Correcting prolactin levels with the help of dopamine agonists like bromocriptine
10 mg/day or amantadine 100 mg/day improves many of the symptoms induced
by antipsychotic-induced hyperprolactineamia, like sexual dysfunctions,
amenorrhoea, and galactorrhoea (Netto and Claro 1993; Valevski et al. 1998).
This restoration of sexual dysfunctions seems to set off before correcting
decreased plasma testosterone levels, suggesting that prolactin might have an
immediate effect on sexual activity (Barnes  and Harvey 1993) while the role of
testosterone is not very convincing.
Prolactin elevation is also an indirect indicator of dopamine blockade (Kapur et al.
1998). Dopamine is an import neurotransmitter in experiencing motivation and
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rewards, probably including sexual motivation (libido) and reward (orgasm)
(Feldman et al. 1997). So it is likely that not only prolactin elevation but also the
dopamine blockade itself might contribute to inducing sexual dysfunctions. 
In fact there is no conclusive evidence from the available studies that
antipsychotic-induced prolactin elevation is directly responsible for sexual
dysfunctions (like in prolactinoma). Prolactin elevation may also (partly) be an
epiphenomenona, a marker, of dopamine blockade.
Other factors may play a role too. For instance, antipsychotics like thioridazine or
sertindole with α-antagonistic properties are associated with priapism or
ejaculation disturbance (diminished semen volume) (Patel  et al. 1996). 
The serotonergic system is also involved in sexual behavior. However there is no
indication that the serotonin-blocking properties of atypical antipsychotics
contribute to sexual dysfunctions; it might even help to improve, for instance SSRI
induced, sexual dysfunctions (Baldwin et al. 1997). 
Conclusions and clinical consequences
Classical antipsychotics, risperidone, and amisulpride used in standard dosages
elevate prolactin significantly; this even more so in women, compared with men.
There are few studies of sexual dysfunctions related to treatment with
antipsychotics. All known studies are open studies and one should be cautious in
drawing firm conclusions.
Less than 10% of the patients mention sexual dysfunctions spontaneously, in
response to structured questionnaires, 40-60% of the patients report experiencing
sexual dysfunctions which they attribute to the use of classical antipsychotics or
risperidone. Although not all studies agree, libido and orgasm disturbances are
found in men and women in more or less the same frequencies.
Comparative studies are rare, still it seems likely that prolactin-sparing
antipsychotics induce sexual dysfunctions only infrequently in comparison to
prolactin elevating antipsychotics. In our randomized study of olanzapine versus
risperidone we indeed found that the prolactin-sparing effects of olanzapine are
associated with significantly less sexual dysfunctions. 
Serum prolactin elevation and dopamine blockade are probably important factors,
not only in inducing sexual dysfunctions but also in causing amenorrhoea and
galactorrhoea. 
Sedation, noradrenergic, serotonergic and cholinergic mechanisms might play an
additional role in inducing some sexual side effects. 
More studies are clearly needed comparing antipsychotics and their tendency to
induce sexual side effects, but also amenorrhoea and galactorrhoea.
Furthermore, studies on the pathogenetic mechanisms of sexual dysfunctions are
lacking. Studies comparing classical antipsychotics, risperidone, quetiapine and
clozapine, for short term and long term effects on sexual performance,
amenorrhoea and galactorrhoea are underway in our center. Especially the
effects of (long-term) prolactin elevation on sexual behavior, social behavior and
health risks like bone demineralization are needed (Halbreich and Palter 1996;
Halbreich et al., 1995). 
Although sexual side effects are often very important to patients and might
influence compliance, patients as well as clinicians are reluctant to discuss it
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(Finn et al. 1990; Strauss and Gross 1984). Clinicians should always actively
query patients for side effects of antipsychotics, especially for sexual
dysfunctions, amenorrhoea, or galactorrhoea. These side effects occur often, but
seem to be difficult to talk about. It is our clinical experience that almost all
patients appreciate when clinicians systematically ask for side effects, including
sexual side effects.  Dose reduction or switching to a prolactin-sparing
antipsychotic is usually effective in reducing sexual side effects. In some cases,
adding bromocriptine or amantadine to antipsychotic treatment might be an
alternative. 
In cases of prolonged amenorrhoea during treatment with antipsychotics, with or
without Hyperprolactinemia, especially when continuing after switching to a
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Summary
A large database of data from 6-week studies was analyzed for sexual side effects
attributed to the use of antipsychotics. The database included patients treated with
conventional antipsychotics, clozapine, olanzapine, quetiapine or risperidone. Men
and women were compared for the incidence of changes in sexual performance
(libido and orgasm). Both groups reported sexual side effects (libido and orgasm)
with about the same frequency.
Comparing the different antipsychotics, risperidone induced significantly more
sexual dysfunction (libido 49.5%, orgasm 46%) than all other treatment groups.
Conventional antipsychotics induced sexual dysfunction (libido 35.7%, orgasm
16.2%) more frequently than clozapine (libido 15.8%, orgasm 7.1%), olanzapine
(libido 16.3%, orgasm 2.6%) or quetiapine (libido 13.8%, orgasm 4.0%). The
differences between conventional antipsychotics and olanzapine or quetiapine
were statistically significant. In men, high frequencies of erectile and ejaculatory
dysfunction were reported in patients treated with risperidone and conventional
antipsychotics, in contrast low frequencies were reported in patients treated with
clozapine, olanzapine or quetiapine. Treatment with risperidone was associated
with significantly greater serum prolactin elevation than other antipsychotics.
Conventional antipsychotics were associated with significantly higher serum
prolactin levels than clozapine, olanzapine, or quetiapine.
Mechanisms involved in inducing sexual side effects were examined by comparing
different subgroups treated with prolactin-elevating versus prolactin-sparing
antipsychotics or high α1- versus low α1-adrenergic antipsychotics. It is concluded
that although dopaminergic and noradrenergic mechanisms may be involved in
inducing sexual side effects, serum prolactin elevation probably plays a more





The data of the patients in this chapter include all data of patients discussed in
chapter 3, 5, 6 and 8. In addition data of new patients from ongoing open
naturalistic studies are added. Chapter 9 reflects the ongoing studies till February
2003. In contrast to the studies presented in chapter 8, patients on clozapine and
quetiapine could be included enabling to discuss the sexual dysfunctions of
antipsychotics in a broader perspective and analyzing the role of prolactin in more
detail. 
Introduction
Our studies on sexual side effects and hormonal influences of antipsychotics
showed, in line with studies from other groups, a high incidence (about 30-60% of
the patients) of sexual side effects in patients treated for six weeks with
conventional antipsychotics (Lingjaerde et al. 1987;  Knegtering et al. 2003a;
Sullivan and Lukoff 1990). Patients treated with risperidone also seemed to
experience a high incidence of sexual side effects.  In contrast, patients treated
with prolactin-sparing antipsychotics such as olanzapine seemed to experience
sexual side effects with a much lower frequency (Knegtering et al. 2003a). 
Although it has been suggested that prolactin elevation plays an important role in
the occurrence of sexual side effects such as diminished libido, erection and
orgasm, the evidence is not conclusive (Wieck and Haddad 2002). Other factors
including dopaminergic, noradrenergic and histaminergic effects also influence
some aspects of sexual performance (Segraves 1989;  Meston and Gorzalka 1992;
Kleinberg et al. 1999;  Meston and Frohlich,  2000). 
Several studies on the relationship of (sexual) side effects with prolactin elevation
have suggested a correlation (Ghadirian et al. 1982;  Burke et al. 1994), but others
have failed to support this (Hamner 2002; Kleinberg et al. 1999).
One of the problems in determining the role of prolactin elevation in sexual side
effects of antipsychotics is the dopamine blockade induced by antipsychotics
(Kapur et al. 2000; Kapur et al. 1998, 1999). Prolactin elevation by antipsychotic
drugs is induced by dopamine blockade in the tubero-infundibular system (Kapur et
al. 2001). The main mechanism of the antipsychotic activity is thought to be
through dopamine blockade in dopaminergic meso-limbic circuits in the brain. The
same dopaminergic mechanisms are probably also involved in motivation and
reward, including sexual motivation (sexual drive or libido) and reward (orgasm)
(Feldman et al. 1997; Giuliano and Allard 2001;  Uitti et al. 1989). The number of
sexual side effects could imply the involvement of dopaminergic mechanisms as
well as prolactin elevation.
To complicate the study of the involvement of prolactin in inducing sexual side
effects even further, some researchers suggest that it is not prolactin elevation but
the secondary effects of prolactin elevation, i.e., reduction of plasma levels of
testosterone, estrogen, luteinizing hormone (LH), or follicle-stimulating hormone
(FSH), that could be the reason for sexual side effects (Rinieris et al. 1989; Smith
et al. 2002). The influence of the primary disease, treatment duration, age (age-
related decreases in libido and some sex hormones such as testosterone) and
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gender (men have lower prolactin levels than women) make it even more difficult to
interpret the data (Nestoros et al. 1981; Rinieris et al. 1989; Smith et al. 2002). 
In studies with small groups of patients it is impossible to unravel many of the
possible different contributing factors. Our collective database, based on a number
of consecutive studies, offers the possibility of analyzing some of these factors in
more detail.  We present data comparing the influence of different antipsychotics
on sexual dysfunction in male and female patients. The effects of dose, serum
levels of antipsychotics and metabolites, prolactin and gender on sexual
dysfunction were examined. 
 
Method
From 1997 to 2002 all patients treated with antipsychotics for six weeks studies
were asked about changes in sexual function that they attributed to the use of
antipsychotics. Some patients received the medication during normal clinical
practice, and in others the treatment was in the context of a randomized clinical
trial (risperidone versus olanzapine and risperidone versus quetiapine). All patients
were included in the present analyses. 
Patients treated with different conventional antipsychotics reported comparable
percentages of sexual dysfunctions with no statistically significant differences
between individual agents in the frequency of individual dimensions of sexual
function or serum prolactin elevation. For these reasons the conventional
antipsychotics were considered to be one group for the analysis. 
Assessments 
Six weeks after initiating treatment with an antipsychotic sexual function was
assessed using a semi-structured interview: the Antipsychotics and Sexual
Functioning Questionnaire (ASFQ) based upon the UKU, administered by 6 trained
physicians (Lingjaerde et al. 1987;  Knegtering and Castelein 2001). The ASFQ
includes items assessing sexual side effects (libido, orgasm, galactorrhea in both
sexes, erection and ejaculation in men, vaginal lubrication and menstruation in
women).  Baseline sexual functioning was not recorded at week 1, because many
patients were psychotic and were considered too ill to participate in an assessment
of sexual function. 
Medication compliance was assessed using interviews and plasma antipsychotic
level sampling: prolactin and antipsychotic serum levels were measured at week 6,
in the morning, but not at baseline, as carry-over effects of previously used
antipsychotics may obscure the interpretation of these data. By excluding patients
treated with long-acting (depot) antipsychotics the influence of carry-over effects
from previous antipsychotics at Week 6 was minimized. Symptom severity was
assessed by the treating physicians using the Clinical Global Improvement (CGI)
scale. 
Some patients could not answer the questions, or indicated sexual dysfunction
considered unrelated to the treatment of antipsychotics. This report only includes
changes in sexual function attributed to treatment with antipsychotics. In some
studies plasma levels of hormones other than prolactin were determined, such as
luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen,
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progesterone and testosterone. Patients entering the studies provided oral and
written informed consent.
Statistics
During studies that started in 1997 additional laboratory facilities became available.
In all patients changes in sexual functioning attributed to the use of antipsychotics
were assessed, while in some patients additional laboratory testing was available,
depending on the year of study entry. The presentation of results includes the
actual number of patients able to answer the questions and/or having plasma
levels of hormones or antipsychotics.
Data from patients treated with conventional antipsychotics, clozapine, olanzapine,
risperidone and quetiapine are analyzed per group. Comparisons were made for
every group to identify possible differences between men and women in reporting
sexual functioning using chi-square tests for pair-wise differences. 
Pair-wise comparisons were made to identify possible differences between
antipsychotics or groups of antipsychotics in inducing sexual side effects. The
statistical methods applied were: chi-square tests for pair-wise differences in
numbers of patients and sexual functioning; two sided t-tests for pair-wise
differences in mean prolactin levels (natural log transformed) were applied. For
evaluating relationships between dosage of individual antipsychotics and libido,
orgasm, ordinal regression was used. Ordinal regression was also used to
evaluate relationships between serum prolactin and α-adrenergic effects of
antipsychotics and dimensions of sexual function. For men, ordinal regression was
also used to evaluate relationships with erection and ejaculation. Serum prolactin
and risperidone levels were normalized by converting them to their natural
logarithm.  For all analyses, the effects were tested at the 2-sided α level of 0.05. 
Results
264 patients completed the studies. Mean age of the male patients was 28 (range
17-54) years, of female patients 26 (range 17-49) years. All patients had a DSM-IV
diagnosis in the schizophrenia spectrum without statistical differences in frequency
of diagnostic subtypes between men or women, or between types of antipsychotic
used. Forty-five patients were treated with conventional antipsychotics and 215
patients with other antipsychotics. Demographic and diagnostic data are
summarized in table 9.1.1. No statistically significant differences were found either
between patient groups or between male or female subgroups in age or diagnosis.
The number of treated patients and mean dosages of the antipsychotics are
summarized in table 9.1.2.
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Table 9.1.1. Demographic and diagnostic data summarized per treatment-group and gender
All
Antipsychotics Clozapine Olanzapine Quetiapine Risperidone Classical
Women       men Women       men Women        men Women       men Women           men Women     men
No. of
patients
88            
186
6            
13
14          
35
12          
22
39             
75




28 (±8)   26
(±6)
28
(±11)   23 (±4) 29( ±10)    26(±5)
24 (±5)   
27(±5) 29 (±9)   25 (±6)





psychosis 7 ( 8)     
12
(6)
2 (14)     
4 (11)
2 (16)     
3 (14) 2 ( 5)      3 (  4)
1 (  7)     
2 (  7)
Schizophre
niform
9 (10)     24
(13)
1 (  7)     
4 (11) 2 (  9) 6 (15)   12 (16)




46 (52)   126
(68)
5 (83)     
12 (92)
7 (50)    
22 (63)
8 (66)     
15 (68) 16 (41)   49 (65)




5 (  6)       
3 (2) 1 ( 8) 1 ( 3)
1 (  8)     
1 (  5) 4 (10) 1 (  3)
Delusional
dis. 2 (  1) 1 (  5) 1 ( 1)
Other
psychosis
21 (24)     19
(10) 1 (17)
4 (28)     
4 (11) 1 (  8) 11 (30)   10 (13)
4 (26)     
5 (17)
No statistical significant differences were found between treatment-groups in gender ratios, age, or
diagnosis.
Table 9.1.2. Number of treated patients, mean dosages and standard deviations of the
antipsychotics
Antipsychotic drugs No. of patients Dosage (mean (SD)) (mg/day)
Conventional
antipsychotics
Bromperidol     1 9.0     (  -   )
Haloperidol     5 4.0     (2.55)
Perphenazine     3 11.7   (2.89)
Penfluridol     1 4.3     (  -   )
Pimozide   19 7.1    (5.23)
Sulpiride     3 300    (50)
Zuclopentixol   13 55.1   (89.7)
Atypical
antipsychotics 
Clozapine   19 351.3 (112.6)
Olanzapine   49 10.7   (  4.05)
Quetiapine   34 558.8 (207.6)
Risperidone 114 3.8     (  1.8 )
Sertindole    3 17.3   (  2.3 )
In the literature there is controversy over whether men and women are equally
vulnerable to the sexual side effects of antipsychotics. For this reason we
examined differences in frequency of libido and orgasm as a first step.  Table 9.2.1
shows the frequency of sexual side effects in male and female patients per
antipsychotic. No significant differences were found between men and women.
Male and female patients experience influences on sexual performance (libido and
orgasm) with the same frequency. Some patients report improvement of sexual
side effects but the majority report unchanged, decreased or strongly decreased
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sexual functioning (libido or orgasm), that they attribute to the treatment with the
listed antipsychotics.
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Table 9.2.1. Frequency of sexual dysfunction attributed to treatment with different antipsychotics
for six weeks in male or female patients
All
antipsychotics 
Women       men
Clozapine 
women       men
Olanzapine 
Women      men
Quetiapine 
women        men
Risperidone 
women        men
Classical 
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2.338;  n=19     
(df=2);  p= .311
3.288;   n=43
(df=3) ;  p= .349
2.442;     n=29
 (df=3) ;  p= .486
4.594;    n=105
(df=3);     p= .204
1.673;    n=42
















              



























3.787;    n=214
(df=3);    p= .285
.636;      n=14
(df=2);   p= .727
.403;    n=39
(df=1);  p = .525
.612;     n=25  
(df=2);   p= .736
1.887;    n=89
(df=2);   p= .389
6.079;    n=37
(df=3);   p= .108
df= degrees of freedom
Figures 9.2.2, 9.2.3, 9.2.4 and 9.2.5 summarize the dichotomized data on sexual
dysfunctions, presenting the percentages of patients reporting sexual dysfunction
attributed to the use of antipsychotics in men and women. For lubrication in women
insufficient data were available to present in a statistical meaningful way. 
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Figure 9.2.2. Percentage of patients reporting
sexual dysfunctions in men and women after six
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Figure 9 .2.3. Percentage of m a le patients
reporting sexual dysfunctions after six weeks
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Figure 9.2.4. Percentage of female patients
reporting sexual dysfunctions after six weeks
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The data presented in the previous figures on libido and orgasm (men and women
together) erection and ejaculation are presented in more detail in table 9.3.1: these
data were used for the statistical analysis shown in table 9.3.2, 9.3.3 and 9.3.4.
These tables show that risperidone is significantly more frequently associated with
sexual dysfunction (libido and/or orgasm) than the conventional antipsychotics,
clozapine, olanzapine or quetiapine. Conventional antipsychotics are more
frequently associated with libido reduction and decreased orgasm than clozapine,
olanzapine or quetiapine. In the comparison between conventional antipsychotics
and olanzapine (libido and orgasm) or quetiapine (orgasm) these differences are
statistical significant. Risperidone was significantly more frequently associated with
erectile dysfunction than was quetiapine. There was also a trend to more frequent
erectile sexual dysfunction with risperidone than with clozapine and olanzapine.
Risperidone was more frequently associated with ejaculatory dysfunction in
comparison to olanzapine and quetiapine. 
Table 9.3.1. Number of patients reporting sexual dysfunction in patients treated with
antipsychotics for six weeks
Men and women Men
Libido
  n/n total      %
Orgasm
   n/n total     %
Erection
n/n total     %
Ejaculation
n/n total     %
Risperidone 52/105    49.5%  41/ 89   46.1% 28/78      39.4% 27/67     40.3%
Classical 15/  42    35.7%    6/ 37   16.2%   8/29      27.6%   5/25     20.0%
Clozapine   3/  19    15.8%    1/ 14     7.1%   1/11        8.3%   2/11     18.2%
Olanzapine   7/  43    16.3%    1/ 39     2.6%   6/30      20.0%   2/27       7.4%
Quetiapine   4/  29    13.8%    1/ 25     4.0%   2/19      10.5%   2/16     12.5% 
Number of patients experiencing sexual dysfunction (n) versus number able to respond on the specific
item (n total), and the corresponding percentage of patients with a sexual dysfunction attributed to
antipsychotic medication (%)
Table 9.3.2. Pair-wise comparison (Chi-square, df and p values) of changes in libido attributed to
treatment with antipsychotics #







































Table 9.3.3. Pair-wise comparison (Chi-square, df and p values) of changes in orgasm attributed
to treatment with antipsychotics





































Table 9.3.4. Pair-wise comparison (Chi-square, df and p values) of changes in erection attributed
to treatment with antipsychotics





































Table 9.3.5. Pair-wise comparison (Chi-square, df and p values) of changes in ejaculation
attributed to treatment with antipsychotics





































# value Pearson Chi-Square, df = degrees of freedom, *= p<.05 (2-sided)
Serum prolactin levels are shown in figures 9.4.1 and table 9.4.2. The
corresponding statistical analysis of the tendency to elevate prolactin is given in
table 9.4.3. Risperidone is associated with significantly higher serum prolactin
levels than conventional antipsychotics, clozapine, olanzapine, or quetiapine.
Conventional antipsychotics are associated with significantly higher serum
prolactin levels than clozapine, olanzapine, or quetiapine. Treatment with
olanzapine was associated with higher serum prolactin levels than clozapine or
Antipsychotics and hormonal changes, mechanisms influencing sexual performance
127
quetiapine: the difference between olanzapine and quetiapine was statistically
significant.
Table 9.4.2. Mean serum prolactin levels in men and women after six weeks treatment with
antipsychotics






*some laboratories use ng/ml to express serum prolactin levels; 
 1 ng/ml≈20mE/L
Table 9.4.3. Pair-wise comparisons of serum prolactin levels (ln-transformed) tested for
statistical significant differences (t-test, df, p-values) between groups





































t-value student T-Test, df=degrees of freedom, *= p<.05 (2-sided)
Figure 9.4.1 Serum prolactin levels (mE/L) after



















As the next step in the analysis antipsychotics were divided into two groups,
prolactin-elevating and prolactin-sparing antipsychotics. All conventional
antipsychotics and risperidone were considered to be prolactin-elevating.
Clozapine, olanzapine, quetiapine and sertindole were considered to be prolactin-
sparing. The data are summarized in table 9.5.1., showing that 15.4% of the
patients treated with a prolactin-sparing antipsychotic reported a decreased libido
they attributed to treatment with antipsychotics versus 45.6% of patients treated
with prolactin-elevating antipsychotics (chi-square 24.790; (df=3), p= .000). For
orgasm, 3.9% of patients treated with prolactin-sparing antipsychotics reported a
decrease, versus 37.4% of patients treated with prolactin-elevating agents (chi-
square 24.790; df=3, p= .000). As the majority of patients were men, their data could
be analyzed in more detail (table 9.5.2). In men, prolactin-sparing antipsychotics
were associated with significantly lower frequencies of decreased libido and orgasm.
Erectile dysfunction was reported in 14.8% of patients treated with prolactin-sparing
antipsychotics versus 35.3% of patients taking prolactin-elevating antipsychotics (chi-
square 9.748; (df=3, p= .021). A decrease in ejaculation volume was reported in
11.1% of patients treated with prolactin-sparing antipsychotics versus in 38.7% of
patients treated with prolactin-elevating antipsychotics. (chi-square 10.355 (df=2) ; p=
.006 ).
Table 9.5.1. Changes in libido or orgasm reported by male and female patients attributed to
treatment with antipsychotics, comparing prolactin-sparing antipsychotics (clozapine, olanzapine,
quetiapine, sertindole), with agents that elevate serum prolactin levels (conventional
antipsychotics and risperidone)  
Antipsychotics prolactin-sparing Prolactin-elevating
  












































* chi-square value Chi-square 30.062: (df=3) n= 204, p= .000* 
df= degrees of freedom
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Table 9.5.2. Changes in libido, orgasm, erection and ejaculation reported by male patients
attributed to treatment with antipsychotics, comparing prolactin-sparing antipsychotics (clozapine,
olanzapine, quetiapine, sertindole) with antipsychotics elevating serum prolactin levels
(conventional antipsychotics and risperidone)
antipsychotics (male patients)    
prolactin-sparing            prolactin elevating






* chi-square value 
               2 (  3.2)                             19   (19)
             11 (17.7)                             25   (25) 
             45 (72.6)                             51   (51)
               4 (  6.2)                               5   (  5)






* chi-square value 
               1 (  1.8)                             15  (16.0)
               2 (  3.6)                             20  (21.2)  
             49 (89.1)                             59  (62.8)
               3 (  5.5)                                         






* chi-square value 
               1 (  1.6)                             13  (13.1)
               8 (13.2)                             22  (22.2) 
             51 (83.6)                             62  (62.7)
               1 (  1.6)                               2  (  2.0)





* chi-square value 
               2  (  3.7)                            17 (18.5)
               4  (  7.4)                            15 (16.9)  
             48 ( 88.9)                            60 (65.2)
                                                           
chi-square 10.355; (df=2) n=146, p= .006
df= degrees of freedom
The relation between dose, serum antipsychotic level and sexual functioning was
examined using ordinal regression analysis. In men and in women, no statistically
significant effects could be identified in the dosage of any specific antipsychotic
upon libido or orgasm. Higher serum levels of risperidone seemed to effect a
decrease in libido (β=-0.510, p=0.018) and orgasm (β=-0.530, p=0.31) (table 9.6.1)
explaining 7.5% and 8% of the variance, respectively. No significant effect between
serum levels and sexual function could be identified for the other antipsychotics. 
In female patients there was no significant association between higher serum




In male patients higher serum prolactin levels were associated with libido reduction
in patients treated with quetiapine (β=-3.461, p=0.046) and conventional
antipsychotics (β=-1.675, p=0.016). In male patients serum prolactin was
associated with a decrease in orgasm in those treated with risperidone (β=-1.083,
p=0.048) and a tendency in the same direction with conventional antipsychotics
(β=-3.250, p=0.060) (table.9.6.3). 
Table 9.6.1. Effects of  (mean, ln transformed) antipsychotic serum levels (parent compound) on
the frequency of sexual dysfunction in male and female patients per antipsychotic (ordinal
regression (link function: logit))
Clozapine Olanzapine Quetiapine Risperidone Conventional
N  #m. prolac n   m. prolac n m. prolac n m. prolac n m. prolac
Libido change
strong decrease 1 4.20 14 2.27 2 2.05
decrease 3 5.71 2 2.71 2 4.52 21 2.02 10 1.28
no change 13 5.19 18 3.44 16 4.58 42 1.55 18 1.19
increase 1 5.16 1 3.69 3 4.59 1 1.61 1 0.00
 estimate (b) -2.007; N=17 1.628; N=21 0.53; N=22 -0.510 N=78 -0.386; N=31
* 95% con in (b) -4.593; .579 -0.557 3.812 -0.640 0.747 -0.933 -0.088 -1.069 0.297
* Wald (df=1) 2.314; P=0.128 2.133; P=0.144 0.32 P=0.880 5.606; p=0.018 1.227; P=0.268
R2 0.075
Orgasm change
strong decrease 14 2.12 3 1.71
Decrease 13 2.29 2 0.50
no change 11 5.11 20 3.37 17 4.46 37 1.52 23 1.31
Increase 1 6.05 2 5.20
 estimate (b) does not exist; n=12 does not exist; n=20 0.453; n=19 -0.530; n=64 0.021; n=28
* 95% con in (b) -0.833 1.739 -1.012 -0.049 -1.020 1.063
* Wald (df=1) 0.477; p=0.490 4.657; p=0.031 0.002; p=0.968
R2  0.080
 #   m. prolac= mean serum level parent compound
*    df= degrees of freedom, 95% con in= 95% confidence interval
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Table 9.6.2 Effects of (mean) serum prolactin levels on the frequency of sexual dysfunction in
female patients per antipsychotic (ordinal  regression (link function: logit)).
Clozapine Olanzapine Quetiapine Risperidone Conventional 
n  #m. prolac n   m. prolac n m. prolac n m. prolac n m. prolac
Libido change
strong decrease 5 7.44
decrease 1 5.84 11 7.41 5 6.25
no change 4 5.59 10 6.16 6 5.36 15 6.93 8 7.11
increase 2 4.93
 estimate (b) does not exist; n=4 .523; N=11 -.799; n=8 -1.001; n=31 1.052; n=13
* 95% con in (b) -2.241 3.287 -.3.330 1.723 -2.215 .212 -.364 2.468
* Wald (df=1) 0.138; p=0.711 0.383; p=0.536 2.616; P=0.106 2.119; p=0.145 
Orgasm change
strong decrease 5 7.42 1 6.85
decrease 4 7.56
no change 1 5.68 11 6.13 7 5.16 10 6.76 7 6.68
increase 1 5.23 2 7.04
 estimate (b) does not exist; n=1 does not exist; n=11 0.079; n=8 -1.642; n=19 0.204; n=10 
* 95% con in (b) -2.247 2.405 -3.823 0.539 -1.268 1.677
* Wald (df=1) 0.004; p=0.947 2.178; p=0.140 0.074; p=0.786 
Table 9.6.3. Effects of (mean) serum prolactin levels on the frequency of sexual dysfunction in
male patients per antipsychotic (ordinal regression (link function: logit)). 
Clozapine Olanzapine Quetiapine Risperidone Conventional 
N  #m. prolac n   m. prolac n m. prolac n m. prolac n m. prolac
Libido change
strong decrease                             1 5,05        1 6.04 13 6,74 2 6,83
decrease 1 5.55   5 5,67 2 4.90 15 6,28   7 6,2
no change 6 5,07 15 5,54 10
       
5.09 29 6,48 16 5,77
increase 1 4,88
                
         
2
     
4.74    4 6,73 1 4,74
 estimate (b) -4.648   n=8 .026; n=21 -3.461; n=15 -0,103 n=61 -1.675 n=26
* 95% con in (b) -11.981 2.685 -1.279 1.331 -6.864 -0,058 -0,872 0,665 -3.041 -0.309
* Wald (df=1) 1.543; p=0,214 0.002; p=0.969 3.973; p=0,046 .069; p=0,792 5.780; p=0,016
R2 0.245   0.244
Orgasm change
strong decrease                           1 5,05
                
      
11 6,97   2  6,48
decrease                             
                
           
                
           
15 6,42 2 6,58
no change 6 5,07 18 5,58 10 5,06 31 6,46 20 5,67
increase                           
                
         
2 4,75
                
         
                      
   
 estimate (b) does not exist; n=6 .769; n=19 -7,878 n=12 -1.083 n=57 -3.250 n=24
* 95% con in (b)  -1.472 3,01 -20,703 4,946 -2,154 -0,011 -6.642 0,142




 # m.prol= mean serum prolactin levels in Meq.L., ln transformed df= degrees of freedom, con in= 95% confidence interval
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To evaluate the effects of serum prolactin on sexual side effects, ordinal regression
was performed separately for men and in both men and women, prolactin levels
influenced libido and orgasm. In male patients no effect of prolactin on erection
was found; in contrast a significant effect of serum prolactin on ejaculation was
found (table 9.7).
Table 9.7. Effects of (mean) serum prolactin levels (ln-transformed) on the frequency of sexual
dysfunction in male and female patients, all antipsychotics together (ordinal regression (link
function: logit))
Serum prolactin levels influence almost all aspects of sexual performance,
including ejaculation. In contrast, a reduction in ejaculate volume is suggested to
be predominantly related to α1 adrenergic mechanisms (chapter 1) (Meston and
Frohlich 2000). To test the hypothesis that these mechanisms are involved, the
antipsychotics were separated into two groups: those with known (in comparison to
the D2 antagonistic affinities) relatively high affinity for α1 (noradrenergic) receptors

































95% conf int (β) -1.488   -0.321
Wald 9.237; p=0.002; R2=0.150
Estimate (β) -0.722
95% conf int (β) –1.150   -0.294




























95% conf int (β) -1.268   -0.022
Wald 2.178; p=0.042; R2=0.089
Estimate (β) -1.837
95% conf int (β) –2.567   -1.107

















95% conf int (β) –0.800   -0.119


















95% conf int (β) –1.728   -0.529
Wald 13.603; p=0.000; R2=0.131
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1992; Leysen et al. 2000).  Relatively high α1 affinity is often clinically expressed in
orthostatic hypotension, so gradual dose escalation is often needed at the
beginning of treatment. Antipsychotics considered as having a high α1/D2
noradrenergic affinity were clozapine, risperidone, sertindole and zuclopentixol,
while those considered having a low α1/D2 noradrenergic affinity were haloperidol,
pimozide and olanzapine.  Although patients treated with a high α affinity
antipsychotic (n=95) reported a higher incidence of reduced ejaculatory volume
versus the low α1 noradrenergic group (n=20), this difference did not reach
statistical significance (Chi-square 2.835; df=2, p=0.242).
Discussion
In line with previous studies the patients in this study reported a high incidence of
sexual side effects attributed to antipsychotics. Differences in incidences of
reported sexual dysfunction between antipsychotics and the effects of serum
prolactin, dopaminergic and noradrenergic mechanisms are discussed. 
What are the differences in incidence of reported sexual dysfunctions between
antipsychotics?
It has been suggested that women are less sensitive to sexual side effects induced
by antipsychotics than men (Ghadirian et al. 1982;  Hummer et al. 1999). We did
not identify significant differences in changes in libido or orgasm attributed by male
or female patients to antipsychotics in any treatment group. As there were no
significant differences in changes in sexual functioning during treatment with
antipsychotics men and women were analyzed as a single group in some
analyses. 
Next, differential effects of the various antipsychotics on sexual performance in
patients groups were analyzed. Although some patients report improvement of
their sexual performance during treatment with antipsychotics, the vast majority
report unchanged or diminished sexual function. There were marked differences
between treatment-groups in sexual performance. 
Libido reduction was significantly more frequently reported by patients treated with
risperidone than by patients treated with conventional antipsychotics, olanzapine,
quetiapine or clozapine. In addition patients taking conventional antipsychotics
more frequently reported libido reduction than patients treated with olanzapine and
quetiapine. Patients treated with clozapine also less frequently reported a decrease
in libido than those treated with conventional antipsychotics, but this did not reach
statistical significance, possibly reflecting the smaller number of patients on
clozapine. No significant differences were found between patients treated with
clozapine, olanzapine or quetiapine, all reporting a relative low incidence of
reduction in libido (figure 9.2.2, table 9.3.1, 9.3.2). 
Concerning changes in orgasm, patients treated with risperidone significantly more
frequently reported a decrease in the ability to obtain an orgasm in comparison to
all other treatment-groups. Also conventional antipsychotics were reported to
decrease orgasm more frequently than clozapine, olanzapine and quetiapine. Only
in the comparison to olanzapine these differences were statistical significant,
possibly reflecting the greater number of patients on olanzapine (figure 9.2.2, table
9.3.1, 9.3.3). 
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Erectile dysfunction was more frequently reported by patients treated with
risperidone than those treated with clozapine, olanzapine or quetiapine. The
difference between risperidone and quetiapine was statistically significant (figure
9.2.3, table 9.3.1and 9.3.4).
Ejaculatory dysfunction was significantly more common in patients treated with
risperidone than with olanzapine or quetiapine (figure 9.2.3, table 9.3.1 and 9.3.5).
Unfortunately, insufficient data were available comparing the influence of
antipsychotics on vaginal lubrication, reflecting the later introduction of this item in
our questionnaire and the fact that many women could not report it.  
What is the influence of dose, serum levels of antipsychotics and prolactin on
sexual functioning in different antipsychotics?
In ordinal regression analysis (men and women analyzed as one group) no dose
response relationship was found between daily dose of individual antipsychotics
and libido or orgasm (tables not shown).
A relation between serum levels and libido or orgasm could only be identified with
risperidone, possibly partly reflecting the larger number of patients treated with this
drug (table 9.6.1). One may argue that the serum levels of the metabolite of
risperidone, better correlating with serum prolactin levels, may have been more
important in explaining sexual function, but there were not enough observations to
include in the tables (see chapter 6).
Within groups of male and female patients taken together treated with an individual
antipsychotic no significant correlation could be identified between serum levels of
prolactin and libido or orgasm (table 9.6.2). 
Analyzing the data of men and women separately, in women no statistically
significant relationship could be identified between serum prolactin levels and
individual antipsychotics (table 9.6.2). This observation may well reflect the small
sample sizes. In contrast in men treated with quetiapine and conventional
antipsychotics, significant effects of serum prolactin on libido were identified (table
9.6.3). In these groups serum prolactin explained 24% of the variance. In men
treated with risperidone and conventional antipsychotics the effects of serum
prolactin on orgasm could be identified as statistically significant only in patients
treated with risperidone, explaining 8% of the variance. 
In conclusion, although differences in sample sizes limit interpretation of the data,
we could not identify a clear relation between dosage of individual (groups of)
antipsychotics and sexual function. For risperidone, but not for the other
antipsychotics, a correlation between serum levels of the antipsychotics and sexual
function was found. The serum risperidone levels explained only 8% of the
variance in sexual libido and orgasm. In men treated with quetiapine, risperidone
and classical antipsychotics, effects of prolactin were identified on libido or orgasm,
for libido explaining 24% of the variance. Again small sample sizes limit the
interpretation of the data.
What is the prolactin elevation in male and female patients treated with different
antipsychotics? 
Serum prolactin levels tend to be higher in female patients than in male patients
during treatment with antipsychotics (figure 9.4.1).  The differences reflect higher
baseline serum prolactin levels in women and a greater rise during treatment with
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antipsychotics, probably influenced by higher physiological estrogen levels in
women (Knegtering et al. 2003a). 
Our data support the often cited dichotomy of “prolactin-elevating” versus
“prolactin-sparing” antipsychotic drugs. Thus, in line with other studies, risperidone
was associated with significantly higher serum prolactin levels in comparison to all
other treatment groups (figure 9.4.1, table 9.4.2 and 9.4.3) (Knegtering et al. 2000).
Treatment with conventional antipsychotics was associated with significantly higher
serum prolactin levels in comparison to treatment with clozapine, olanzapine or
quetiapine. Olanzapine showed greater prolactin elevation than quetiapine. These
findings are in line with studies reporting a modest dose-dependent serum prolactin
elevation in patients treated with olanzapine versus an often not detectable or
transient prolactin elevation during treatment with quetiapine (Beasley Jr et al.
1996; Beasley Jr. et al. 1997; Borison et al. 2002; Hamner 2002; Tran et al. 1997).  
Thus, as Turrone et al., stated earlier, the difference between prolactin-sparing and
prolactin-elevating is not qualitative but quantitative (Turrone et al. 2002). Since all
antipsychotic drugs exert their antipsychotic effect through the blockade of
dopamine neurotransmission, they all inevitably induce elevation of serum
prolactin. All antipsychotics are approximately equivalent in terms of suppressing
psychotic symptoms. However, as a group risperidone and the conventional
antipsychotics statistically significantly differed from olanzapine, quetiapine and
clozapine in the tendency to elevate serum prolactin. Interestingly, olanzapine took
an intermediate position, showing some prolactin elevation.  This raises interesting
questions about how antipsychotic drugs differentially affect dopamine
neurotransmission.  For example, the high serotonin to dopamine ratio is not a
likely candidate, as risperidone has a high 5HT2/D2 ratio and yet it induces the
highest prolactin levels. A lower affinity for the dopamine-D2 receptor may in part
explain these findings. However, sulpiride and amisulpride both have low
dopamine affinity, but both lead to high prolactin levels. As for risperidone, its
active metabolite may be responsible (see chapter 6). This metabolite has similar
receptor affinities as risperidone, but has a longer half-life.  
In reviewing the differences between serum prolactin elevation in atypical
antipsychotics Hamner concludes that although there are significant differences
between antipsychotics in the tendency to induce serum prolactin elevation,
“correlations between prolactin elevations and clinical symptoms have not been
well-established” (Hamner 2002). One of the central issues in the following
discussion is how to address this conclusion.
Is prolactin elevation correlated with sexual side effects?
As serum prolactin levels showed greater effects on sexual functioning (libido and
orgasm) than dose or serum levels, one may consider a causal relation between
serum prolactin elevation and diminished sexual function. A possible causal role of
serum prolactin was examined in three steps. 
In the first step (discussed before) individual antipsychotics were compared. It was
shown that patients treated with risperidone reported most frequently impairment of
sexual function, the same group also showing most prolactin elevation. Patient
treated with conventional antipsychotics reported fewer sexual side effects than
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those treated with risperidone but more than those treated with the ‘prolactin-
sparing’ clozapine, olanzapine or quetiapine. 
The second step was an ordinal regression analysis in which a comparison was
made between patients treated with the prolactin-elevating risperidone and
conventional antipsychotics versus those treated with the prolactin-sparing
clozapine, olanzapine or quetiapine. In this comparison, the prolactin-elevating
antipsychotics were associated with significantly more frequently and serious
sexual dysfunction including libido, orgasm, erection and ejaculation (table 9.5.2).
In the third step, an ordinal regression analysis was performed analyzing the
effects of prolactin on individual dimensions of sexual functioning in men and
women. Significant effects of serum prolactin levels on libido, orgasm and in men
also on ejaculation were shown, explaining 8-24% of the variance (table 9.7). 
In all three steps of the analysis serum prolactin levels may have contributed to
reduced sexual function. But could this observation be only an epiphenomenon? 
What mechanisms are associated with sexual dysfunction attributed to
antipsychotics: is there a role of prolactin?
Previous analyses were designed to reveal possible mechanisms involved in
inducing sexual dysfunction, focusing on serum prolactin elevation. The
comparison between prolactin-elevating and prolactin-sparing antipsychotics
showed that the former were associated with a significantly higher incidence of
sexual dysfunction in men and in women, in all dimensions of sexual performance
(libido, orgasm, and in men also erection and ejaculation) (tables 9.4.1 and 9.4.2).
Also examining the effect of serum prolactin on sexual dysfunction without
specifying groups of antipsychotics revealed significant effects of serum prolactin
on libido, orgasm and ejaculation (table and 9.7).  
It can be argued that this does not reflect the influence of serum prolactin on
sexual performance but that prolactin elevation is merely an epiphenomenon of
dopamine blockade in the brain. According to this view dopamine blockade would
be primarily responsible for the sexual side effects, and prolactin elevation is only
reflecting this. Indeed clozapine and quetiapine occupy dopamine receptors much
than risperidone or conventional antipsychotics (Farde. et al. 1992; Kapur et al.
2000; Kapur and Seeman 2001). This may be true for clozapine and quetiapine,
but does not explain the marked differences between olanzapine and risperidone in
serum prolactin levels and incidence of reported sexual side effects, although both
have quite similar affinities for postsynaptic dopamine-2 receptors (Leysen et al.
2000). In addition, in several PET studies patients treated with olanzapine or
risperidone at dosages comparable with those used in our studies, show almost
the same striatal (and limbic) D2 occupancy (Nyberg et al. 1993; Nyberg et al.
1999).  Risperidone and conventional antipsychotics also tend to occupy D2
receptors to more or less the same extent, not explaining the significant differences
in prolactin elevation and sexual side effects between these drugs (Boer den  et al.
1996; Farde et al. 1992; Farde et al. 1995). In conclusion: in contrast to serum
prolactin elevation, differences in limbic and striatal dopamine receptor occupancy
can not sufficiently explain the differences between antipsychotics in the tendency
to alter serum prolactin levels and sexual function.
For risperidone, it was shown that high serum prolactin elevation probably does not
reflect limbic or striatal dopamine receptor occupancy, but dopamine receptor
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occupancy in the pituitary mainly caused by 9-hydroxyrisperidone (see also
chapter 6). These observations allow us to conclude that striatal (and limbic)
dopamine blockade does not explain differences in incidence of sexual side effects
in patients treated with antipsychotics. 
It can be concluded that it is highly likely that serum prolactin levels play a major
role in inducing sexual side effects and also explain why conventional
antipsychotics, but even more so risperidone, seem to induce sexual side effects
so frequently.
In our data differences in serum prolactin levels can explain between 8% and 24%
of the variance on libido, orgasm and ejaculation. 
Is serum prolactin the main factor involved in sexual dysfunction attributed to
antipsychotics?
Although serum prolactin elevation seems to play an important role in inducing
sexual side effects, much of the variance in sexual performance remains
unexplained, suggesting that other factors not addressed in this study are involved.
Many factors have been suggested as possibly contributing to the occurrence
sexual dysfunction such as schizophrenia, social factors and the dopaminergic,
histaminergic, serotonergic and cholinergic properties of antipsychotics (see
chapter 1) (Meston and Gorzalka 1992; Meston and Frohlich 2000; Meston and
Frohlich 2001). Many of these factors are not addressed in this study. One factor
that could be examined was the involvement of noradrenergic (α1) mechanisms in
ejaculate volume during orgasm.  Reduction in ejaculate volume is suggested to be
caused by the α1 blocking properties of antipsychotics (Shiloh et al. 1999). To test
this hypothesis, a comparison was made between strong and weak α1-blocking
antipsychotics. It could not be shown that these α1-blocking properties have a
major impact on reported ejaculate volumes. In contrast, serum prolactin did show
significant effects on the ejaculate volume, again, surprisingly, suggesting a major
role of serum prolactin in also inducing these sexual side effects. 
Limitations of the study
Limitations of this study are that the data are from different, partly randomized
partly naturalistic, open studies. Also no assessment of sexual performance was
done before entering the studies. The datasets did not always consist of the same
elements, reflecting progress in the studies and available laboratory facilities.
Although for studies on sexual dysfunction the number of patients is relatively high,
for many analyses and in many subgroups the analyses will not have the power to
reveal possible differences between antipsychotics and possible contributing
factors or mechanisms involved. As women are less often referred to our clinic than
men, their data can not be studied in the same detail.
Another methodological problem is that data for most antipsychotics in this study
reflect first- or second-line treatment with antipsychotics. In contrast, patients
treated with clozapine had not responded sufficiently to at least 2 other
antipsychotics (treatment refractory) for at least six weeks treatment each.
General considerations
Despite the methodological limitations we feel that the findings of this study are
meaningful for the understanding of the physiology and patho-physiology of sexual
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functioning in patients treated with antipsychotics. Significant differences between
antipsychotics, that may have already been identified in relatively small treatment-
groups, suggest that these findings may have important clinical implications. The
study indicates that conventional antipsychotics, and even more so, risperidone,
induce sexual dysfunction much more frequently than olanzapine or quetiapine,
and possibly also clozapine. The role of serum prolactin in all dimensions of sexual
performance evaluated in these studies is at least very suggestive.  The role of α1
blocking properties in inducing reduction in ejaculatory volume could not be
confirmed. 
The role of serum prolactin in sexual performance is also suggested by the
symptoms of diminished sexual performance in patients with prolactinomas, a
condition with no known direct influence on the dopaminergic system, clearly
elevated serum prolactin levels and frequently reported sexual side effects (Netto
and Claro 1993). Recently, in studies on human volunteers, prolactin elevation has
been detected during sexual intercourse, especially orgasm (Exton et al. 2001;
Exton et al. 1999). The elevation of serum prolactin lasted as long as the
volunteers felt inhibited in sexual activity after orgasm. Some volunteers did not
show a rise in serum prolactin levels during sexual activity: this seemed to coincide
with the absence of a post-coital period of inhibition of sexual activity (Haake et al.
2002). These researchers suggest that prolactin may be involved in mechanisms
indicating sexual satiety (Kruger et al. 2002). How prolactin exhibits its effects is
unclear. Animal studies seem to suggest that serum prolactin influences
dopaminergic output, although the impact may be different over varying locations in
the brain suggesting a possible involvement in controlling behavior patterns. The
dopamine system is involved in many functions of the brain including attention,
fine-tuning of movements, the reward system, sexual arousal and orgasm. In
studies in rats the involvement in sexual arousal and orgasm has been shown,
including the inhibiting effects of dopamine antagonists (antipsychotics) on sexual
behavior (Damsma et al. 1992;  Pfaus et al. 1995;  Pfaus et al. 1990; Pfaus and
Phillips 1989). Thus, from data of previous human and animal studies as well as
the study presented in this article it seems plausible that antipsychotics decrease
sexual performance through blockade of dopamine as well as through elevating
serum prolactin finally decreasing all dimensions of sexual performance. 
It has been suggested that in reducing ejaculate volumes, α1 -adrenergic effects
may be involved (Shiloh et al. 1999). Our observations do not support a major
contribution of these mechanisms reducing the ejaculate volumes in patients
treated with antipsychotics: dopamine and prolactin may be more important, a
doubt shared by other authors (Shader and Elkins 1980). In contrast, in a recent
study of conventional antipsychotics Smith did find a correlation between
ejaculation disturbance and α-adrenergic blocking properties of antipsychotics
(Smith et al. 2002). An explanation of these apparently contradicting findings could
be that more than one mechanism is involved and that our study, also including
newer antipsychotics, was underpowered to detect the possible involvement of an
α1-adrenergic effects partly by being overshadowed by stronger dopamine- and
prolactin-related mechanisms. 
Recently, several case histories have been published suggesting that several
antipsychotics may be involved in inducing priapism (Emes and Millson 1994;
Gordon and de Groot 1999; Kuperman et al. 2001; Moinfar et al. 1994; Pais and
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Ayvazian 2001;  Patel et al. 1996;  Reeves and Mack 2002). Until now in our
studies we did not find any patient reporting this potentially serious sexual side
effect. This may suggest, although priapism is an important clinical problem being
treated as a medical emergency, it is probably rare.
Clinical consequences of treatment with prolactin elevating antipsychotics:
The number of patients needed to identify significant differences of sexual side
effects between individual prolactin-elevating or prolactin-sparing antipsychotics is
small, indicating that these findings are important in clinical practice. To illustrate
this, the Number Needed to Treat (NNT) comparing prolactin-elevating to prolactin-
sparing antipsychotics to prevent one experiencing sexual side effects is very
small, only 3 for both libido and orgasm.
From former studies we know that patients consider sexual side effects important
and that they may influence adherence to antipsychotics therapy (see also chapter
1 and 5) (Finn et al. 1990; Halbreich et al. 2003; Knegtering et al. 2003b; Smith et
al. 2002). In contrast, previous studies show that patients are not likely to report
sexual side effects spontaneously while clinicians tend to avoid discussing these
side effects (Jacobs and Bobek 1991; Knegtering et al. 2003a; Strauss and Gross
1984).
In our experience it is the clinician that needs tools to explore side effects,
especially sexual side effects. In the first pilot study, using the UKU, mostly a
checklist without guiding questions, clinicians felt embarrassed about discussing
these side effects with patients (Lingjaerde et al. 1987). After introducing a
questionnaire (ASFQ) guiding the physicians in discussing and evaluating sexual
side effects, clinicians no longer reported difficulties in discussing these items with
patients (see chapter 3) (Knegtering and Castelein 2001). From interviewing the
patients with the ASFQ we noted that patients may have difficulties answering
some questions about sexual side effects, but patients never reported difficulties
being asked for sexual side effects (see chapter 3) (Knegtering and Castelein
2001).
Our data suggest that if patients report sexual side effects during treatment with
prolactin-elevating antipsychotics, switching to a prolactin-sparing agent is
probably the first step to consider. As alternative option, although no clear dose
effects were identified, dose reduction could be considered. Some authors suggest
adding a dopamine agonist to the antipsychotic treatment (Matsuoka et al. 1986;
Smith 1992). 
In the rehabilitation of patients, including socio-sexual rehabilitation, clinicians
should consider the possible changes in sexual behavior and fertility when
switching toward antipsychotics with less detrimental influences on sexual
performance. The consequences include providing adequate sex education,
contraception and clinical guidance within a comprehensive treatment plan (Lukoff
et al. 1986; Cournos et al. 1994;  Hilger et al. 1983;  Jacobs and Bobek 1991;
Dickson and Edwards 1997;  Dickson and Dawson 1998;  Currier and Simpson
1998;  Dickson and Glazer 1999).  
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The aim of this thesis is to investigate the frequency and nature of sexual side
effects and hormonal alterations related to treatment with antipsychotic drugs.
Other goals are to increase insight into the pathophysiological mechanisms of
antipsychotic-induced sexual side effects, and to generate information in order to
improve clinical guidance of patients treated with antipsychotics. 
In this general discussion we will briefly summarize our findings. The focus will be
on pathophysiological considerations, and on the role of dopamine and prolactin.
Possible clinical consequences of prolonged elevation of serum prolactin levels are
discussed for osteoporosis and cardiovascular disease, and for behavior in




The most important findings of this thesis
Sexual side effects are only infrequently (10%) spontaneously reported by patients.
However, in response to structured questionnaires, 20-60% of the patients
reported  detrimental effects on libido, erection, lubrication, orgasm or ejaculation,
which they attributed to the use of antipsychotics (Chapters 1,4,5,7,8,9). Only
reduction in libido seems to be related to schizophrenia as well as to treatment with
antipsychotics (Chapters 1,7). Other sexual dysfunctions seem mainly to be related
to the  antipsychotics prescribed (Chapters 1 and 7). Preliminary results from a
cross-sectional study suggest that sexual side effects do not subside during
prolonged (over many years) treatment with antipsychotics (Chapters 1 and 7).
Although our studies, and studies done by others, show that sexual side effects are
very important to patients, both patients and clinicians seem reluctant to discuss
these side effects (Chapters 1 and 3). In our studies, interviewers were at first also
reluctant to discuss sexual side effects with patients, but providing clinicians with a
questionnaire (the Antipsychotics and Sexual Functioning Questionnaire (ASFQ))
has facilitated these discussions (Chapter 3). Although some patients experienced
no sexual side effects and indicated that they felt little need for studying these
effects, the vast majority of our patients felt that studying sexual side effects was
important to them (Chapter 5).
Before starting our studies, little was known about the incidence of sexual side
effects with different antipsychotics. Studies in this thesis show that not only sexual
side effects do to occur very often, but also that they occur more often with certain
groups of antipsychotics. Antipsychotics which elevate serum prolactin levels the
most induce the highest incidences of sexual side effects, as in the case of
classical antipsychotics and even more with risperidone (Chapters 2,4,5,8 and 9).
Patients treated with clozapine, olanzapine and quetiapine reported low
frequencies of sexual side effects (Chapters 4,5,8 and 9). In chapter 2, studies are
presented indicating that risperidone elevates serum prolactin levels more than
most classical antipsychotics. These findings are confirmed in the comparison of
risperidone with classical antipsychotics, clozapine, olanzapine and quetiapine
(Chapters 4,5,8,9). The mechanism by which risperidone elevates serum prolactin
levels so greatly is explored in chapter 6; the explanation may be the slow passage
of the blood-brain barrier of  the metabolite 9-OH-risperidone. Some investigators
report that although serum prolactin levels may be elevated during treatment with
some antipsychotics, there is little evidence of side effects induced by serum
prolactin elevation during treatment with antipsychotics. By making multiple
comparisons between treatment groups, chapter 9 tries to disentangle the role of
serum prolactin in the occurrence of sexual dysfunction. 
It was concluded that serum prolactin elevation is not just an epiphenomenon of
cerebral postsynaptic dopamine blockage by antipsychotics. Serum prolactin
probably plays a major role in the pathogenesis of sexual side effects during
treatment with antipsychotics for libido, orgasm and ejaculation, explaining 8-24%
of the statistical variance found in our studies (Chapter 9). Although women have
higher baseline serum prolactin levels and higher serum levels during treatment
with antipsychotics in comparison to men, men and women experience influences
on libido and orgasm by antipsychotics in more or less the same frequencies
(Chapters 5 and 9).
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Can serum prolactin influence sexual behavior?
Serum prolactin elevation may inhibit several aspects of sexual behavior, perhaps
best illustrated by sexual dysfunction related to prolactinoma. These sexual
dysfunctions are sometimes the first symptom of this neuro-endocrine active tumor
of the pituitary (Meston and Frohlich 2000; Meston and Frohlich 2001; Schwartz et
al. 1982; Yen and Jaffe 1999). The symptoms in patients with prolactinoma
suggest that prolactin elevation, not caused by postsynaptic dopamine 2 receptor
blockage, can indeed inhibit sexual behavior. How serum prolactin levels influence
sexual functioning remains unclear. Elevation of serum prolactin does not seem to
influence nightly erections in men during REM sleep, but it may modulate libido
and sexual behavior (Carani et al. 1996). This suggests that the mechanism
enabling erection may not be influenced by serum prolactin level elevation.
Interestingly, in line with the study by Carani, we found no clear correlation
between erection and serum prolactin levels, but we did find a clear correlation with
libido. A conclusion could be that the effects of serum prolactin may take place
primarily through the central nervous system. 
A secondary effect of serum prolactin elevation may be the lowering of serum
testosterone (Siris et al. 1980). Recent studies suggest that lowering of
testosterone, especially in women, may inhibit sexual behavior (Riley and Riley
2000). This lowering of serum testosterone seems to be associated with a lower
frequency of sexual thoughts and a lower coital frequency. In men, low serum
testosterone may decrease nightly erections. The role of serum testosterone in
male sexual functioning is unclear (Carani et al. 1996). 
Serum prolactin levels interfere with dopamine in the striatal and limbic areas of the
brain and with neurogenesis in the olfactory system (Cruz-Casallas et al. 1999).
From studies in animals and humans, the involvement of dopaminergic systems in
all phases (appetitive, arousal, orgasm) of sexual behavior seems likely (Damsma
et al. 1992; Meston and Frohlich 2000; Meston and Frohlich 2001; Pfaus et al.
1990; Pfaus et al. 1995; Pfaus and Phillips 1989).
Animal studies have shown that neurogenesis in the olfactory system may be
involved in parenting behavior, especially in recognizing offspring by smell (Shingo
et al. 2003). In humans, changes in olfactory function during pregnancy are also
found. These changes are thought to protect the child by preventing the mother
from eating potentially harmful foods, and by improving recognition of the child
(DiPasquale et al. 2001; Kolble et al. 2001). 
Recent studies in humans volunteers suggest that prolactin may also be involved
in inhibition of sexual behavior after orgasm, suggesting it has a role in satiety
(Haake et al. 2002). These studies have shown that serum prolactin levels rise
during sexual activity, reaching a peak during orgasm. After orgasm, the elevation
of serum prolactin lasted as long as people felt disinterested in sexual activity.
Some volunteers did not show a rise in serum prolactin levels during sexual
activities; this seemed to coincide with the absence of a post-coital period of
inhibition towards sexual activity (Haake et al. 2002). 
It may be speculated that prolactin is involved in inducing behavior switches,
ending sexual and feeding activity and enhancing behavior involved in parenting. In
line with this hypothesis, observations in several animal studies suggest that
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prolonged prolactin elevation is associated with parenting behavior (Ziegler 2000).
Artificially lowering serum prolactin levels, using gene knock-out techniques in
mice, and by administering bromocriptine to marmosets (monkeys), all seemed to
disrupt parental behavior (Lucas et al. 1998; Roberts et al. 2001). In humans, as in
most mammals, serum prolactin levels are elevated during pregnancy and in the
first months after childbirth during lactation. In prolonged lactation in humans,
serum prolactin declines after three to six months, followed by resumption of the
menstrual cycle. Based on these observations, it can be speculated that
antipsychotics, by inducing prolonged prolactin elevation, accidentally induce a
switch in behavior, physiologically and psychologically meant to prepare for
parenting. The intertwining of serum prolactin and the dopamine system suggests
that prolactin may be in a key position to change dopaminergic activities, possibly
changing priority settings in such areas as attention, motivation, reward and sexual
behavior.
Is prolonged artificial serum prolactin elevation a serious medical condition?
Possible secondary effects of long-term serum prolactin elevation include
menstrual disorders, the development of breast cancer, decreased bone density
and elevated risk for cardiovascular disorders (Dickson and Glazer 1999; Halbreich
et al. 2003). Recent studies do seem to indicate an increased risk of developing
breast cancer after treatment with prolactin-elevating medication (Wang et al.
2002). Other recent studies suggest that the duration of treatment with
antipsychotics may be linked to a decrease in bone marrow density (Bilici et al.
2002).
Behaviorally, possible secondary effects of prolonged prolactin elevation, in
combination with changes in the levels of other hormones, are not known. Still, we
may wonder what these could be, especially in the maturating brains of young
children. We know that the sensitivity of the brain to hormones influencing behavior
varies throughout life, creating time windows for different influences. Also, the
influence of hormones on the brain may change in the context of the
concentrations of other hormones, or in the context of the order of hormone
fluctuations (Pfaff 1999). For instance, in order for female rats to be in oestrus,
increased levels first of estrogen, followed by an increase of progesterone are
essential; giving these hormones together, or changing the order causes female
rats not to be in oestrus, and not to exhibit sexual behavior. Several times in the
past years we have been consulted about young boys who are showing breast
development while being treated with prolactin-elevating antipsychotics. This made
us worry about what effects prolonged serum prolactin elevation, which has
possible secondary effects on testosterone, estrogens, progesterone and other
hormones, may have on sexual behavior in later life. To our knowledge, this has
not been studied, especially not in patients with schizophrenia being treated with
antipsychotics. The only study addressing this concern we could find, by Siimes et
al., was of children being treated for cancer. This study implies that these concerns
may be more than a hypothetical problem (Siimes et al. 1993). The possible
relationship between serum prolactin elevation and psychosexual development
was studied, comparing pubertal stage, testicular size, serum follicle-stimulating
hormone (FSH), luteinizing hormone (LH), testosterone, thyroxine, thyroid-
General discussion
149
stimulating hormone (TSH), and prolactin concentrations in 94 adolescent males
who had survived malignancies in childhood. Of the patients, 22% had elevated
serum prolactin, > 300 mU/L. A significant inverse relation existed between serum
prolactin concentration and dating with the opposite sex; none of the patients with
elevated serum prolactin were dating. The investigators concluded that even a
slight elevation of serum prolactin above normal is associated with or may be
reflected in the psychosexual development of adolescent males who have survived
malignancies in childhood. 
We should be careful in interpreting these findings. Although prolactin-elevating
antipsychotics have been available for more than 50 years and have been used
extensively, only a few studies, all with clear methodological limitations, are
suggesting that prolonged serum prolactin elevation may be hazardous. So it may
be too early to state that antipsychotic-induced serum prolactin elevation is a
serious medical condition. Clearly, more studies are needed, investigating possible
influences of prolonged serum prolactin elevation on psychosocial behavior and
possible health risks. For future drug development it is probably wise to develop
antipsychotics that do not induce sustained serum prolactin elevation. 
How should sexual side effects and serum prolactin elevation be weighed in
the context of other side effects?
Antipsychotics are effective in the symptomatic improvement of psychotic
symptoms, but cannot cure schizophrenia. So for many patients, prolonged
treatment is necessary in order to prevent the recurrence of psychotic symptoms.
As this prolonged treatment often continues for many years, or even lifelong, side
effects inducing chronic discomfort or social and medical problem become very
important. Side effect research is not popular with pharmaceutical industries, nor
with clinicians; however, patients are extremely interested in and worried by side
effects. None of the presently available antipsychotics, classical or atypical, are
without important side effects. But the many different side effects are often difficult
to compare in their clinical importance. Many classical antipsychotics cause all
kinds of often very distressing movement disorders in about 60% of the patients.
Most of these movement disorders are reversible, but some, like tardive
dyskinesia, may be irreversible. Clozapine, being the first atypical antipsychotic
without extrapyramidal side effects, is a very effective antipsychotic, but many
patients experience serious sedation, dizziness, weight gain or even sporadic life-
threatening cardiovascular or haematological side effects. Other newer
antipsychotics may induce serious weight gain with long-term increased risks for
developing diabetes and cardiovascular problems. None of these side effects occur
in all patients. Some patients are clearly more sensitive to developing, for instance,
movement disorders or weight gain than others. Most antipsychotics are more or
less equally effective. But the side effects induced seem to vary a great deal
between individuals. The available data do not permit preferring any single
antipsychotic over the others in all cases. 
Systematic side effect evaluation and systematic long-term follow-up studies
evaluating medical and psychosocial (side) effects of antipsychotics following strict
protocols are clearly needed. The systematic evaluation of side effects should be
based on formal questionnaires like the UKU or Liverpool University Neuroleptic
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Side Effect Rating Scale (LUNSERS), which includes sexual side effects (Day
1995). The objective medical condition and the subjective well-being of the patient
should guide clinical practice (Ten Brink et al. 1998). A recently developed
questionnaire, the Subjective Response to Antipsychotics (SRA), may help the
patient and clinician to weigh the beneficial and detrimental effects of antipsychotic
medication in the perspective of the patient´s subjective well-being (Wolters et al.
2002).
Laboratory investigation and physical examination on a regular basis should be
included in good clinical practice for patients treated with antipsychotics over a long
period. Evaluation of sexual and hormonal aspects should be incorporated into the
daily routine of clinical practice, neither overemphasizing nor neglecting this
important aspect of human life. 
What are the clinical consequences of this thesis?
Sexual side effects frequently occur in patients treated with classical antipsychotics
and even more so in patients treated with risperidone. Men and women seem to be
equally likely to experience sexual side effects. As patients often do not report
these effects spontaneously, clinicians should actively inquire about these side
effects, and should discuss the individual impact with patients. The use of
questionnaires like the ASFQ may help clinicians to discuss these problems with
patients.
Some patients feel relieved by a diminished sexual drive, some patients even
seem to feel rather indifferent about sexual side effects, but for the majority of the
patients sexual side effects are a burden. Sexual side effects of antipsychotics can
be managed well. In patients treated with prolactin-elevating antipsychotics and
experiencing sexual side effects, switching to an antipsychotic that does not raise
prolactin levels is probably the best option. Alternatively, lowering the dosage could
be considered. If switching to another antipsychotic or lowering dosages are not
possible, adding a dopamine agonist may be considered (Matsuoka et al. 1986,
Smith, S. 1992). 
Some clinicians tend to alter the antipsychotic treatment in response to raised
levels of serum prolactin, often accidentally found. Up to now, there is no evidence
to support changing treatment only because of serum prolactin elevation. Also,
there is no reason to advise clinicians to evaluate serum prolactin levels routinely.
In our opinion, the symptoms of the patient rather than alterations in laboratory
findings should direct clinical guidance.
In the rehabilitation of patients, including socio-sexual rehabilitation, clinicians
should consider the possible changes in sexual behavior and fertility when
switching to antipsychotics with less detrimental effects on sexual performance.
Clinicians should provide adequate sex education and contraception and clinical
guidance within a comprehensive treatment plan (Lukoff et al. 1986; Cournos et al.
1994; Hilger et al. 1983; Jacobs and Bobek 1991; Dickson and Edwards 1997;
Dickson and Dawson 1998; Currier and Simpson 1998; Dickson and Glazer 1999).  
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What new research on sexual dysfunctions and serum prolactin elevation is
needed? 
More studies allowing for the evaluation of sexual functioning in more detail and for
comparison of treatment with different antipsychotics are needed. Larger sample
sizes of women and also of each antipsychotic will increase the reliability of the
studies. The influence of prolactin-elevating antipsychotics on other hormones like
estrogen, progesterone and testosterone, which possibly contribute to the side
effects profile, is understudied. 
Possible secondary effects of long-term serum prolactin elevation on menstruation,
the development of breast cancer, decreased bone density or elevated risk for
cardiovascular disorders have been suggested but only infrequently studied (Bilici
et al. 2002;  Halbreich and Palter 1996; Wang et al. 2002;  Halbreich et al. 1995;
Halbreich et al. 2003). Future studies are needed to address these possible
serious medical consequences. 
Recently, some clinicians reported successful treatment of sexual side effects
induced by antipsychotics with sildenafil (oral communication). These clinical
observations should be studied in a controlled trial as they may offer a treatment
alternative, and may enlarge our understanding of the pathophysiology of sexual
functioning.
In our studies a significant proportion of the variance of the reported sexual
dysfunctions remain unexplained. This suggests that other possible factors
influence the findings on sexual functioning, including methodological,
pharmacological, social and disease-related factors. These factors need to be
addressed in future studies. It is also important to investigate the influence of
prolonged treatment with prolactin-elevating antipsychotics on psychosocial and
sexual development, especially in children and adolescents (Siimes et al. 1993;
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Antipsychotica en seksueel functioneren bij mensen met schizofrenie
Rikus Knegtering
Inleiding
Klinische problemen bij mensen die met antipsychotische medicijnen werden
behandeld vormden de aanleiding voor een aantal onderzoeken uitmondend in dit
proefschrift. In de laatste tien jaar van het vorige decennium kwam een nieuwe
generatie antipsychotica beschikbaar. Bij sommige antipsychotica waren er
opmerkelijk veel patiënten die problemen in het seksueel functioneren
rapporteerden. Ook waren er patiënten die menstruatiestoornissen meldden. In
laboratoriumonderzoek werden bij een aantal patiënten onverwacht grote
hoeveelheden van het hormoon prolactine in het bloed gevonden. Onduidelijk was
of de verhoging van hoeveelheden van dit hormoon de oorzaak kon zijn van
seksuele functiestoornissen en menstruatiestoornissen. Ook was onduidelijk in
hoeverre deze problemen samenhingen met de behandeling met antipsychotische
medicijnen of met de psychose waarvoor behandeld werd. Tenslotte was niet
bekend of alle (nieuwe) antipsychotica dezelfde effecten zouden hebben op
seksueel functioneren, menstruatie problemen en hormonale veranderingen. 
Veel mensen die behandeld worden met antipsychotica lijden aan een psychose
zoals schizofrenie. Steeds vaker worden antipsychotica ook toegepast bij mensen
die lijden aan een manische periode bij een bipolaire stoornis. Om te voorkomen
dat psychosen of manisch periodes terugkomen, wordt veel mensen aangeraden
antipsychotica gedurende vele jaren te gebruiken. Bij langdurig gebruik van
geneesmiddelen is het van groot belang dat er zo min mogelijk onaangename
effecten optreden. 
Voor veel mensen zijn seksuele problemen niet eenvoudig te bespreken. Toch zijn
seksuele bijwerkingen waarschijnlijk van belang voor het al dan niet blijven
gebruiken van antipsychotica. Om deze reden werd een aantal onderzoeken
gestart naar de vraag hoe vaak seksuele problemen voorkomen bij mensen die
behandeld worden met antipsychotica. 
Doel van deze onderzoeken was geïnformeerd te worden over de frequentie en de
ernst van seksuele functiestoornissen tijdens de behandeling van psychosen.
Gehoopt werd door antipsychotica onderling te vergelijken de oorzaken van het
optreden van de seksuele functiestoornissen beter te kunnen begrijpen.
Uiteindelijke doel was gegevens te verkrijgen die de klinische begeleiding van
patiënten met psychosen zouden kunnen verbeteren ten aanzien van seksuele
bijwerkingen van antipsychotica.
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Hoofdstuk 1
Schizofrenie, seksueel functioneren en behandeling met antipsychotica, een
literatuuronderzoek 
In hoofdstuk 1 van het proefschrift wordt op basis van de bestaande literatuur tot
het jaar 2001 onderzocht hoe vaak mensen met schizofrenie problemen hebben in
het seksueel functioneren. Er blijkt maar weinig onderzoek in het verleden te zijn
gedaan. Uit dat onderzoek blijkt dat seksuele behoeften bij mensen met
schizofrenie in het algemeen weinig verschillen van mensen die niet lijden aan
schizofrenie. Wel blijkt dat mensen met schizofrenie, vooral mannen, minder vaak
een partner hebben. Ook zou bij schizofrenie wat vaker een interesseverlies voor
seks optreden. Masturbatie (zelfbevrediging) is voor veel mensen met schizofrenie
een belangrijke seksuele activiteit.
Er blijkt ook weinig onderzoek te zijn gedaan naar seksuele bijwerkingen van
antipsychotica. Dit komt waarschijnlijk mede doordat dokters en patiënten weinig
over seksuele bijwerkingen praten. In tegenstelling tot wat veel artsen lijken te
denken toont het beschikbare onderzoek aan dat mensen met psychosen het
optreden van seksuele bijwerkingen een groot probleem vinden. 
Er is een beperkt aantal onderzoeken gedaan naar de frequentie en ernst van
seksuele functiestoornissen bij antipsychoticagebruik. Het gaat hierbij om open,
niet vergelijkende studies, voornamelijk bij mannen die klassieke antipsychotica
gebruikten. De gebruikte, steeds verschillende, vragenlijsten bij deze onderzoeken
zijn niet onderzocht op hun betrouwbaarheid en validiteit. Het voorgaande
bemoeilijkt het beoordelen en onderling vergelijken van de onderzoeken. De
onderzoeken tonen aan dat zogenaamde klassieke antipsychotica vaak (in 30-60%
van de gevallen) seksuele functiestoornissen veroorzaken. Deze seksuele
functiestoornissen zijn minder zin in seks (vermindering van libido) en problemen
met het krijgen of houden van een erectie. Ook melden antipsychoticagebruikers
vaker  moeilijk een orgasme te krijgen en sommige mannen melden een
vermindering van de hoeveelheid sperma tijdens een orgasme. Sommige
onderzoekers melden ook een verminderde kwaliteit van het orgasme bij
antipsychoticagebruik. Mogelijk hebben vrouwen bij antipsychoticagebruik minder
vochtafscheiding tijdens seksuele activiteit, maar dat is nauwelijks onderzocht.
Onduidelijk is of vrouwen en mannen even vaak seksuele functiestoornissen
ervaren. In het beperkte beschikbare onderzoek wordt gesuggereerd dat sommige
klassieke antipsychotica zoals thioridazine mogelijk wat vaker seksuele
functiestoornissen geven dan andere klassieke middelen. Het atypische
antipsychoticum clozapine zou mogelijk minder vaak seksuele functiestoornissen
veroorzaken, maar onderzoeken hierover spreken elkaar tegen.
Waarom antipsychotica zo vaak seksuele functiestoornissen geven is onduidelijk.
Bepaalde eigenschappen van antipsychotica worden, vooral vanuit onderzoek met
proefdieren, als reden voor bepaalde seksuele functiestoornissen genoemd.
Voorbeelden van deze eigenschappen zijn: dopamine (D2) blokkade, serotonine
(5HT) blokkade, noradrenaline (α1) blokkade, cholinerge blokkade en hormonale
veranderingen zoals verhoging van de hoeveelheid prolactine in het bloed of  de




De hoeveelheid prolactine in het bloed en seksuele functiestoornissen bij
gebruik van antipsychotica zoals risperidon
In hoofdstuk 2 wordt een literatuurstudie beschreven en een vergelijkend open
onderzoek gepresenteerd naar het optreden van seksuele functiestoornissen bij
mensen die zes weken werden behandeld met het nieuwe antipsychoticum
risperidon of klassieke antipsychotica. Mensen behandeld met risperidon (n=28,
mediane dosering 3.2 mg/dag) rapporteerden vaker seksuele functiestoornissen
(78%) dan mensen behandeld met klassieke antipsychotica (n=27, mediane dosis
6 mg/dag haloperidol equivalenten (46%). Bij beide groepen patiënten werd een
verhoging van de hoeveelheid prolactine in het bloed gevonden, echter bij
risperidon was deze verhoging sterker dan bij klassieke antipsychotica. Uit de
literatuurstudie wordt duidelijk dat blokkade van dopamine in de hypofyse, de rem
(inhibitie) op de uitscheiding van prolactine blokkeert, waardoor antipsychotica de
hoeveelheid prolactine in het bloed verhogen. Onder andere vanuit dierproeven
wordt voorspeld dat blokkade van serotonine (HT), van met name 5HT2a
receptoren, het effect van de remming door dopamine op prolactine uitscheiding
kan verminderen. Uit literatuuronderzoek blijkt dat clozapine, zowel dopamine als
serotonine (5HT2a) blokkeert en het geen blijvende verhoging geeft van prolactine
in het bloed. Risperidon blokkeert eveneens dopamine en serotonine (5HT2a),
maar het wordt niet duidelijk waarom door risperidon de prolactine zo wordt
verhoogd, mogelijk zelfs meer dan door klassieke antipsychotica. Een verband
tussen de hoge waarden van prolactine in het bloed en het optreden van seksuele
functiestoornissen valt op, maar onduidelijk is of er ook een oorzakelijk verband is.
Hoofdstuk 3
De ontwikkeling van een vragenlijst voor antipsychoticagebruik en seksueel
functioneren ‘The Antipsychotic and Sexual Functioning Questionnaire’
In dit hoofdstuk wordt ingegaan op de vraag hoe seksuele functiestoornissen
tijdens antipsychoticagebruik bij mensen met psychosen zoals schizofrenie het
best onderzocht kunnen worden. Geconcludeerd wordt dat geen goed onderzochte
vragenlijst beschikbaar was om onderzoek te doen naar de effecten van
antipsychotica op seksuele functiestoornissen. Op basis van een bestaande, goed
onderzochte, vragenlijst voor bijwerkingen van antipsychotica in het algemeen, de
UKU werd een nieuwe vragenlijst gemaakt. De vragen voor seksuele
functiestoornissen werden zodanig aangepast dat interviewers en patiënten
werden geholpen deze problemen bespreekbaar te maken. De scoringsinstructies
werden aangepast zodat zowel verbetering als verslechtering in seksueel
functioneren gescoord kunnen worden. De zo verkregen vragenlijst werd de
Antipsychotic and Sexual Functioning Questionnaire (ASFQ) genoemd. De
gegevens van een eerste onderzoek naar de bruikbaarheid (betrouwbaarheid en
validiteit) van de ASFQ worden in hoofdstuk 3 gepresenteerd. Hoewel de ASFQ
nog niet bij veel patiënten is onderzocht, suggereren eerste onderzoeksresultaten
een goede bruikbaarheid in de praktijk, met een acceptabele test-hertest
betrouwbaarheid, redelijke concurrente betrouwbaarheid en goede gevoeligheid
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voor therapeutische veranderingen. De ASFQ werd gebruikt voor de verdere
onderzoeken in dit proefschrift.
Hoofdstuk 4
Een gerandomiseerd open vergelijkend onderzoek naar de invloed van
olanzapine en risperidon op seksueel functioneren 
Tijdens de eerste onderzoeken met risperidon en klassieke antipsychotica kwamen
nog andere nieuwe, atypische, antipsychotica op de markt, zoals olanzapine,
sertindole en quetiapine. Al deze antipsychotica delen als eigenschap met
clozapine en risperidone een relatief sterke neiging om serotonine (5HT2a) te
blokkeren en een zwakkere neiging om dopamine (met name postsynaptische
dopamine D2 receptoren) te blokkeren. De komst van nieuwe antipsychotica bood
de gelegenheid vergelijkend onderzoek te gaan doen naar de frequentie van
tijdens de behandeling van nieuwe (atypische) antipsychotica gerapporteerde
seksuele functiestoornissen en hormonale veranderingen. In het in hoofdstuk 4
beschreven onderzoek werd voor mensen met een psychose door middel van
loting bepaald of ze behandeld zouden worden met risperidon of olanzapine. Het
stond de behandelaars vrij om de dosering te kiezen die nodig werd geacht.
Patiënten en behandelaars kenden het gelote antipsychoticum (open onderzoek).
Na zes weken werd met behulp van de ASFQ nagevraagd of er seksuele
bijwerkingen waren. Ook werd gekeken naar de hoeveelheden antipsychoticum en
prolactine in het bloed. Patiënten en de onderzoekers die de ASFQ afnamen,
wisten niet of er een bepaalde hypothese was over het al dan niet vaker
voorkomen van bepaalde seksuele bijwerkingen. In totaal deden 46 patiënten mee
aan dit onderzoek. In overeenstemming met de aanmeldingen in onze kliniek,
bestond de meerderheid uit mannen. Van de mensen die olanzapine (mediane
dosis 9.4 mg/dag) kregen, rapporteerden 3 (12%) seksuele functiestoornissen
vergeleken bij 11 (52.4%) patiënten die risperidon kregen (mediane dosis 3.4
mg/dag), een significant verschil (p=0.008). Ook verschilden de waarden van
prolactine in het bloed sterk tussen de twee behandelgroepen. Bij patiënten die
olanzapine gebruikten, was de mediane hoeveelheid 25.1 ng/ml (hoog normaal) en
bij patiënten die risperidon gebruikten, was dit 43.5 ng/ml (sterk verhoogd). Hoewel
olanzapine veel sterker dopamine D2 blokkeert dan bijvoorbeeld clozapine, werd
de prolactine spiegel nauwelijks verhoogd. Dit past in de hypothese dat de 5HT2a
antagonistische eigenschappen de eventuele neiging om prolactine te verhogen
zouden kunnen compenseren (hoofdstuk 2). Onverklaard blijft waarom risperidon,
dat niet veel sterker aan dopamine bindt dan olanzapine toch prolactine in het




Een gerandomiseerd open vergelijkend onderzoek naar de invloed van
quetiapine en risperidon op seksueel functioneren 
Het onderzoek gepresenteerd in dit hoofdstuk heeft grotendeels dezelfde opzet als
dat van het onderzoek dat werd beschreven in hoofdstuk 4. Het is een vergelijkend
onderzoek, waarbij mensen die antipsychotica nodig hadden gevraagd zijn mee te
doen aan onderzoek. Vervolgens werd door loting bepaald wie risperidon of
quetiapine ging gebruiken. Van de 25 mensen die behandeld werden met
quetiapine (mediane dosis 580 mg/dag) rapporteerden 4 (16%) seksuele
functiestoornissen. Van de 24 mensen die risperidon kregen (mediane dosis 3.2
mg/dag) rapporteerden 12 (50%) seksuele functiestoornissen. Het verschil tussen
beide antipsychotica was significant (p=0.006). Zowel voor mannen als voor
vrouwen was de frequentie van seksuele functiestoornissen significant lager bij
mensen behandeld met quetiapine. De mediane prolactine spiegels waren voor
mensen met quetiapine 13.6 ng/ml en voor risperidon 57.7 ng/ml; ook dat is sterk
verschillend (statistisch significant). Theoretische en klinische consequenties van
het onderzoek worden besproken. 
Hoofdstuk 6
De rol van 9-OH-risperidon bij prolactineverhoging in het bloed
Vanaf de tweede helft van het jaar 2000 kwamen er betere laboratorium
bepalingen beschikbaar. Hiermee werd het mogelijk in het bloed niet alleen de
hoeveelheid risperidon te meten, maar ook 9-OH-risperidon (9-OH-RIS), wat een
afbraakproduct is van risperidon. Het belang van het bepalen van deze
zogenaamde metaboliet was dat inmiddels duidelijk was geworden dat 9-OH-RIS
een werkzame dopamine antagonist is, dus ook een antipsychoticum. 9-OH-RIS
bleek grotendeels dezelfde eigenschappen te hebben als risperidon. Wel wordt 9-
OH-RIS minder snel afgebroken (langere halfwaardetijd). 
In hoofdstuk 6 wordt gerapporteerd over de eerste 25 mensen die met risperidon
behandeld werden waarbij gegevens waren over de dosering van risperidon,
samen met de hoeveelheid risperidon, 9-OH-RIS en prolactine in het bloed. De
dosering van risperidon bleek (statistisch significant) samen te hangen met de
hoeveelheden in het bloed van risperidon, 9-OH-RIS, en prolactine. Echter geen
(statistisch significant) verband werd gevonden tussen de hoeveelheid risperidon in
het bloed en de hoeveelheid prolactine in het bloed. Een sterk verband werd
gevonden tussen 9-OH RIS en de hoeveelheid prolactine in het bloed. De
hoeveelheid 9-OH RIS in het bloed is ook veel hoger dan de moederstof.
Deze bevindingen werden samen gebracht met recente bevinding van onder
andere Kapur betreffende het relatief moeizaam door de bloed-hersen-barrière
dringen van risperidon in vergelijking met olanzapine of quetiapine. Het volgende
model wordt voorgesteld. De hypofyse is de plaats waar prolactine wordt
afgegeven. Dit orgaan ligt onder de hersenen, buiten de bloed-hersenbarrière.
Risperidon, en waarschijnlijk meer nog 9-OH RIS, dringen relatief moeilijk door de
bloed-hersenbarrière, veel moeilijker bijvoorbeeld dan olanzapine en quetiapine. 9-
OH RIS heeft bovendien een langere halfwaarde tijd dan risperidon en mede
daardoor hogere bloedspiegels. Om een antipsychotisch effect te bereiken
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(voldoende dopamine blokkade in het limbische systeem van de hersenen, voorbij
de bloed-hersen barrière) dient daarom relatief hoog te worden gedoseerd. Hierbij
treedt een (te) sterke dopamine blokkade op buiten de bloed-hersenbarrière, in de
hypofyse. Dit laatste leidt tot een sterke stijging van de hoeveelheid prolactine in
het bloed. De blokkade van dopamine in de hypofyse is daarbij zo sterk dat geen
verlaging van de hoeveelheid prolactine in het bloed via 5HT2a meer kan
optreden. Het bovenstaand model vormt een verklaring voor de opvallend sterke
prolactine verhoging in het bloed bij behandeling met risperidon. Daarmee is
overigens de relatie tussen het optreden van seksuele bijwerkingen en de
verhoging van prolactine niet bewezen of verklaard. Op het mogelijke belang van
prolactine stijging voor het optreden van seksuele functiestoornissen wordt in de
hoofdstukken  8 en 9 verder ingegaan.
Hoofdstuk 7
De lange termijn bijwerkingen van klassieke (depot) antipsychotica en
clozapine op seksueel functioneren, eerste resultaten.
De meeste onderzoeken, ook die van vorige hoofdstukken, beperken zich tot het
voorkomen van seksuele bijwerkingen bij mensen die slechts relatief kort worden
behandeld met antipsychotica, vaak zo’n 6 weken. Echter voor veel mensen met
schizofrenie is het nodig vele jaren antipsychotica te gebruiken. Het is dan van
belang te weten of seksuele bijwerkingen op den duur verdwijnen dan wel of ze
blijven bestaan zolang de behandeling voortduurt. Dit hoofdstuk beschrijft het
voorkomen van seksuele functiestoornissen bij mensen die langer dan 6 maanden
(meestal vele jaren) klassieke depot antipsychotica gebruiken of clozapine. Door
de frequentie van seksuele bijwerkingen tussen clozapine gebruikers en depot
gebruikers te vergelijken kon ook worden onderzocht of clozapine minder seksuele
functiestoornissen heeft dan klassieke (depot) antipsychotica. In het begin van het
onderzoek werd in een omschreven gebied in en rond de stad Groningen een
doelpopulatie van 200 patiënten geïdentificeerd. Voornamelijk doordat veel
mensen meerdere medicamenten tegelijk gebruikten, konden velen niet meedoen
aan het onderzoek.
Uiteindelijk werden 35 patiënten bereid gevonden om aan het onderzoek mee te
doen (21 klassieke depot antipsychoticagebruikers, 14 clozapine gebruikers).
Libidovermindering werd gemeld door 33% van de patiënten in beide langdurige
behandelgroepen. Dit komt overeen met het aantal patiënten dat 6 weken
klassieke antipsychotica gebruikte. Er was een trend dat mensen die langdurig
clozapine gebruikten minder klachten meldden als erectiestoornissen,
orgasmestoornissen en problemen in de zaadlozing in vergelijking met langdurig
depot gebruikers. Dit verschil was niet statistisch significant. De grootte van de
groepen in deze studie is nog onvoldoende om definitief over de resultaten te
oordelen. Het feit dat mensen die lange termijn klassieke antipsychotica gebruiken
dezelfde frequenties van seksuele functiestoornissen melden als korte termijn
gebruikers lijkt de gedachte te ondersteunen dat seksuele bijwerkingen niet vanzelf
na verloop van tijd verdwijnen. Van belang is zich te realiseren dat dit een open
onderzoek betrof bij mensen die veelal lijden aan meer ernstige vormen van
schizofrenie waarbij slechts een geselecteerde groep onderzocht kon worden. Het
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onderzoek wordt momenteel voortgezet om de onderzoeksvragen beter te kunnen
beantwoorden.
Hoofdstuk 8
Wat zijn de effecten van antipsychotica op seksuele functiestoornissen en
endocriene functies?
Op verzoek van de redactie van het tijdschrift Psychoneuroendocrinology werd een
literatuuroverzicht geschreven over antipsychotica en seksuele functiestoornissen.
Daarbij werd gevoegd een nieuwe analyse van onderzoeksgegevens verkregen in
de recente onderzoeken in het Academisch Ziekenhuis te Groningen. Uit de
literatuur blijkt dat seksuele functiestoornissen door dertig tot zestig procent van de
antipsychoticagebruikers gemeld worden. Uit recent eigen onderzoek blijkt dat
patiënten  behandeld met risperidon vaker seksuele functiestoornissen melden
vergeleken met patiënten die olanzapine gebruiken. Door gegevensbestanden
samen te voegen kon gekeken worden naar verschillen tussen klassieke
antipsychotica, olanzapine en risperidon in het effect op seksueel functioneren en
veranderingen in het hormoon prolactine.
Mensen die risperidon gebruikten meldden in 64% van de gevallen seksuele
functiestoornissen. Klassieke antipsychoticagebruikers meldden in 43% van de
gevallen seksuele functiestoornissen, olanzapine gebruikers meldden in 18 % van
de gevallen seksuele functiestoornissen.  Risperidon veroorzaakt eveneens meer
prolactine verhoging dan klassieke antipsychotica; olanzapine veroorzaakt de
minste prolactine verhoging. De verschillen tussen de drie groepen waren
statistisch significant.    
Hoofdstuk 9
Antipsychotica en hormonale veranderingen, mechanismen die seksueel
functioneren beïnvloeden
In dit hoofdstuk worden de gegevens uit de gerapporteerde onderzoeken in dit
proefschrift bij elkaar gebracht. De invloed op seksueel functioneren van
risperidon,  klassieke antipsychotica, clozapine, olanzapine en quetiapine worden
met elkaar vergeleken. Conform de eerder studies gaven mensen die risperidon
gebruikten het vaakst aan seksuele functiestoornissen te ervaren (libido 50%
orgasme 46%), gevolgd door klassieke antipsychotica (libido 38%, orgasme 16%).
Bij clozapine, olanzapine en quetiapine vermeldde minder dan 17% libido
vermindering en minder dan 8% orgasme stoornissen. Prolactine spiegels waren
het hoogst bij mensen behandeld met risperidon, gevolgd door klassieke
antipsychotica. Olanzapine gebruikers toonden een geringe prolactine verhoging,
bij clozapine en quetiapine bleven prolactine waarden binnen de norm.  De rol van
dosering, hoeveelheid medicijn in het bloed en prolactine werd geanalyseerd met
verschillende statistische methoden (verschillende groepen vergeleken met
ordinale regressie). De hoeveelheid prolactine in het bloed leek de belangrijkste
factor te zijn bij veranderingen in libido, orgasme en zaadlozing (8-24% van de
verklaarde variantie). De rol van andere factoren wordt besproken. 
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Algemene discussie
In de algemene discussie wordt naast een korte samenvatting ingegaan op de
vraag waarom het hormoon prolactine van invloed zou kunnen zijn op seksueel
functioneren. Een aantal recente onderzoeken wordt besproken waaruit blijkt dat
prolactine verschillende rollen speelt. De meest bekende rol van prolactine is
tijdens de zwangerschap het mede zorgen voor het groter worden van de borsten
ter voorbereiding op het zogen van het kind. Daarnaast lijkt het hormoon
veranderingen in onder andere reukgebieden van de hersenen te brengen. Recent
onderzoek wijst er bovendien op dat prolactine van belang is bij het ervaren van
verzadiging, zowel van voedsel als seksuele verzadiging. Uit onderzoek met onder
andere antipsychotica blijkt dat dopamine de afgifte van prolactine mede reguleert.
Uit dieronderzoek blijkt echter dat prolactine ook bepaalde dopamine systemen in
de hersenen stimuleert en andere afremt. Het dopamine systeem is van groot
belang bij aandacht, concentratie en het kunnen ervaren van belonen en straf.
Blokkeren van prolactine in proefdieren leidt tot verstoring van de zorg voor jongen.
Een theorie wordt gepresenteerd waarbij wordt verondersteld dat prolactine van
belang is om van gedrag te veranderen: van op de buitenwereld gericht
onderzoekend gedrag te schakelen naar zorgverlenend gedrag voor
nakomelingen. Antipsychotica zijn dopamine remmers en sommige schakelen,
hoewel dat niet door de arts bedoeld is, door prolactine te verhogen het gedrag
van onder andere seksueel gedrag naar gedrag dat bedoeld is om de zorg voor
nakomelingen te bevorderen.
De mogelijke lange termijn risico’s van aanhoudende prolactine verhoging worden
ook kort besproken. Vanuit al wat ouder onderzoek bij kinderen wordt gewezen op
de noodzaak  te onderzoeken wat de invloed van vroegkinderlijke prolactine
verhoging op sociaal en seksueel gedrag zou kunnen zijn. Tenslotte wordt de
klinische betekenis van het proefschrift bediscussieerd. Het proefschrift belicht een
facet van de bijwerkingen van antipsychotische medicijnen, die in de bredere
context van andere bijwerkingen dient te worden gewogen. Seksuele
functiestoornissen dienen net als andere bijwerkingen actief door artsen te worden
uitgevraagd om in de discussie met de individuele patiënt te onderzoeken wat met
de bevindingen te doen. Bij het optreden van seksuele functiestoornissen bij
prolactine verhogende antipsychotica is overstappen op een prolactine sparend
antipsychoticum eerste keus. Dosisverlaging of toevoegen van een dopamine
agonisten (onder andere bromocriptine) aan prolactine verhogende antipsychotica
zijn tweede en derde keus alternatieven.
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